MOBILE VIEW  | 

ETHANOL

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) Ethanol is a CNS depressant.

Specific Substances

    1) Aethanolum
    2) Alcohol etilico
    3) Alkohol
    4) Ethanolum
    5) Ethyl alcohol
    6) ETOH
    7) Spiritus
    8) ALCOHOL (BEVERAGE)
    9) ALCOHOLIC BEVERAGE
    10) BOOZE (SLANG FOR ANY ALCOHOLIC BEVERAGE)
    11) BRANDY
    12) COCKTAILS (ALCOHOLIC BEVERAGE)
    13) ETHANOL, AND SOLUTIONS
    14) MOTOR FUEL, GASOHOL
    15) MOTOR FUEL, N.O.S.
    16) MOTOR SPIRIT
    17) R AND R (SLANG FOR RIPPLE WINE INGESTION WITH SECONAL INGESTION)
    18) RIPPLE & RED (SLANG FOR RIPPLE WINE INGESTION WITH SECONAL INGESTION)
    19) SHORT FLIGHT, TEENAGE (SLANG FOR CORICIDAN & BEER COMBINATION)
    20) WINE COOLER
    1.2.1) MOLECULAR FORMULA
    1) CH3CH2OH

Available Forms Sources

    A) FORMS
    1) "DEHYDRATED ALCOHOL" and "ABSOLUTE ALCOHOL" refer to 100% ethanol. The terms "ALCOHOL" and "95% ALCOHOL" refer to a binary azeotrope possessing a distillate composition of 95.57% ethanol by weight and a boiling point of 78.15 degrees C. "ALCOHOL, USP" is defined as containing not less than 92.3% and not more than 93.8% ethanol (by weight); this corresponds to not less than 94.9% and not more than 96.0% ethanol (by volume) at 15.56 degrees C. "DILUTED ALCOHOL" is a mixture of equal volumes of 95% alcohol and water; by weight, this mixture contains 41.5% ethanol, and by volume it contains 48.9% ethanol (Budavari, 2000; Sandmann & Widders, 1988).
    2) The terms "ETHYL ALCOHOL, DENATURED," "DENATURED ETHANOL," etc refer to ethanol where one or more substances have been added. Denatured ethanol is unfit for use in alcoholic beverages. "SD ALCOHOL," "SDA ALCOHOL," and "ALCOHOL, SD, or SDA" refer to special denatured alcohols (Budavari, 2000).
    B) SOURCES
    1) Denatured ethanol is produced mostly from synthetic production from ethylene. This is mainly by direct hydration process (replacing the earlier method of indirect hydration using sulfuric acid) (Bingham et al, 2001a).
    2) In addition, ethanol can be obtained from fermentation of sugar, cellulose, or starch. Such is the method used in the production of beverage alcohol. The supply for beverage alcohol is not augmented by synthetic ethanol (Bingham et al, 2001a; Harbison, 1998a).
    3) Enzymatic hydrolysis of cellulose also generates ethanol (Lewis, 1997a).
    4) Ethanol can also be obtained through the reaction of methanol with synthesis gas at 185 degrees C and under pressure (HSDB, 2002).
    5) Anhydrous ethanol is manufactured by azeotropic distillation (Bingham et al, 2001a; Bingham et al, 2001a).
    C) USES
    1) Ethanol is used in alcoholic beverages; in coupling/wetting agents (coatings, cleaners, polishes); in organic synthesis as an intermediate (less so in recent years); in antifreeze (less so in recent years); in explosives; in plastics and synthetic rubber industries; in the production of vinegar; as a solvent/co-solvent (eg, perfume and toiletries, pharmaceuticals, dyes, inks, paints, resins, fatty acids, oils, hydrocarbons); as a gasoline octane booster; as a preservative (bacteriostatic or germicide); as a yeast growth medium; and as a disinfectant or soap, as well as many other specific uses in human and veterinary medicine. It is also used industrially in producing denatured alcohol (Ashford, 1994a; Budavari, 2000; HSDB, 2002; ILO , 1998a; Sittig, 1991a; Snyder, 1992a).
    2) In addition, it is used to extract nucleic acids from whole tissue or tissue culture in virtually all biotechnology processes (Baxter et al, 2000).
    3) Ethanol may also be administered in methanol or ethylene glycol poisoning in order to interfere with the generation of toxic metabolites (Cooney, 1995; Howland, 1994).
    4) As a solvent, ethanol blended with denaturants is also known as "INDUSTRIAL METHYLATED SPIRIT" (Ashford, 1994a).
    5) It is incorporated into many elixirs: 15% to 90% volume per volume (v/v) in aftershave, 50% v/v in colognes and perfumes, and 14% to 27% v/v in mouthwashes (Baselt, 1997; Scherger et al, 1988; Weller-Fahy et al, 1980).
    6) Ethanol is incorporated into cooking extracts (eg, vanilla, lemon) that are used as flavorings in food. In one ruling, the FDA required that vanilla extracts contain at least 35% ethanol (Dayton et al, 2015).
    a) Ethanol intoxication was reported in a 14-year-old boy who ingested approximately 24 ounces of lemon cooking extract. His serum ethanol concentration was 233 mg/dL. It was determined that lemon extract has a similar alcohol content as bourbon and absinthe (Dayton et al, 2015).
    7) Alcohol-based hand sanitizers, formulated as low-viscosity rinses, gels, or foams, may contain 60% to 95% ethanol (Doyon & Welsh, 2007).
    8) Ethanol is found in alcoholic beverages at various concentrations:
    BEVERAGEPROOFPERCENT ETHANOL v/v
    Ale10-165-8
    Beer8-124-6
    Light Beer5-72.5-3.5
    Wine20-4010-20
    Bourbon80-9040-45
    Gin80-9440-47
    Rum80-8240-41
    Tequila80-9240-46
    Whiskey80-9040-45
    Vodka80-8240-41
    Liqueurs
    Amaretto34-5617-28
    Anisette40-6020-30
    Brandy70-8035-40
    Cognac80-8240-41
    Coconut Rum34-6317-31.5
    Cream de Banana50-5625-28
    Creme de Cacao50-5425-27
    Cream de Cassis35-4017.5-20
    Creme de Menthe42-6021-30
    Coffee Liqueurs42-5321-26.5
    Orange Caracao6030
    Fruit Liqueurs40-5020-25
    Irish Cream34-5217-26
    Kirschwasser Fruit Liqueurs8442
    Midori Melon Liqueur4623
    Pina Colada5025
    Schnapps40-10020-50
    Sloe Gin40-6020-30
    Triple Sec6030

    a) CISCO is a carbonated, fortified wine that has an alcohol content of 20% and is bottled in 357 mL and 750 mL bottles. It may be mistaken for wine coolers or other beverages of lower alcohol content. Sixteen cases of teenage intoxication with average alcohol blood levels of 200 mg/dL have been reported (AAPCC, 1991).
    b) Cider is widely available in Sweden and contains a maximum of 2.3% of alcohol (1.8 g/100 mL) (Jones, 1996).
    9) The most commonly utilized denaturants (used singly or in combination) are (Budavari, 2000):
    1) acetone
    2) aldehol
    3) amyl alcohol
    4) aniline dyes
    5) benzene
    6) cadmium
    7) iodide
    8) camphor
    9) castor oil
    10) diethyl phthalate
    11) ether
    12) gasoline
    13) isopropanol
    14) kerosene
    15) methanol
    16) nicotine
    17) pyridine bases
    18) sulfuric acid
    19) terpineol
    a) Information on specific denatured alcohol formulas can be found in 27 CFR PART 21.
    10) Ethanol vapor is used as a glaze in confections (Harbison, 1998a).

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) USES: Found primarily in alcoholic beverages. Also found in a variety of over-the-counter products, including some cough/cold medicines, perfumes, colognes, mouthwashes, food flavorings (eg, vanilla extract), and hand sanitizers. Also used clinically as a treatment of ethylene glycol or methanol poisonings.
    B) PHARMACOLOGY: When used therapeutically, ethanol's high affinity for alcohol dehydrogenase inhibits the metabolism of methanol and ethylene glycol.
    C) TOXICOLOGY: Ethanol enhances the inhibitory effects of GABA at the GABA-A receptor. It also competitively inhibits the binding of glycine at the NMDA receptor, disrupting excitatory glutaminergic neurotransmission. The net result is CNS depression. Chronic ethanol use causes desensitization and down-regulation of GABA-A receptors and NMDA up-regulation. Abrupt cessation of ethanol use then causes a hyperexcitable state, producing ethanol withdrawal syndrome. Please refer to the ALCOHOL WITHDRAWAL SYNDROMES management for further information.
    D) EPIDEMIOLOGY: Extremely common exposure that rarely results in morbidity or death. However, ethanol frequently precipitates traumatic injury.
    E) WITH POISONING/EXPOSURE
    1) MILD TO MODERATE TOXICITY: Intoxication, euphoria, ataxia, nystagmus, disinhibition, aggressive behavior, nausea, vomiting, flushing, and supraventricular tachyarrhythmias (primarily atrial fibrillation) can develop.
    2) SEVERE TOXICITY: Coma, respiratory depression, pulmonary aspiration, hypoglycemia, and hypothermia can occur. Abrupt cessation of chronic ethanol use causes withdrawal, manifested by hypertension, tachycardia, tremors, seizures, and in severe cases, delirium.
    0.2.3) VITAL SIGNS
    A) WITH POISONING/EXPOSURE
    1) Hypothermia is common. Hypotension and tachycardia may be present. Bradypnea may occur early, and tachypnea may develop in cases of metabolic acidosis. Elevated body temperature and labored breathing (possibly from aspiration) have been reported in infants.
    0.2.20) REPRODUCTIVE
    A) Women who consume ethanol during pregnancy may give birth to a child with Fetal Alcohol Syndrome. No safe consumption level is known.
    0.2.21) CARCINOGENICITY
    A) Alcohol consumption has been associated with various cancers, including liver, esophageal, breast, prostate, and colorectal cancer.

Laboratory Monitoring

    A) Obtain an ethanol concentration (either blood or breath).
    B) A bedside dextrose is indicated for patients with an altered mental status.
    C) Consider a head CT for comatose patients or those with evidence of trauma.
    D) Monitor serum chemistries.
    E) Obtain arterial or venous blood gases, and serum and urine ketones for alcoholic ketoacidosis.

Treatment Overview

    0.4.2) ORAL/PARENTERAL EXPOSURE
    A) MANAGEMENT OF MILD TO MODERATE TOXICITY
    1) Patients who appear mildly intoxicated may be simply managed with supportive care only. An ethanol concentration is generally not needed for management. Patients can be discharged when they are not clinically intoxicated (no ataxia, nystagmus, or slurred speech). Significant CNS depression indicates a more severe poisoning.
    B) MANAGEMENT OF SEVERE TOXICITY
    1) Measure a serum ethanol level if ethanol is believed to be the cause of altered mental status, and consider and rule out other reversible causes of altered mental status, such as hypoglycemia, hypoxia, and opiate intoxication. Patients who are comatose may require airway protection. Other causes of altered mental status should be considered, because ethanol is often a coingestant with other drugs, and intoxicated patients are predisposed to traumatic injuries. Children may be susceptible to hypoglycemia following an ethanol ingestion. Alcoholic ketoacidosis is a condition that typically develops in chronic drinkers that results in impaired gluconeogenesis. It often develops after binge drinking combined with malnutrition. Vomiting, abdominal pain, and an anion-gap metabolic acidosis develop. Treatment is with fluid replacement and dextrose supplementation. Thiamine, folate, and other vitamins should also be provided intravenously. Ethanol withdrawal is a potentially life-threatening condition that may result in chronic drinkers following a period of abstinence. It usually begins with autonomic hyperactivity, tachycardia, tremor, hypertension, agitation leading to hallucinations, and seizures. Treatment is generally with benzodiazepines for sedation. In patients with resistant symptoms, consider the use of propofol or a barbiturate such as phenobarbital.
    C) DECONTAMINATION
    1) PREHOSPITAL: There is no role for prehospital decontamination.
    2) HOSPITAL: Activated charcoal is not indicated, because it poorly adsorbs to ethanol, but it may be used in the appropriate conditions if there are coingestants. Consider the use of nasogastric suction for patients who present with massive ingestions within 30 minutes. This procedure is rarely indicated.
    D) AIRWAY MANAGEMENT
    1) Patients who are comatose or with an altered mental status may need orotracheal intubation and mechanical ventilation.
    E) ANTIDOTE
    1) There is no specific antidote.
    F) ENHANCED ELIMINATION
    1) Hemodialysis can eliminate ethanol but is rarely indicated. Consider for patients with severe intoxication (eg, hypotension) not responding to supportive care.
    G) PATIENT DISPOSITION
    1) HOME CRITERIA: Patients who are minimally intoxicated with no use of coingestants can be observed at home if there is another responsible, nonintoxicated adult. Symptomatic children or children with ingestions that are expected to cause more than minimal symptoms should be referred to a healthcare facility.
    2) OBSERVATION CRITERIA: Patients should be observed until they are not clinically intoxicated. If they are minimally intoxicated; there is a responsible, nonintoxicated adult who can provide care; and there is no evidence of trauma or other medical problems, they can potentially be discharged, depending on the circumstances. Refer patients with chronic alcoholism or high-risk drinking for detoxification and rehabilitation.
    3) ADMISSION CRITERIA: Admit patients with unstable vital signs, altered mental status that does not improve, concerning coingestants, associated serious trauma or medical conditions, or signs and symptoms of withdrawal.
    4) CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings.
    H) PITFALLS
    1) Ethanol is often a coingestant with other drugs. Intoxicated patients are predisposed to traumatic injuries, which may be more difficult to diagnose in an intoxicated patient. Ethanol can account for an elevated osmolar gap. Small amounts of concentrated ethanol solutions may result in significant toxicity in children.
    I) PHARMACOKINETICS
    1) Ethanol is well absorbed (80% to 90%). Peak concentrations are achieved within 0.5 to 1.5 hours after a single ingestion. Volume of distribution is approximately 0.6 L/kg. Hepatically metabolized, primarily by alcohol dehydrogenase (which is saturable at low ethanol concentrations) and to a lesser extent by cytochrome P2E1 (which is inducible with chronic consumption) and by the peroxidase-catalase system.
    J) TOXICOKINETICS
    1) Elimination changes from first-order to zero-order kinetics at low blood ethanol concentrations. Non-tolerant drinkers typically eliminate ethanol at a rate of approximately 15 to 20 mg/dL/hr, whereas chronic drinkers have an elimination rate of approximately 20 to 30 mg/dL/hr. Patients also develop tolerance to some effects.
    K) DIFFERENTIAL DIAGNOSIS
    1) The differential diagnosis includes other xenobiotics that present with intoxication, including ingestions of isopropanol and methanol, benzodiazepines, barbiturates, and GHB. The differential diagnosis of altered mental status is extremely broad and includes toxicologic and nontoxicologic causes.
    L) DRUG INTERACTIONS
    1) Coingestions with other CNS and respiratory depressants (eg, benzodiazepines, barbiturates, opioids) increases toxicity.

Range Of Toxicity

    A) TOXICITY: Ethanol levels that cause clinical intoxication can vary widely, depending on an individual's tolerance to ethanol. The legal driving limit in most of the states in the US is 80 mg/dL. In casual drinkers, coma likely occurs at a level of approximately 200 mg/dL, and death may occur at an approximate level of 450 mg/dL.
    B) A dose of about 1 mL/kg (1 g/kg) of absolute ethanol (95% to 99% ethanol) generally results in blood levels of 100 to 150 mg/dL (21 to 32 mmol/L), which would be expected to cause mild to moderate intoxication in most adults. However, a dose of 0.5 mL/kg absolute ethanol (an estimated blood alcohol level of 50 to 75 mg/dL) may cause significant intoxication in young children.
    C) INTOXICATION: Blood ethanol concentrations between 150 and 300 mg/dL (32.6 to 65.2 mmol/L) will generally cause obvious signs and symptoms.
    D) DEATH Generally reported at 5 to 6 g/kg in the non-tolerant adult and at 3 g/kg in children. Usually associated with blood ethanol levels greater than 400 mg/dL (86.8 mmol/L), although levels as low as 250 mg/dL have proven fatal. Cases of ethanol ingestion complicated by aspiration of gastric contents, coingestants, preexisting disease, or other factors may cause death at lower blood ethanol levels.
    E) RECOVERY Reported in patients with blood ethanol levels greater than 1510 mg/dL (327.8 mmol/L). Supportive care was provided; a history of chronic ethanol abuse (and thus tolerance) was present in at least 1 case.

Summary Of Exposure

    A) USES: Found primarily in alcoholic beverages. Also found in a variety of over-the-counter products, including some cough/cold medicines, perfumes, colognes, mouthwashes, food flavorings (eg, vanilla extract), and hand sanitizers. Also used clinically as a treatment of ethylene glycol or methanol poisonings.
    B) PHARMACOLOGY: When used therapeutically, ethanol's high affinity for alcohol dehydrogenase inhibits the metabolism of methanol and ethylene glycol.
    C) TOXICOLOGY: Ethanol enhances the inhibitory effects of GABA at the GABA-A receptor. It also competitively inhibits the binding of glycine at the NMDA receptor, disrupting excitatory glutaminergic neurotransmission. The net result is CNS depression. Chronic ethanol use causes desensitization and down-regulation of GABA-A receptors and NMDA up-regulation. Abrupt cessation of ethanol use then causes a hyperexcitable state, producing ethanol withdrawal syndrome. Please refer to the ALCOHOL WITHDRAWAL SYNDROMES management for further information.
    D) EPIDEMIOLOGY: Extremely common exposure that rarely results in morbidity or death. However, ethanol frequently precipitates traumatic injury.
    E) WITH POISONING/EXPOSURE
    1) MILD TO MODERATE TOXICITY: Intoxication, euphoria, ataxia, nystagmus, disinhibition, aggressive behavior, nausea, vomiting, flushing, and supraventricular tachyarrhythmias (primarily atrial fibrillation) can develop.
    2) SEVERE TOXICITY: Coma, respiratory depression, pulmonary aspiration, hypoglycemia, and hypothermia can occur. Abrupt cessation of chronic ethanol use causes withdrawal, manifested by hypertension, tachycardia, tremors, seizures, and in severe cases, delirium.

Vital Signs

    3.3.1) SUMMARY
    A) WITH POISONING/EXPOSURE
    1) Hypothermia is common. Hypotension and tachycardia may be present. Bradypnea may occur early, and tachypnea may develop in cases of metabolic acidosis. Elevated body temperature and labored breathing (possibly from aspiration) have been reported in infants.
    3.3.2) RESPIRATIONS
    A) HYPOVENTILATION
    1) WITH POISONING/EXPOSURE
    a) Bradypnea can occur (Goldfrank et al, 1994). Significant respiratory depression developed in 3 children following percutaneous exposure (Gimenez et al, 1968) and in a hypoglycemic, comatose child following ethanol ingestion (Ricci & Hoffman, 1982).
    B) HYPERVENTILATION
    1) WITH POISONING/EXPOSURE
    a) Tachypnea may develop as a compensatory mechanism in cases of ethanol-induced ketoacidosis (Goldfrank et al, 1994). Rapid, shallow, and noisy respirations with chest retractions occurred in a severely intoxicated child (Vogel et al, 1995). Aspiration of vomitus may have occurred.
    3.3.3) TEMPERATURE
    A) HYPOTHERMIA
    1) WITH POISONING/EXPOSURE
    a) Hypothermia is common (McGinnity de Laveaga & Caravati, 2015; Ruck et al, 2010; Lien & Mader, 1999; Wade & Gammon, 1999; Szpak et al, 1995; Selbst et al, 1985; Weyman et al, 1974; Moss, 1970). Combined exposure to ethanol and sedative-hypnotics can enhance vasodilation (Goldfrank et al, 1994) and increase hypothermia.
    b) CASE REPORT: An 80-year-old man presented with a decreased level of consciousness 1 hour after intentionally ingesting 750 mL of vodka (40% ethanol by volume). Within 30 minutes of presentation, the patient became unresponsive, hypotensive, and hypothermic. Following supportive care, the patient gradually recovered without sequelae (Wilson & Waring, 2007). Prior alcohol abstinence by the patient may have contributed to the severity of symptoms.
    B) HYPERTHERMIA
    1) WITH POISONING/EXPOSURE
    a) Elevated body temperature has been reported in 3 pediatric cases of significant ethanol ingestion (Vogel et al, 1995; Hornfeldt, 1992).
    3.3.4) BLOOD PRESSURE
    A) HYPOTENSION
    1) WITH POISONING/EXPOSURE
    a) Hypotension and bradycardia may occur (Ruck et al, 2010; Wilson & Waring, 2007; Lien & Mader, 1999; Goldfrank et al, 1994; Eilam & Heyman, 1991).
    3.3.5) PULSE
    A) TACHYCARDIA
    1) WITH POISONING/EXPOSURE
    a) Tachycardia may be present (Ruck et al, 2010; Osborn, 1994).

Heent

    3.4.3) EYES
    A) WITH POISONING/EXPOSURE
    1) SUMMARY
    a) Eye exposure to liquid generally causes transient pain, irritation, and reflex lid closure. A foreign-body sensation may persist for 1 to 2 days (Grant & Schuman, 1993). Vapors produce transient stinging and tearing but no apparent adverse effects (Grant & Schuman, 1993).
    2) HAND SANITIZERS: In a retrospective review of 647 pediatric (age range, 1 month to 5 years; mean age, 1.89 years) exposures to ethanol-based hand sanitizers (599 ingestions, 105 dermal, 29 ocular, and 2 inhalational), the reported ocular effects were eye irritation (n=9), lacrimation (n=1), and conjunctivitis (n=1) (Mrvos & Krenzelok, 2009).
    3) CHROMATOPSIA
    a) Transiently impaired color vision may occur with acute ingestion or chronic alcoholism. Abstinence from alcohol generally restores normal color vision in chronic alcoholics (Grant & Schuman, 1993).
    4) IMPAIRED EYE MOVEMENTS
    a) Poor control of eye movements, with diplopia and nystagmus, may occur and alter vision and performance (Grant & Schuman, 1993). Acute overdoses of ethanol have caused spontaneous (not gaze-evoked) horizontal nystagmus (Anon, 1971). The greatest effects are on saccadic and smooth pursuit movements (Willoughby, 1987; Wilkinson et al, 1974).
    5) RARE EFFECTS-BLINDNESS
    a) Temporary blindness, with normal pupil reactivity and fundi, has been rarely associated with acute intoxication. Methanol ingestion was excluded (Walsh, 1957). Most cases of blindness reported in the earlier literature were caused by methanol and not by ethanol (Grant & Schuman, 1993).
    6) AMBLYOPIA
    a) Amblyopia due to peripheral neuritis has been reported in chronic alcoholics. Bilaterally decreased vision occurs. Vitamin deficiencies correlate with the ocular defects, and early administration of B vitamins causes recovery in some patients (Grant & Schuman, 1993).
    7) OCULAR EFFECTS IN FETAL ALCOHOL SYNDROME
    a) Abnormal eye features, ptosis, strabismus, myopia, amblyopia, and optic disc pallor have been reported (Grant & Schuman, 1993; Galea & Goel, 1989).
    3.4.6) THROAT
    A) WITH POISONING/EXPOSURE
    1) HYPERAMYLASEMIA
    a) Acute intoxication has been reported to result in non-pancreatic hyperamylasemia due to salivary isoamylase (Block et al, 1983).

Cardiovascular

    3.5.2) CLINICAL EFFECTS
    A) CARDIAC ARREST
    1) WITH POISONING/EXPOSURE
    a) An adult presented pulseless and apneic with a blood ethanol concentration of 1.127 g/dL. She was intubated, resuscitated, and treated with hemodialysis, and she recovered (Sanap & Chapman, 2003).
    b) Cardiopulmonary arrest occurred in a 2-year-old who may have ingested 120 mL of tequila, 26.5% ethanol (Vogel et al, 1995).
    c) Sudden death following acute intoxication have been reported in 6 cases, but the exact causes of death were not known, and preexisting medical conditions were present in some cases (Odesanmi, 1979).
    d) Sudden death has occurred in patients with alcoholic cardiomyopathy who did not have angina or coronary artery disease (Sheehy, 1992).
    e) CASE REPORT: A 36-year-old man, with a history of schizophrenia, presented to the emergency department (ED) with ethanol intoxication. The patient was uncooperative with slurred speech and nystagmus. A breath ethanol reading was 278 mg/dL. Four hours later, with supportive care, the patient was calm with a steady gait and was discharged. Thirty minutes later, the patient was found unresponsive and pulseless in the bathroom at the ED, with an empty 354-mL hand sanitizer containing 62% ethanol and less than 5% isopropanol. Following resuscitation, the patient developed spontaneous circulation with normal sinus rhythm, but never regained consciousness. His serum ethanol concentration was 526 mg/dL. A brain MRI showed extensive bilateral cortical infarction, cerebral edema, and sulcal effacement, indicating anoxic brain injury. The patient died on hospital day 7 following withdrawal of care. Based on his post-resuscitation serum ethanol concentration, it is suspected that the patient had ingested the majority of the contents of the hand sanitizer container (Schneir & Clark, 2013).
    B) ATRIAL FIBRILLATION
    1) WITH POISONING/EXPOSURE
    a) Acute alcohol intoxication may result in atrial fibrillation (Thorton, 1984; Ettinger et al, 1978). Precipitation of fibrillation was reported in a man who consumed 5.8 mg of denatured alcohol in a breath spray (Ridker et al, 1989).
    b) CASE REPORT: A 16-year-old adolescent developed atrial fibrillation with a heart rate of 77 beats per minute approximately 1 hour following hospital admission for CNS depression secondary to consumption of an unknown amount of alcohol. The patient also complained of transient nonlocalizing chest pain. His chest x-ray was normal, and there was no evidence of hemodynamic instability. His blood alcohol level was 153.5 mg/dL. The patient was placed on heparin therapy, and his atrial fibrillation resolved 8 hours later as his blood alcohol level decreased. The patient was discharged without further sequelae (Koul et al, 2005).
    C) ATRIOVENTRICULAR BLOCK
    1) WITH POISONING/EXPOSURE
    a) Wenckebach-type AV block was reported in a 49-year-old comatose patient with a serum alcohol level of 536 mg/dL. Underlying organic heart disease and ingestion of other drugs were ruled out as potential causes (Eilam & Heyman, 1991).
    D) ANGINA
    1) WITH POISONING/EXPOSURE
    a) A 71-year-old man with variant angina repeatedly developed chest pain after the consumption of moderate amounts of alcohol, but not after exercise. This patient had no history of hypertension or smoking. Myocardial ischemia was confirmed by ECG and thallium-201 exercise myocardial scintigrams (Ando et al, 1993).
    b) Coronary artery spasm was induced approximately 9 hours after ingestion of 400 mL rice wine (17% ethanol) in 4 cases with histories of ethanol-induced variant angina and preexisting coronary artery stenosis. Blood ethanol levels were not elevated during the angina (Oda et al, 1994). Other human studies have also reported ethanol-induced angina (Miwa et al, 1994).
    E) HEART FAILURE
    1) WITH POISONING/EXPOSURE
    a) Acute intoxication may decrease cardiac output in persons with preexisting cardiac conditions (Osborn, 1994).
    F) TACHYCARDIA
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT (INFANT): A 15-day-old infant presented to the emergency department with flushed skin, hypoactive, and somnolent approximately 3 hours after drinking formula milk. At presentation, the patient was hypotensive (55/29 mmHg) and tachycardic (214 beats/min), and arterial blood gases indicated metabolic acidosis (pH 7.186, HCO3 16.7 mmol/L, pCO2 45.8 mmHg, base excess -10.1 mmol/L). The patient's serum ethanol concentration, obtained at admission, was 43 mg/dL. With supportive care, including IV fluid administration, the patient gradually recovered within 12 hours post-admission. An interview with the parents, 24 hours post-admission, revealed that the infant's formula had been inadvertently mixed with 10 mL of sake (Japanese wine prepared from fermented rice). Follow up of the patient over the next 12 months showed no evidence of psychomotor sequelae (Zaitsu et al, 2013).
    G) CARDIOMYOPATHY
    1) WITH POISONING/EXPOSURE
    a) EARLY EFFECTS/PRECLINICAL STAGE: Alcoholic cardiomyopathy has insidious onset and can be clinically inapparent (Kouvaras & Cokkinos, 1986). Symptoms of alcoholic cardiomyopathy are often present for an average of 10.5 months before diagnosis (Sheehy, 1992), but as many as 85% of cases have not been diagnosed through routine screening, unless angiography was performed (Bertolet et al, 1991).
    1) Fatigue, dyspnea on exertion, palpitations, and chest pain may occur (Estruch et al, 1993; Parker, 1974). Decreased left ventricular function and sinus tachycardia with an S4 (atrial) gallop may be present (Parker, 1974).
    2) Cessation of alcohol use before significant manifestations of cardiac dysfunction may result in improved or restored cardiac function (Kouvaras & Cokkinos, 1986).
    b) LATER EFFECTS/CLINICAL STAGE: Findings may include (Estruch et al, 1993; Bertolet et al, 1991; Kouvaras & Cokkinos, 1986; Parker, 1974):
    1) Cardiomegaly with ventricular enlargement and left ventricular dysfunction, indicated by decreased left ventricular ejection fraction and wall motion abnormalities.
    2) ECG abnormalities (eg, bundle branch block, delayed ventricular conduction, poor R-wave progression, atrial fibrillation).
    3) Decreased heart tones, ventricular S3 gallop, weak pulse, slightly elevated diastolic pressure.
    4) Systemic emboli, congestive heart failure, and sudden death.
    5) Fatty deposits, myocardial fiber loss or degeneration, and other histopathology.
    6) Cirrhosis is usually absent; malnutrition may not be present (Parker, 1974). Angina and coronary artery disease may be absent, even in cases in which sudden death occurs (Sheehy, 1992).
    c) INCIDENCE/RISK FACTORS: Regular consumption of large amounts of alcohol for 5 or more years may lead to alcoholic cardiomyopathy in a small percentage of adults (1% out of 12%); some susceptible individuals may develop cardiomyopathy after doses as low as 3 ounces of strong alcoholic beverages daily for 10 years (Parker, 1974).
    1) Beverages consumed include high-alcohol-content spirits, beer, and wine (Kouvaras & Cokkinos, 1986).
    2) Individual susceptibility to ethanol reportedly is a very important determinant of cardiac effects (Bertolet et al, 1991).
    H) MYOCARDIAL INFARCTION
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: An acute myocardial infarction occurred in a 47-year-old man 6 hours after ingesting 0.5 liters of ethanol within 30 to 60 minutes (calculated plasma ethanol concentration was 2.36 g/kg). The patient recovered following treatment with aspirin, nitroglycerin infusion, and a streptokinase infusion. Three months later, a coronary angiography showed normal coronary arteries but marked hypokinesia of the left ventricular wall (Starc et al, 1999).
    I) HYPOTENSIVE EPISODE
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: An 80-year-old man presented to the emergency department with a decreased level of consciousness 1 hour after intentionally ingesting 750 mL of vodka (40% ethanol by volume). Within 30 minutes following presentation, the patient became unresponsive, hypotensive (lowest mean arterial pressure 45 mmHg), and hypothermic (34.8 degrees C). Following supportive care, the patient gradually recovered without sequelae (Wilson & Waring, 2007). Prior alcohol abstinence by the patient may have contributed to the severity of symptoms.
    b) CASE REPORT (INFANT): A 15-day-old infant presented to the emergency department with flushed skin, hypoactive, and somnolent approximately 3 hours after drinking formula milk. At presentation, the patient was hypotensive (55/29 mmHg) and tachycardic (214 beats/min), and arterial blood gases indicated metabolic acidosis (pH 7.186, HCO3 16.7 mmol/L, pCO2 45.8 mmHg, base excess -10.1 mmol/L). The patient's serum ethanol concentration, obtained at admission, was 43 mg/dL. With supportive care, including IV fluid administration, the patient gradually recovered within 12 hours post-admission. An interview with the parents, 24 hours post-admission, revealed that the infant's formula had been inadvertently mixed with 10 mL of sake (Japanese wine prepared from fermented rice). Follow up of the patient over the next 12 months showed no evidence of psychomotor sequelae (Zaitsu et al, 2013).
    c) CASE REPORT/CHILD: A 3-year-old child presented to the emergency department with an altered mental status following suspected ingestion of a hand sanitizer containing 70% ethanol. Vital signs indicated a heart rate of 97 beats/minute and a blood pressure of 95/54 mmHg. Her Glasgow Coma Scale score was 10. Within an hour of presentation, she became hypotensive (70/22 mmHg). Her serum ethanol concentration was 260 mg/dL. Following administration of IV fluids and epinephrine, and continued observation, the patient gradually recovered and was discharged within 24 hours of presentation (Barrett & Babl, 2015).
    d) CASE REPORT (CHILD): A 3-year-old child with cerebral palsy was found cold, pale, and unresponsive (Glasgow Coma score of 3) by emergency personnel and presented to the emergency department with hypotension (56/25 mmHg), tachycardia (130 beats/min) and hypothermia (33.9 degrees C), with pinpoint pupils. Arterial blood gas analysis revealed lactic acidosis (pH 7.15, pCO2 43, HCO3 14.3 mmol/L, lactate 5.3 mmol/L). Serum ethanol concentration was 958 mg/dL. Despite supportive care, the patient's hypotension (65/48 mmHg) and acidosis persisted. Hemodialysis was performed approximately 5 hours post-presentation for a period of 4 hours. Immediately following hemodialysis, the patient's serum ethanol concentration decreased to 70 mg/dL. Her blood pressure stabilized, the acidosis resolved, and she became increasingly responsive (McGinnity de Laveaga & Caravati, 2015).
    3.5.3) ANIMAL EFFECTS
    A) ANIMAL STUDIES
    1) CARDIAC FAILURE
    a) Ethanol plus cocaine injected IV in anesthetized dogs synergistically depressed left ventricular contraction, left ventricular relaxation, and stroke volume but increased heart rate and mean pulmonary arterial pressure. Oxygen saturation of the venous blood was also significantly decreased by the combined treatments. Ethanol alone did not significantly alter mean arterial pressure, ventricular relaxation, ventricular contraction, heart rate, or mixed venous blood oxygen saturation (Henning et al, 1994).
    b) Other studies have reported additive depression of the left ventricular ejection fraction in dogs following IV ethanol and cocaine (Uszenski et al, 1992).

Respiratory

    3.6.2) CLINICAL EFFECTS
    A) HYPOVENTILATION
    1) WITH POISONING/EXPOSURE
    a) Respiratory depression has been reported in substantial ingestions (Johnstone & Witt, 1972)(Johnstone & Reier, 1973) and in 3 pediatric cases of dermal exposure (Gimenez et al, 1968). Death due to respiratory failure can occur after significant ingestions (Osborn, 1994).
    b) INCIDENCE: A prospective observational study was conducted to determine the incidence of hypoventilation in adolescents with acute alcohol intoxication, as well as determine if there is a correlation between alcohol concentrations and the incidence of hypoventilation. The study included 65 patients, ages ranging from 14 to 19 years old. Hypoventilation episodes, measured via capnography, occurred in 28% of the patients, with the majority of episodes (92%) identified as hypopneic hypoventilation (end-title carbon dioxide [ETCO2] of 30 mmHg or less). There were also 2 episodes of apnea (ETCO2 of 0 mmHg) and 2 episodes of bradypneic hypoventilation (an ETCO2 of at least 50 mmHg). There was no significant difference in the mean alcohol concentration between the patients who experienced hypoventilation (186 mg/dL; n=18), and the patients who did not experience hypoventilation (185 mg/dL; n=47). There was also no significant difference in the number of hypoventilation episodes that occurred on arrival to the hospital and during the first 5 hours of capnographic measurements. No episodes were recorded after the fifth hour of monitoring (Langhan, 2013).
    B) CHEYNE-STOKES RESPIRATION
    1) WITH POISONING/EXPOSURE
    a) Cheyne-Stokes respirations may be present in comatose cases (Cummins, 1961).
    C) HYPERVENTILATION
    1) WITH POISONING/EXPOSURE
    a) Dyspnea, which may progress to Kussmaul respirations (deep and sighing respirations with variable rate), may be present in cases of alcohol-induced ketoacidosis (Larremore, 1984; Edwards & Hoyt, 1973; Jenkins et al, 1971).
    D) PNEUMONIA
    1) WITH POISONING/EXPOSURE
    a) Aspiration of vomitus may occur, resulting in pneumonitis and pulmonary edema (Johnson, 1985; Dickerman et al, 1968).
    E) PHARYNGITIS
    1) WITH POISONING/EXPOSURE
    a) Vapors may cause coughing and transient irritation of the upper respiratory tract (American Conference of Governmental Industrial Hygienists, 2010).
    F) BRONCHOSPASM
    1) WITH POISONING/EXPOSURE
    a) Exacerbation of asthma has been reported after ingestion of ethanol and exposure to ethanol vapors (Ayres, 1997; Zellweger, 1997).
    G) HYPOXEMIA
    1) WITH POISONING/EXPOSURE
    a) Moderate ethanol intoxication (1 mg/kg of ethanol as a 45% aqueous solution) reduces peripheral oxygen delivery and metabolism and causes mitochondrial oxidative dysfunction, possibly resulting in shock or hypoxia in the acutely intoxicated patient (Gutierrez et al, 1999).
    H) COUGH
    1) WITH POISONING/EXPOSURE
    a) HAND SANITIZERS: In a retrospective review of 647 pediatric (age range, 1 month to 5 years; mean age, 1.89 years) exposures to ethanol-based hand sanitizers (599 ingestions, 105 dermal, 29 ocular, and 2 inhalational), cough developed in 4 patients (Mrvos & Krenzelok, 2009).

Neurologic

    3.7.2) CLINICAL EFFECTS
    A) CENTRAL NERVOUS SYSTEM DEFICIT
    1) WITH POISONING/EXPOSURE
    a) CNS depression can be profound and may lead to death. Lethal blood levels range from 260 mg% to greater than 700 mg%. Alcoholics tolerate higher levels than abstainers, who tolerate higher levels than children. Coingestion of sedative hypnotics or tranquilizers may be lethal with relatively low blood ethanol levels.
    b) Loss of consciousness has been reported in teenagers intoxicated by Cisco, a carbonated, fortified wine that has an alcohol content of 20%. Average blood alcohol levels in 16 cases were about 200 mg/dL (AAPCC, 1991).
    c) CNS depression (Glasgow Coma Scale [GCS] of 11), disorientation, incoherence, and ataxia were reported in a 16-year-old adolescent following consumption of an unknown amount of alcohol. His blood alcohol level was 153.5 mg/dL (Koul et al, 2005).
    d) CASE REPORT: An 80-year-old man presented to the emergency department with a decreased level of consciousness 1 hour after intentionally ingesting 750 mL of vodka (40% ethanol by volume). Within 30 minutes following presentation, the patient became unresponsive, hypotensive, and hypothermic. Following supportive care, the patient gradually recovered without sequelae (Wilson & Waring, 2007). Prior alcohol abstinence by the patient may have contributed to the severity of symptoms.
    e) CASE REPORT (PEDIATRIC): A 3-year-old child presented to the emergency department with a loss of balance, vomiting, drowsiness, and unresponsiveness to painful stimuli following a suspected ingestion of an alcohol-based hand sanitizer, containing 62% ethanol. In addition, the patient also developed nystagmus, mydriasis, hypotension (108/56 mmHg), tachycardia (108 bpm), and hypothermia (94.7 degrees F). An initial blood ethanol level, obtained approximately 1 hour post-presentation, was 212 mg/dL. With supportive care, the patient's condition improved with a decrease in her blood ethanol level to 45 mg/dL, 6 hours after the first level, and undetectable 8 hours later (Ruck et al, 2010). In order for the patient to initially present with a blood ethanol level of 212 mg/dL, it is believed that she ingested approximately 45 mL of the hand sanitizer.
    f) CASE REPORT (INFANT): A 15-day-old infant presented to the emergency department with flushed skin, hypoactive, and somnolent approximately 3 hours after drinking formula milk. At presentation, the patient was hypotensive (55/29 mmHg) and tachycardic (214 beats/min), and arterial blood gases indicated metabolic acidosis (pH 7.186, HCO3 16.7 mmol/L, pCO2 45.8 mmHg, base excess -10.1 mmol/L). The patient's serum ethanol concentration, obtained at admission, was 43 mg/dL. With supportive care, including IV fluid administration, the patient gradually recovered within 12 hours post-admission. An interview with the parents, 24 hours post-admission, revealed that the infant's formula had been inadvertently mixed with 10 mL of sake (Japanese wine prepared from fermented rice). Follow up of the patient over the next 12 months showed no evidence of psychomotor sequelae (Zaitsu et al, 2013).
    g) CASE REPORT (INFANT): A 9-week-old infant presented to the emergency department acting "strangely" and smelling of alcohol. Examination of the infant revealed decreased mental status and vital signs indicated an increased heart rate (160 beats/minute) and respirations (22 breaths/minute). Interview of the family revealed that the grandmother had inadvertently prepared the child's formula with 90 mL of vodka instead of water. The patient's blood glucose concentration, obtained by fingerstick at admission and at 1 hour and 3 hours postadmission, was 167 mg/dL, 160 mg/dL, and 98 mg/dL, respectively. His serum blood alcohol level, obtained at presentation, was 330 mg/dL. Three hours and 24 hours later, the blood alcohol level decreased to 0.27 mg/dL and less than 0.01 mg/dL, respectively. Following IV administration of 5% dextrose with normal saline (D5NS), the patient recovered and was discharged to home approximately 24 hours postadmission (Minera & Robinson, 2014).
    h) CASE REPORT (CHILD): A 3-year-old child presented to the emergency department with altered mental status following suspected ingestion of a hand sanitizer containing 70% ethanol. Vital signs indicated a heart rate of 97 beats/minute and a blood pressure of 95/54 mmHg. Her Glasgow Coma Scale score was 10. Within an hour of presentation, she became hypotensive (70/22 mmHg). Her serum ethanol concentration was 260 mg/dL. Following administration of IV fluids and epinephrine, and continued observation, the patient gradually recovered and was discharged within 24 hours of presentation (Barrett & Babl, 2015).
    i) CASE REPORT (ADOLESCENT): A 14-year-old boy presented to the emergency department with an altered mental status and an inability to walk on his own. Examination of the patient demonstrated a Glasgow Coma score of 6 and an absence of a gag reflex, necessitating intubation. Arterial blood gas analysis revealed metabolic acidosis, and laboratory data revealed a serum ethanol concentration of 233 mg/dL. Other toxicologic screening was negative for drugs of abuse and acetaminophen level was normal. Following supportive care, he was extubated and referred to psychiatry for consultation. Interview of the patient's friends indicated that he had ingested 24 ounces of lemon cooking extract. It was determined that lemon extract has a similar alcohol content as bourbon and absinthe (Dayton et al, 2015).
    B) COMA
    1) WITH POISONING/EXPOSURE
    a) Coma has been reported in children (McGinnity de Laveaga & Caravati, 2015; Hornfeldt, 1992; Cummins, 1961).
    b) CASE REPORT (ADULT): A 38-year-old hospitalized man with a history of alcohol abuse was found collapsed on a bathroom floor of a general medical ward. Neurologic assessment in the emergency department showed that he was comatose with a GCS of 3, necessitating intubation. His blood alcohol level was greater than 500 mg/dL. Approximately 90 minutes later, the patient regained consciousness and was extubated. It was later determined that he had consumed an unknown amount of hand-wash gel containing 70% alcohol in glycerol (Roberts et al, 2005).
    c) CASE REPORT (ADULT): A 52-year-old woman presented to the emergency department comatose, apneic, and hypothermic after consuming 1 liter of methylated spirits (consisting of 95% ethanol and small amounts of fluorescein, denatonium benzoate, and methyl isobutyl ketone). Her initial blood ethanol level was 1.127 g/dL (245 mmol/L). Following early resuscitation and dialysis, the patient's clinical status improved, and she was discharged approximately 8 days post-admission without neurologic sequelae (Sanap & Chapman, 2003).
    d) CASE REPORT (PEDIATRIC): Coma (GCS of 3) occurred in a 3-year-old boy following ingestion of an ethanol-containing mouthwash. The patient was awake and alert 30 minutes after receiving supportive treatment (Wade & Gammon, 1999).
    e) CASE REPORT (PEDIATRIC): A 3-year-old child presented to the emergency department in a comatose state after ingesting an unknown amount of alcohol-based hand sanitizer, containing 65% ethanol. An initial blood ethanol level was 164 mg/dL. With supportive care, the patient's mental status improved, and a repeat blood ethanol level, obtained 2 hours later, was 127 mg/dL. The patient's condition returned to baseline the following day and she was discharged (Thomas et al, 2010).
    C) SEIZURE
    1) WITH POISONING/EXPOSURE
    a) Seizures have occurred in children secondary to hypoglycemia following dermal exposure or ingestion (Hornfeldt, 1992; Leung, 1986; Selbst et al, 1985; Gimenez et al, 1968; Cummins, 1961).
    D) DECREASED MUSCLE TONE
    1) WITH POISONING/EXPOSURE
    a) Children may experience severe lethargy and hypotonia after acute exposure (Da Dalt et al, 1991; Ricci & Hoffman, 1982; Weller-Fahy et al, 1980).
    b) CASE REPORT (INFANT): A 1-month-old child whose ethanol level was 362 mg% was severely hypotonic and lethargic after home treatment with dermal ethanol soaks for 3 days. With supportive treatment and removal of the ethanol-impregnated wraps, her mental status improved to normal within 18 hours (Da Dalt et al, 1991).
    c) CASE REPORT (PEDIATRIC): A 33-month-old child was stuporous 2 hours after possibly ingesting 11 ounces of mouthwash (48.2 g of absolute ethanol). Blood ethanol level was 306 mg% 3.5 hours after ingestion. Treatment included normal saline nasogastric lavage, warming by radiant heater, IV fluids, and bicarbonate. Eight hours postingestion, the blood ethanol level was 128 mg%. Recovery occurred by 18 hours after admission (Weller-Fahy et al, 1980).
    d) CASE REPORT (PEDIATRIC): A 4-year-old child became "floppy" but responsive after ingesting approximately 6 ounces of an ethanol-based liquid hand sanitizer. The patient' blood ethanol level, obtained approximately 60 to 90 minutes post-ingestion, was 221 mg/dL. The patient recovered with supportive care (Reed et al, 2010).
    e) CASE REPORT (INFANT): A 29-day old 3.5 kg infant was brought to the emergency department because of suspected ethanol intoxication due to reported ingestion of soy formula that was mixed with 1 to 3 ounces of gin instead of water. At presentation, approximately 1.5 hours post-ingestion, the patient had a weak cry and cough, with a variable tone, described as "flat", "floppy", and "normal". Her initial heart rate was 181 beats/min, blood pressure of 85/67 mmHg and respiratory rate of 47 breaths/min; oxygenation was normal on room air. Physical examination was normal. Laboratory data revealed an initial blood alcohol concentration, obtained approximately 2 hours post-ethanol ingestion, was 301 mg/dL. All other laboratory parameters, including serum electrolytes, renal function tests, and glucose were within normal limits. With supportive care, including continuous administration of IV fluids containing 5% dextrose and 0.45% sodium chloride at 6 mL/kg/hour, the patient was awake and alert, and feeding normally. Continued observation revealed a slight increase in a liver enzyme level (AST 87 units/L) approximately 13 hours post ethanol-ingestion, but resolved 12 hours later. All other cardiovascular, neurologic, respiratory, and glycemic parameters remained normal, and the patient was discharged 3 days post-admission (Fong & Muller, 2014).
    E) ATAXIA
    1) WITH POISONING/EXPOSURE
    a) Blood levels below 50 mg% (11 mmol/L) rarely lead to marked sensory or motor impairment. Values above 150 mg% (32.6 mmol/L) may cause ataxia and are consistent with intoxication (Koul et al, 2005; Goldfrank et al, 1998).
    b) Ataxia may be an indication of alcoholic cerebellar degeneration (Juntunen, 1982).
    c) CASE REPORT (PEDIATRIC): A 4-year-old child was unable to walk and had slurred speech after ingesting an unknown amount of an alcohol-based liquid hand sanitizer. The patient's blood ethanol level, obtained approximately 1 hour post-ingestion, was 200 mg/dL. With supportive therapy and overnight observation, the patient recovered and was discharged (Reed et al, 2010).
    F) HYPOREFLEXIA
    1) WITH POISONING/EXPOSURE
    a) Reflexes may be normal, absent, decreased, or increased (Ricci & Hoffman, 1982; Gimenez et al, 1968).
    G) DOLL'S HEAD REFLEX FINDING
    1) WITH POISONING/EXPOSURE
    a) Doll's eyes have been reported in children (Vogel et al, 1995; Ricci & Hoffman, 1982).
    H) NEUROPATHY
    1) WITH POISONING/EXPOSURE
    a) CHRONIC ABUSE: Peripheral neuropathy has been reported in alcoholics (Juntunen, 1982). In one study, alcoholics reported more symptoms consistent with peripheral neuropathy than controls, but electrophysiological testing did not confirm peripheral neuropathy in most of these alcoholics (Estruch et al, 1993).
    I) DISTURBANCE IN THINKING
    1) WITH POISONING/EXPOSURE
    a) DRIVING IMPAIRMENT: Deterioration of driving skills occurs at blood ethanol levels of 100 mg% and becomes progressively more serious as the level increases (Goldfrank et al, 1998).
    b) The probability of causing an accident is related to the blood ethanol level (Council on Scientific Affairs, 1986).
                                    Approximate
         Blood Ethanol Level     Crash Probability
               40 mg%                   1%
              100 mg%                   7%
              140 mg%                  20%
              160 mg%                  35%
    

    c) CASE REPORT/IMPAIRED OBJECTIVE PERFORMANCE: A randomized, double-blind, placebo-controlled, 4-way crossover study using 20 healthy male volunteers showed impairment of psychomotor function (Gengo et al, 1990). Changes in objective performance test scores were well correlated with the estimated blood alcohol concentration.
    1) The threshold estimated blood alcohol concentrations (est BAC) needed to produce changes in the objective test scores greater than those in the placebo group were as follows:
    1) Digit Symbol Substitution: 60 +/- 10 mg/dL
    2) Choice Reaction Time: 40 +/- 20 mg/dL
    3) Simulated Driving: 40 +/- 10 mg/dL
    2) Disparities between self-rated degree of impairment and decrements in objective test performance were greatest 1 hour after peak est BAC and maximum decrements in test performance. This may account for the motorists' choice to drive while impaired (Gengo et al, 1990).
    J) DEMENTIA
    1) WITH POISONING/EXPOSURE
    a) Wernicke-Korsakoff syndrome (a more severe deficit in learning and memory) and dementia have been reported in alcoholics (Zubaran et al, 1997; Filley & Kelly, 1993).
    b) One study examined a population-based sample of 554 subjects (from a prospective Finnish twin cohort study; 65 years or older at the time of demential assessment) to determine the long-term effects of midlife alcohol use on cognitive performance later in life. At the end of the follow-up period (25 years), 103 individuals had developed dementia. Midlife alcohol binge drinking (5 bottles of beer or a bottle of wine) at least once per month was associated with a relative risk of 3.2 (95% CI, 1.2 to 8.6) for dementia. Passing out following excessive alcohol use at least twice during the previous year was associated with a relative risk of 10.5 (2.4 to 46) for dementia. The authors concluded that binge drinking in midlife is associated with an increased risk of dementia and cognitive decline later in life (Jarvenpaa et al, 2005).
    K) AMNESIA
    1) WITH POISONING/EXPOSURE
    a) Blackout spells may occur, particularly with frequent ingestion of large volumes of ethanol. These amnesia episodes affect specific memories and are not associated with loss of consciousness. The person is unable to recall events of several hours and may not appear intoxicated. Patients do not have long-term memory impairment of immediate recall (Jennison & Johnson, 1994; Myerson & Rubin, 1992).
    b) Blackouts can be eliminated if ethanol intake is significantly reduced (Jennison & Johnson, 1994).
    c) Memory in alcoholics may improve with prolonged abstinence. Abstinence of an average of 7 years was associated with normal learning and memory scores; deficits were present in alcoholics who had abstained for only an average of 30 days or 2 years (Reed et al, 1982).
    L) PSYCHOTIC DISORDER
    1) WITH POISONING/EXPOSURE
    a) Auditory and/or visual hallucinations may occur in chronic ethanol abusers (Tsuang et al, 1994).
    M) IDIOSYNCRATIC INTOXICATION
    1) WITH POISONING/EXPOSURE
    a) Although the subject of some professional dispute, some data indicate that a small number of people may be exceptionally sensitive to ethanol, exhibiting combative and irrational behavior after ingesting nonintoxicating amounts. This has been termed pathological intoxication or ethanol idiosyncratic intoxication (Perr, 1986).
    N) FATIGUE
    1) WITH POISONING/EXPOSURE
    a) CNS EFFECTS OF VAPOR INHALATION: Dose-related (1000 to 5000 parts per million) effects include headache, fatigue, and stupor (American Conference of Governmental Industrial Hygienists, 2010).
    3.7.3) ANIMAL EFFECTS
    A) ANIMAL STUDIES
    1) NEUROPATHY
    a) RATS: Long-term dietary ethanol resulted in loss of hippocampal neurons in the rat brain (Paula-Barbosa et al, 1993).

Gastrointestinal

    3.8.2) CLINICAL EFFECTS
    A) GASTRITIS
    1) WITH POISONING/EXPOSURE
    a) Nausea, vomiting, abdominal pain, and gastrointestinal bleeding often occur (Fields et al, 1994; Watson et al, 1974).
    b) HAND SANITIZERS: In a retrospective review of 647 pediatric (age range, 1 month to 5 years; mean age, 1.89 years) exposures to ethanol-based hand sanitizers (599 ingestions, 105 dermal, 29 ocular, and 2 inhalational), oral irritation and vomiting were reported in 2 and 5 patients, respectively (Mrvos & Krenzelok, 2009).
    B) DIARRHEA
    1) WITH POISONING/EXPOSURE
    a) Diarrhea has been reported in children following dermal exposure (Gimenez et al, 1968) and in adults who had normal pancreatic function (Fields et al, 1994; Estruch et al, 1993).
    C) PANCREATITIS
    1) WITH POISONING/EXPOSURE
    a) CHRONIC ethanol abuse is a common cause of acute and chronic pancreatitis with both endocrine and exocrine insufficiency (Singh & Simsek, 1990).
    b) Acute pancreatitis or pancreatic fibrosis can result from chronic alcohol consumption (Edwards & Hoyt, 1973; Jenkins et al, 1971). Symptoms include nausea, vomiting, and abdominal pain, often radiating to the back (Myerson & Rubin, 1992).
    D) COLITIS
    1) WITH POISONING/EXPOSURE
    a) Inflammation and hemorrhage developed in a case following a 140 mL enema containing 95% ethanol (Triantafillidis et al, 1994).
    E) ESOPHAGEAL VARICES
    1) WITH POISONING/EXPOSURE
    a) Esophageal varices that may cause fatal hemorrhage have been reported in alcoholics with cirrhosis and portal hypertension (Kartsonis et al, 1986; Dagradi, 1973).
    F) ULCERATIVE STOMATITIS
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: Oral mucosal ulcerations were reported following misuse of an undiluted OTC mouthwash containing 70% ethanol. An intraoral exam showed an erythematous oral mucosa with necrotic areas and linear clefts resembling bullae. The patient recovered following topical application of a mixture containing diphenhydramine, Maalox(R), and 2% viscous lidocaine (Moghadam et al, 1999).

Hepatic

    3.9.2) CLINICAL EFFECTS
    A) TOXIC HEPATITIS
    1) WITH POISONING/EXPOSURE
    a) ACUTE EFFECTS: Ethanol can cause acute hepatitis, characterized by an enlarged and tender liver (Myerson & Rubin, 1992).
    1) Acute ethanol ingestion has been associated with a significant increase in the rate of acetylation (Olsen & Morlan, 1978).
    B) CIRRHOSIS OF LIVER
    1) WITH POISONING/EXPOSURE
    a) CHRONIC EFFECTS: Chronic, excessive ethanol use can cause hepatomegaly, hepatic fibrosis, steatosis, necrosis, cirrhosis, chronic hepatocellular failure, elevated serum aminotransferase, and elevated gamma-glutamyltransferase (Estruch et al, 1993; Flannery et al, 1991; Richardson et al, 1991). Patients with cirrhosis may be asymptomatic (Estruch et al, 1993).
    1) Women may be more susceptible than men to the development of ethanol-induced cirrhosis, and at lower doses. The progression to more severe liver damage appears to be accelerated in women as well (Lieber & DeCarli, 1991).
    2) Patients with iron overload may be more susceptible to ethanol-induced hepatotoxicity than patients with normal iron levels (Stal & Hultcrantz, 1993).
    3) CASE REPORT: Ascites, increased liver function test results, icterus, and hepatic cirrhosis were present in an adult with a 20-year history of ethanol abuse who had over the past 3 years consumed daily the contents of a spray disinfectant, resulting in an ethanol dose of about 170 g/day (Morse & Thomas, 1984).
    b) ACETAMINOPHEN: Hepatotoxicity was associated with recent ethanol use in 8 out of 8 cases (7 out of 8 were chronic ethanol users) who had ingested more than 10 g/day acetaminophen, doses above the recommended acetaminophen limit of 4 g/day (Whitcomb & Block, 1994). Five out of 8 cases were also fasting, a risk factor associated with significant hepatotoxicity after acetaminophen doses, which generally cause minimal hepatotoxicity (4 to 10 g/day acetaminophen).
    1) Significant hepatotoxicity in 2 alcoholics following acetaminophen doses that are generally nontoxic have also been reported (Kartsonis et al, 1986a).
    c) Chronic ethanol use interferes with storage of glycogen and causes depletion of vitamin A (Lieber & DeCarli, 1991; Dukes, 1981).
    3.9.3) ANIMAL EFFECTS
    A) ANIMAL STUDIES
    1) HEPATOCELLULAR DAMAGE
    a) Cocaine-induced hepatotoxicity was increased by chronic ethanol treatment in a murine model (Odeleye et al, 1993).
    b) ACUTE ethanol administration inhibited hepatic metabolism (biotransformation) of pentobarbital in rats and meprobamate in rat liver slices, and inhibited hepatic aniline hydroxylase, pentobarbital hydroxylase, aminopyrine, and ethylmorphine demethylase activities in vitro (Rubin et al, 1970).
    c) CHRONIC ethanol exposure potentiated carbon tetrachloride-associated hepatotoxicity, effects on hepatic drug metabolizing enzymes (decreased total cytochrome P450 and aminopyrine N-demethylase activities) in vivo, and increased biotransformation of carbon tetrachloride in vitro (Hasumura et al, 1974).

Genitourinary

    3.10.2) CLINICAL EFFECTS
    A) ACUTE RENAL FAILURE SYNDROME
    1) WITH POISONING/EXPOSURE
    a) Two patients developed acute renal failure associated with the combination of "binge" drinking and chronic ingestion of NSAIDS (Calvino et al, 2013).
    1) The first patient was a 33-year-old man who presented with a 2-day history of nausea, flank pain bilaterally, and lumbar pain. Interview of the patient revealed a 7-day history of oxicam therapy for treatment of arthritis of the knee and heavy drinking 1 week prior to presentation. Laboratory data indicated an elevated serum creatinine concentration (4.4 mg/dL) , with normal electrolyte and creatine kinase concentrations. With supportive therapy, the patient recovered and was discharged 15 days later (Calvino et al, 2013).
    2) The second patient was a 25-year-old man who presented to the emergency department following ingestion of greater than 5 heavy drinks and an unknown amount of ibuprofen and benzodiazepines in a suicide attempt. Laboratory data, including renal function, indicated normal values. With supportive care, the patient was discharged 2 days later following psychiatric assessment. Four days after discharge, the patient presented with bilateral acute flank pain. The patient admitted to ingesting 2 ibuprofen tablets the day before to treat a headache, although he denied ingestion of any other drugs or ethanol. Laboratory data revealed elevated BUN and creatinine concentrations (28.9 and 2.9 mg/dL, respectively), indicating acute renal failure. With supportive therapy, his flank pain disappeared and laboratory values normalized, and he was discharged three days later (Calvino et al, 2013).

Acid-Base

    3.11.2) CLINICAL EFFECTS
    A) LACTIC ACIDOSIS
    1) WITH POISONING/EXPOSURE
    a) Lactic acidosis has been reported in children (Leung, 1986; Selbst et al, 1985) and in alcoholics (Lien & Mader, 1999; Braden et al, 1993) after acute ingestions.
    b) Acute lactic acidosis can produce a number of nonspecific effects, including fatigue, confusion, stupor, respiratory collapse, shock, and coma (Myerson & Rubin, 1992).
    c) Lactic acidosis occurred in an alcoholic 10 hours after discontinuing ethanol (Flannery et al, 1991).
    d) CASE REPORT (CHILD): A 3-year-old child with cerebral palsy was found cold, pale, and unresponsive (Glasgow Coma score of 3) by emergency personnel and presented to the emergency department with hypotension (56/25 mmHg), tachycardia (130 beats/min) and hypothermia (33.9 degrees C), with pinpoint pupils. Arterial blood gas analysis revealed lactic acidosis (pH 7.15, pCO2 43, HCO3 14.3 mmol/L, lactate 5.3 mmol/L). Serum ethanol concentration was 958 mg/dL. Despite supportive care, the patient's hypotension (65/48 mmHg) and acidosis persisted. Hemodialysis was performed approximately 5 hours post-presentation for a period of 4 hours. Immediately following hemodialysis, the patient's serum ethanol concentration decreased to 70 mg/dL. Her blood pressure stabilized, the acidosis resolved, and she became increasingly responsive (McGinnity de Laveaga & Caravati, 2015).
    e) CASE REPORT: A 59-year-old man with a history of type 2 diabetes mellitus, presented with agitation and lower back pain after ingesting ethanol in combination with a laminate floor cleaner. Prior to presentation, the patient had been abusing ethanol for several weeks and had not been taking his insulin and metformin during this period. His glucose level was 23.8 mM (reference range, 3.5 to 7.1 mM), blood gas analysis revealed severe metabolic acidosis with an elevated anion gap and a lactate level of 22 mM (reference range, 0.5 to 2.2 mM), and a urinalysis was positive for ketones, indicating diabetic ketoacidosis. At admission, his blood ethanol level was 1 mg/mL; however, it was estimated that his peak blood alcohol level 8 hours prior to presentation, following his reported ethanol and laminate floor cleaner ingestion, was at least 2.4 mg/mL. With supportive care, he gradually recovered with normalization of his blood glucose and lactate levels (Hendrikx et al, 2014).
    B) METABOLIC ACIDOSIS
    1) WITH POISONING/EXPOSURE
    a) A prospective study was conducted to determine the association between ethanol intoxication and the development of acidosis. The study enrolled 192 patients, of which 147 were classified as nonintoxicated and 45 were classified as ethanol-intoxicated, with a mean blood alcohol level (BAL) of 205 +/- 81 mg/dL. The results of this study showed that there was a statistically significant difference in the prevalence of metabolic acidosis in ethanol-intoxicated patients (42%) compared with the nonintoxicated group (1%). The ethanol-intoxicated group had a lower arterial base deficit (BD) (mean difference: 2.19 mmol/L; 95% CI, 1.37 to 3.01 mmol/L) and a higher lactate level (LAC) (mean difference: 0.69 mmol/L; 95% CI, 0.11 to 1.27 mmol/L). However, there did not appear to be any significant correlation between the BD or LAC and the serum ethanol level in the ethanol-intoxicated patients, indicating that the degree of acidosis cannot be predicted by the serum ethanol level; thus severe metabolic or lactic acidosis cannot be completely attributed to ethanol consumption (Zehtabchi et al, 2005).
    b) CASE REPORT (INFANT): A 15-day-old infant presented to the emergency department with flushed skin, hypoactive, and somnolent approximately 3 hours after drinking formula milk. At presentation, the patient was hypotensive (55/29 mmHg) and tachycardic (214 beats/min), and arterial blood gases indicated metabolic acidosis (pH 7.186, HCO3 16.7 mmol/L, pCO2 45.8 mmHg, base excess -10.1 mmol/L). The patient's serum ethanol concentration, obtained at admission, was 43 mg/dL. With supportive care, including IV fluid administration, the patient gradually recovered within 12 hours post-admission. An interview with the parents, 24 hours post-admission, revealed that the infant's formula had been inadvertently mixed with 10 mL of sake (Japanese wine prepared from fermented rice). Follow up of the patient over the next 12 months showed no evidence of psychomotor sequelae (Zaitsu et al, 2013).
    C) KETOSIS
    1) WITH POISONING/EXPOSURE
    a) Ketoacidosis may be present, particularly following an ethanol binge in patients with a history of chronic ethanol abuse and malnutrition (Larremore, 1984). An anion-gap metabolic acidosis, ketonemia, or ketonuria and normal, elevated, or low serum glucose may be present (Wade & Gammon, 1999; Braden et al, 1993; Edwards & Hoyt, 1973; Jenkins et al, 1971).
    b) CASE REPORT: A 59-year-old man with a history of type 2 diabetes mellitus, presented with agitation and lower back pain after ingesting ethanol in combination with a laminate floor cleaner. Prior to presentation, the patient had been abusing ethanol for several weeks and had not been taking his insulin and metformin during this period. His glucose level was 23.8 mM (reference range, 3.5 to 7.1 mM), blood gas analysis revealed severe metabolic acidosis with an elevated anion gap and a lactate level of 22 mM (reference range, 0.5 to 2.2 mM), and a urinalysis was positive for ketones, indicating diabetic ketoacidosis. At admission, his blood ethanol level was 1 mg/mL; however, it was estimated that his peak blood alcohol level 8 hours prior to presentation, following his reported ethanol and laminate floor cleaner ingestion, was at least 2.4 mg/mL. With supportive care, he gradually recovered with normalization of his blood glucose and lactate levels (Hendrikx et al, 2014).

Hematologic

    3.13.2) CLINICAL EFFECTS
    A) ANEMIA
    1) WITH POISONING/EXPOSURE
    a) Anemia is associated with chronic, excessive ethanol use (Nakao et al, 1991; Bottiger, 1973; Edwards & Hoyt, 1973; Bauer & Strass, 1972).
    B) THROMBOCYTOPENIC DISORDER
    1) WITH POISONING/EXPOSURE
    a) Transient thrombocytopenia is common in alcoholics (Nakao et al, 1991; Bottiger, 1973).
    C) PANCYTOPENIA
    1) WITH POISONING/EXPOSURE
    a) Severe pancytopenia and bone marrow hypoplasia developed 1 month after an adult with a 7-year history of excessive ethanol use greatly increased his daily ethanol intake. Abstinence resulted in improved hematopoiesis, but thrombocytopenia and bone marrow hypoplasia developed with resumed ethanol use (Nakao et al, 1991).
    D) LEUKOPENIA
    1) WITH POISONING/EXPOSURE
    a) Mild leukopenia is common in chronic alcoholics (Osborn, 1994).
    E) BLOOD COAGULATION PATHWAY FINDING
    1) WITH POISONING/EXPOSURE
    a) Prolonged PT, PTT, and INR are common in patients with significant alcoholic cirrhosis (Osborn, 1994).
    3.13.3) ANIMAL EFFECTS
    A) ANIMAL STUDIES
    1) BLOOD DYSCRASIA
    a) RATS: Significant decreases in red blood cell count, white blood cell count, hemoglobin, and hematocrit, but significant increases in mean cell volume, erythrocyte sedimentation rate, and neutrophil count occurred in rats after chronic, high-dose ethanol ingestion (Kanwar & Tikoo, 1992).

Dermatologic

    3.14.2) CLINICAL EFFECTS
    A) SYSTEMIC DISEASE
    1) WITH POISONING/EXPOSURE
    a) PERCUTANEOUS ABSORPTION: Pediatric cases indicate that ethanol can be absorbed through the skin, particularly if the skin is damaged, resulting in significant toxicity (Da Dalt et al, 1991; Puschel, 1981; Moss, 1970; Gimenez et al, 1968).
    B) FLUSHING
    1) WITH POISONING/EXPOSURE
    a) Facial flushing may occur. Ingestion of ethanol and exposure to solvents (eg, trichloroethylene, carbon disulfide, formamide) can result in flushing of the face, arms, and chest; this is sometimes called degreaser's flush (Cox & Mustchin, 1991).
    b) CASE REPORT (INFANT): A 15-day-old infant presented to the emergency department with flushed skin over her entire body, hypoactive, and somnolent approximately 3 hours after drinking formula milk. At presentation, the patient was hypotensive (55/29 mmHg) and tachycardic (214 beats/min), and arterial blood gases indicated metabolic acidosis (pH 7.186, HCO3 16.7 mmol/L, pCO2 45.8 mmHg, base excess -10.1 mmol/L). The patient's serum ethanol concentration, obtained at admission, was 43 mg/dL. With supportive care, including IV fluid administration, the patient gradually recovered within 12 hours post-admission. An interview with the parents, 24 hours post-admission revealed, that the infant's formula had been inadvertently mixed with 10 mL of sake (Japanese wine prepared from fermented rice). Follow up of the patient over the next 12 months showed no evidence of psychomotor sequelae (Zaitsu et al, 2013).
    C) DERMATITIS
    1) WITH POISONING/EXPOSURE
    a) Ethanol and other alcohols can cause drying and irritation of the skin with repeated or prolonged exposure as a result of skin defatting (Ophaswongse & Maibach, 1994).
    D) CONTACT DERMATITIS
    1) WITH POISONING/EXPOSURE
    a) Allergic contact urticaria has been reported as a result of ethanol exposure. Impurities, decomposition products, or metabolites may be responsible for the sensitization (Ophaswongse & Maibach, 1994).
    E) ERYTHEMA
    1) WITH POISONING/EXPOSURE
    a) HAND SANITIZERS: In a retrospective review of 647 pediatric (age range, 1 month to 5 years; mean age, 1.89 years) exposures to ethanol-based hand sanitizers (599 ingestions, 105 dermal, 29 ocular, and 2 inhalational), dermal erythema developed in 4 patients (Mrvos & Krenzelok, 2009).

Musculoskeletal

    3.15.2) CLINICAL EFFECTS
    A) ALCOHOL MYOPATHY
    1) WITH POISONING/EXPOSURE
    a) Acute and chronic skeletal myopathies have been recorded in ethanol abusers (Estruch et al, 1993; Myerson & Rubin, 1992).
    b) Muscle weakness, with or without pain, myoglobinuria, or hypokalemia can occur in chronic alcoholics after large ethanol ingestions (Estruch et al, 1993; Martin et al, 1971).
    c) BRACHIAL PLEXOPATHY: Brachial plexopathy, characterized by profound weakness in the affected limbs, was associated with ethanol intoxication in 2 alcoholic patients and was thought to be the result of either stretch or compression of the plexus while intoxicated. The brachial plexopathy was also associated with rhabdomyolysis in one of the patients, due to either direct ethanol myotoxicity or prolonged immobilization on a hard surface, or a combination of both (Silber et al, 1999). Both patients recovered within 4 months after presentation.
    B) DISORDER OF BONE
    1) WITH POISONING/EXPOSURE
    a) Low bone density and higher serum calcium levels, suggestive of loss of calcium from bone into the blood, were seen in a group of 26 chronic heavy drinkers in the absence of liver disease (Diez et al, 1994).
    C) RHABDOMYOLYSIS
    1) WITH POISONING/EXPOSURE
    a) Rhabdomyolysis developed following acute ethanol use in a person who had a history of frequent alcoholic binges (Pittman & Decker, 1971) and in an abstinent alcoholic who had pneumonia and sepsis (Ifudu & Markel, 1992).

Endocrine

    3.16.2) CLINICAL EFFECTS
    A) HYPOGLYCEMIA
    1) WITH POISONING/EXPOSURE
    a) Hypoglycemia, which can result in seizures and coma, is a serious complication of acute alcoholic intoxication, especially in children (Hornfeldt, 1992; Selbst et al, 1985; Ricci & Hoffman, 1982; Cummins, 1961). Hypoglycemia has occasionally been reported in alcoholics (Kallas & Sellers, 1975; Field et al, 1963).
    1) Ethanol-induced hypoglycemia appears to be an uncommon effect in adults. There was no statistically significant difference found in the incidence of hypoglycemia between intoxicated (blood ethanol greater than 0.1% ) and nonintoxicated patients. Ethanol level and serum electrolytes did not correlate with ethanol-induced hypoglycemia. An increased anion gap positively correlated with hypoglycemia (Sporer et al, 1992).
    2) CASE REPORT: An 18-year-old man, arrested for theft, was agitated, disoriented, clammy, and sweating. The arresting officer, suspecting drug intoxication, requested a forensic medical assessment. Pupils and blood pressure were normal, but his pulse rate was slightly increased (95 beats per minute), and his blood glucose was 2 mmol/L. The individual stated that he had ingested an entire bottle of brandy approximately 4 hours prior to arrest; however, alcohol could not be detected on his breath. He also stated that he had not eaten all day. After receiving sugary drinks, the individual became fully oriented, and his blood glucose increased to 5 mmol/L. His hypoglycemia was felt to be induced by alcohol intoxication and prolonged fasting (Gregory, 2003).
    b) PEDIATRIC CASE SERIES: In one series of 27 children who had acutely ingested ethanol, 6 (22%) developed a blood sugar less than 40 mg/dL (2.2 mmol/L), and 1 had a seizure (Leung, 1986).
    c) PEDIATRIC CASE SERIES: In another series of 109 cases of pediatric mouthwash ingestion, hypoglycemia was documented in 2 of 59, with adequate follow-up (Henretig & Vuignier, 1989).
    d) CASE REPORT: Fatality secondary to hypoglycemia was reported in a 4 -year old who ingested an estimated 12 ounces of a mouthwash containing 10% ethanol (Selbst et al, 1985).
    B) HYPERGLYCEMIA
    1) WITH POISONING/EXPOSURE
    a) Hyperglycemia has been reported in a case of ethanol withdrawal (Flannery et al, 1991) and in alcoholics, many of whom were acidotic (Braden et al, 1993; Lieber & DeCarli, 1991; Kallas & Sellers, 1975; Jenkins et al, 1971).
    b) CASE REPORT (INFANT): A 9-week-old infant presented to the emergency department acting "strangely" and smelling of alcohol. Examination of the infant revealed decreased mental status and vital signs indicated an increased heart rate (160 beats/minute) and respirations (22 breaths/minute). Interview of the family revealed that the grandmother had inadvertently prepared the child's formula with 90 mL of vodka instead of water. The patient's blood glucose concentration, obtained by fingerstick at admission and at 1 hour and 3 hours postadmission, was 167 mg/dL, 160 mg/dL, and 98 mg/dL, respectively. His serum blood alcohol level, obtained at presentation, was 330 mg/dL. Three hours and 24 hours later, the blood alcohol level decreased to 0.27 mg/dL and less than 0.01 mg/dL, respectively. Following IV administration of 5% dextrose with normal saline (D5NS), the patient recovered and was discharged to home approximately 24 hours postadmission (Minera & Robinson, 2014).
    C) HYPERCORTISOLISM
    1) WITH POISONING/EXPOSURE
    a) PSEUDO-CUSHING SYNDROME: Four cases of alcoholics who presented with clinical and biochemical characteristics that suggested Cushing syndrome have been reported. Discontinuation of ethanol resulted in disappearance of the cushingoid manifestations (Rees et al, 1977).
    D) DECREASED HORMONAL ACTIVITY
    1) WITH POISONING/EXPOSURE
    a) HYPOTHALAMIC-PITUITARY-GONADAL HORMONES: Acute ethanol ingestion (1.3 g/kg) in 7 healthy, nonalcoholic men resulted in transiently increased plasma prolactin and decreased plasma testosterone, cortisol, and adrenocorticotropic hormone levels, with no significant effects on luteinizing hormone during the 180-minute postingestion monitoring period. Similar effects on prolactin and testosterone occurred with daily ethanol for 7 days; plasma measurements were only made for 60 minutes postingestion (Ida et al, 1992).
    b) Significant elevations of plasma cortisol have occurred in men during ethanol withdrawal (Adinoff et al, 1991).

Immunologic

    3.19.2) CLINICAL EFFECTS
    A) ANAPHYLACTOID REACTION
    1) WITH POISONING/EXPOSURE
    a) An anaphylactic reaction due to an immediate-type allergy to acetic acid, the main metabolite of ethanol, has been reported in a 22-year-old woman following the ingestion of as little as 1 mL of ethanol (Przybilla & Ring, 1983). Wine, but not other ethanol-containing beverages, resulted in anaphylaxis in another case, indicating that something in wine other than ethanol was the likely causative agent (Clayton & Busse, 1980).
    B) ACUTE ALLERGIC REACTION
    1) WITH POISONING/EXPOSURE
    a) A late-phase allergic reaction (IgE-mediated), characterized by pruritic erythema and edema, was reported in a woman after ingesting ethanol or using dermal preparations containing ethanol (Kanzaki & Hori, 1991).
    b) Allergic contact urticaria has been reported as a result of ethanol exposure. Impurities, decomposition products, or metabolites may be responsible for the sensitization (Ophaswongse & Maibach, 1994a). Urticaria associated with ethanol use, but possibly due to trace quinine, has also been reported (Ting, 1992).
    3.19.3) ANIMAL EFFECTS
    A) ANIMAL STUDIES
    1) IMMUNE SYSTEM DISORDER
    a) IMMUNOSUPPRESSION/IMMUNOSTIMULATION: Variable results concerning ethanol-associated immunologic effects have been reported in humans and animals. Genetic predisposition may contribute to individual susceptibility or resistance to the effects of ethanol, based on animal studies that demonstrated strain-related differences in ethanol-associated immunologic effects (Razani-Boroujerdi et al, 1994).
    b) Acute versus chronic administration of ethanol also produces different immunologic responses in animals. Decreased circulating cytokines have resulted from acute ethanol, but increased or unaltered cytokine levels were associated with chronic ethanol administration (Marway et al, 1994).
    c) Increased susceptibility to Listeria monocytogenes and decreased splenic expression of cytokine (IL-2) genes have been reported in rats fed ethanol for 7 days. Ethanol treatment did not significantly affect clearance of L monocytogenes and did not alter inflammatory cell recruitment to the site of infection (Jerrells et al, 1992).

Reproductive

    3.20.1) SUMMARY
    A) Women who consume ethanol during pregnancy may give birth to a child with Fetal Alcohol Syndrome. No safe consumption level is known.
    3.20.2) TERATOGENICITY
    A) CONGENITAL ANOMALY
    1) FETAL ALCOHOL SYNDROME (FAS): This syndrome is characterized by facial dysmorphia and other congenital abnormalities, prenatal growth retardation, and neurodevelopmental abnormalities, including developmental delay or mental retardation, in some children of mothers who abused ethanol during pregnancy. Attention deficits, short-term memory, sequential processing deficits, and behavioral problems have been associated with FAS in school-aged children. Characteristic physical features are evident only in those children with the highest prenatal ethanol exposures.
    a) DOSE: It is unclear what dose of ethanol is necessary to cause adverse effects in an individual; however, FAS has been documented in infants of mothers who consume large amounts of alcohol throughout their pregnancy (80 mL daily).
    b) INCIDENCE: FAS has been reported to occur at a frequency of 4 to 7 per 1000 live births, or, more conservatively, at 0.33 per 1000 live births in the Western world. According to another estimate, approximately 1 of 3 children of alcoholic mothers will have FAS.
    c) It is unlikely that a single acute overdose would be responsible for these effects, but "binge" drinking early in pregnancy and chronic heavy abuse throughout pregnancy have been associated with the syndrome.
    d) The question of whether "social drinking" causes FAS is unanswered at this time; hence, a safe level of exposure cannot be determined. The actual mechanism(s) of FAS is not well understood, with the offspring of only a small percentage of alcoholic women being affected. However, the association with ethanol is clear.
    e) (Streissguth et al, 1994a; Filley & Kelly, 1993; Abel & Sokol, 1991; Boyd et al, 1991; Coles et al, 1991; Eliason & Williams, 1990; Galea & Goel, 1989; Hill et al, 1989; Abel, 1984; Rosett, 1983; Little & Streissguth, 1981; Jones & Smith, 1973).
    f) Black inner-city children had deficits in Bayley Scale performance, regardless of the trimester in which the mother drank ethanol. Incidence of very poor performance was twice as high in the group whose mothers drank at least 0.5 ounces (oz) of ethanol per day. These developmental defects were seen with maternal alcohol ingestions LESS THAN THOSE ASSOCIATED WITH FETAL ALCOHOL SYNDROME (Jacobson et al, 1993).
    g) Decreased psychomotor development at age 4.5 years, measured as a decrease of 7 points on the general cognitive index of the McCarthy Scales, was associated with maternal consumption of 1.5 oz or more (approximately 3 drinks per day) during pregnancy, in a group of 155 French children. This level of consumption is well below that required for development of fetal alcohol syndrome (Larroque et al, 1995).
    h) Fetal alcohol syndrome is not confined to infancy and childhood. Although the abnormal physical appearance seems to lessen with age, neurodevelopmental deficits continue well into adolescence and adulthood. In one study, the average IQ of adolescents and adults born with fetal alcohol syndrome was considerably lower than average, and maladaptive behaviors were common (Streissguth et al, 1991).
    i) The dose-response relationships between maternal alcohol consumption and risks for various fetal effects are not well defined. Although heavy ethanol drinking is clearly a risk factor (Ouellette et al, 1977), even moderate drinking (approximately 1 oz per day) has also been associated with fetal alcohol syndrome (Ernhart, 1985; Hanson, 1978) .
    j) Low birth weight has been linked in a dose-related manner with maternal alcohol consumption in the National Natality Survey, even with moderate alcohol ingestion (1 to 13 drinks per week) (Virji, 1991).
    1) Shorter gestational age has been correlated with consumption of at least 120 g of ethanol per week, and intake in the range of 100 to 110 g per week has been associated with smaller head size (Sulaiman et al, 1988).
    2) Children exposed prenatally to alcohol had significantly smaller head circumferences and diminished weights, heights, and palpebral fissure widths at the age of 6 years (Day et al, 1994).
    3) The magnitude of these effects has been rather small, and the actual clinical relevance of these effects is unclear (Madlom, 1991).
    2) MISCELLANEOUS PHYSICAL DEFECTS: Seventy-one percent of newborns born to heavy ethanol users were rated as abnormal, compared with a rating of 35% in the abstinent/rare ethanol use group. Congenital anomalies were present in 32 percent of infants in the high ethanol use group, as compared with 9% or 14% in the abstinent/rare and moderate ethanol use groups, respectively (Ouellette et al, 1977). Tobacco smoking and use of other drugs were possible confounding variables associated with ethanol use.
    3) ANIMAL STUDIES
    a) Ethanol has produced apoptotic neurodegeneration in the developing rat forebrain, which may explain the reduced brain mass associated with human fetal alcohol syndrome (Ikonomidou et al, 2000). Exposure to ethanol at a concentration of 280 to 300 mg/dL leads to increased production of chorionic gonadotrophic hormone in human placental trophoblasts in culture (Fisher, 1993).
    B) CLEFT LIP
    1) In a review of birth defects involving the cranial neural crest in infants born in Boston, Philadelphia, Toronto, and 5 counties in Iowa from 1983 through 1987, the relative risk for CLEFT LIP was increased 3-fold in children of women who ingested at least 5 alcoholic drinks per day during the first trimester (Werler et al, 1991).
    2) Cleft palate has occurred in 8.9% of fetal alcohol syndrome cases reported in the literature, as well as spina bifida in 1.8% , ventricular and atrial septal defects in 8.5%, tetralogy of Fallot in 0.9%, pulmonary stenosis in 2.7%, and patent ductus arteriosus in 11 cases (Abel & Sokol, 1991).
    3) ANIMAL STUDIES
    a) Ethanol given at levels up to 6.4% of the diet by volume potentiated the activity of 80,000 International Units of vitamin A in reducing fetal size and inducing cleft palate, supernumerary ribs, and misshapen zygomatic arch in fetal rats (Whitby et al, 1994).
    b) Aspirin decreased the birth defects in rats caused by ethanol, without significantly altering the mothers' blood alcohol levels (Randall et al, 1991). Exposure to 500 mg% ethanol in mouse whole embryo culture produced superoxide anions, increased levels of lipid peroxidation and cell death, and a 63% incidence of failure to close the anterior neural tube. Diminishment of these effects by superoxide dismutase indicates a free-radical mechanism for ethanol's effects (Kotch et al, 1995).
    C) SKELETAL MALFORMATION
    1) Increased risk for limb defects with heavy prenatal alcohol exposure has been suggested in a study of 1,213,913 consecutive liveborn infants in British Columbia from 1952 to 1984. Six of 8 cases of limb defects were associated with heavy prenatal exposure to alcohol and involved a terminal transverse defect of the forearm or hand, mainly on the right side (Froster & Baird, 1992).
    2) There were 659 total cases of limb defects; only 1% of these cases were associated with heavy prenatal alcohol exposure. However, the proportion of terminal limb defects was much greater (75%) in cases associated with heavy maternal alcohol drinking than in cases in which ethanol was evidently not a factor (33%) (Froster & Baird, 1992).
    D) GROWTH RETARDED
    1) Decreased head circumference and increased alcohol dysmorphia scores were present in children (mean age 5 years, 10 months) whose mothers had consumed ethanol at a mean dose of 11.80 ounces absolute alcohol per week throughout pregnancy (Coles et al, 1991).
    2) Decreased head circumference, birth weight, and birth length were associated with high maternal ethanol use during pregnancy. Potential confounding variables were the use of cigarettes and other drugs by heavy ethanol users (Ouellette et al, 1977).
    3) Symmetric growth retardation in the neonates was associated with heavy ethanol use during pregnancy, with confounding factors (eg, smoking, cocaine use) controlled. Cigarette smoking, cocaine, and/or opiate use also caused deficits in birth weight, length, and/or head circumference (Jacobson et al, 1994).
    4) Perfusion of human placental villous tissue with up to 200 mmol/L ethanol decreased nitric oxide availability, which may account for the growth restriction seen in ethanol-exposed fetuses (Kay et al, 2000).
    5) ANIMAL STUDIES
    a) Significantly decreased cranial dimensions, decreased mandibular growth, and decreased birth weight were produced in rats exposed in utero (gestational day 6 to 20) to ethanol. Maternal weight gain was significantly depressed by ethanol consumption (Edwards & Dow-Edwards, 1991).
    b) There is extensive literature on the reproductive effects of ethanol in laboratory animals. Typically, lower birth weights, retarded development, and structural malformations have been produced in many species when ethanol is given to the pregnant female. The spectrum of effects in the offspring is generally similar to that reported in humans (Heminki & Vineis, 1985). Ethanol is equally fetotoxic in experimental animals through inhalation or oral exposure (Shoemaker, 1981).
    c) In rats, reduction of birth weight is a sensitive indicator of ethanol exposure during gestation, even after adjustment for differences in caloric intake (Hannigan et al, 1993). Prenatal exposure to ethanol produced smaller numbers of neurons in the principal sensory nucleus of the trigeminal nerve in rats; early postnatal exposure produced less of a reduction (Miller, 1995).
    d) In rats, prenatal exposure to ethanol depressed the postnatal surge of testosterone, which is required for normal sexual development in males (McGivern et al, 1993).
    E) UROGENITAL MALFORMATION
    1) Genitourinary malformations have been reported with Fetal Alcohol Syndrome (Hill et al, 1989), but a small study found no significant renal abnormalities in association with prenatal ethanol exposure (Taylor et al, 1994).
    2) ANIMAL STUDIES
    a) A significantly increased incidence of hydronephrosis and hydroureter was reported in mouse fetuses born to dams exposed to ethanol once on gestational day 10 (Boggan et al, 1989).
    F) NEOPLASM
    1) NEUROBLASTOMA: Features consistent with Fetal Alcohol Syndrome, neuroblastoma, and chromosomal and developmental abnormalities were reported in a 28-month-old child born at term to a 34-year-old diabetic mother with a history of chronic ethanol use before and during pregnancy (Battisti et al, 1993). The sole contribution of ethanol to the reported defects cannot be determined.
    G) PERSONALITY DISORDER
    1) BEHAVIORAL/ATTENTION/LEARNING DEFICITS: High levels of prenatal alcohol exposure are associated with an increased risk for intellectual functioning deficits and may occur in children who do not have all of the physical features and growth deficits required for a diagnosis of fetal alcohol syndrome (Mattson et al, 1997).
    2) Attention/memory deficits in 14-year-old children were related in a dose-dependent fashion to ethanol use during pregnancy (Streissguth et al, 1994).
    3) Five-year-olds of mothers who continued to drink ethanol during pregnancy had more behavioral, learning, mood, and attention deficits, based on ratings by teachers and examiner testing of attention; however, these effects were not significant when the data were controlled for current ethanol use by the caregiver (Brown et al, 1991).
    4) Significantly lower scores on some tests of intellectual function were associated with maternal ethanol consumption throughout pregnancy (mean intake of 11.80 ounces absolute alcohol per week) or with maternal ethanol consumption only during early pregnancy, even when the confounding effects of current ethanol use by the caregiver were controlled (Coles et al, 1991).
    5) Another study failed to find any significant effect of prenatal ethanol exposure on attention in 4-year-old children (Boyd et al, 1991).
    6) Decreased cognitive scores in children (mean age 5 years, 10 months) were associated with maternal ethanol consumption during pregnancy that was ceased in the second trimester but resumed postpartum, or with maternal ethanol consumption throughout pregnancy. These effects were present even when the current ethanol use by the caregiver was controlled (Coles et al, 1991).
    7) One study reported no significant effect of maternal ethanol use during pregnancy on cognitive development in children (without Fetal Alcohol Syndrome) during the first 5 years of life (Greene et al, 1991).
    8) Effects suggestive of slowed information processing and less complex elicited play in 6.5- to 13-month-old infants were associated with repeated moderate to high maternal ethanol use during pregnancy.
    a) Performance deficits were suggested to begin with the calculated ethanol dose of 1 ounce/day (2 drinks); the typical pattern of drinking was 4 to 5 drinks per day on a less than daily basis. Infrequent binge drinking (eg, 1 or 2 episodes) or current ethanol use by the caregiver did not appear to correlate positively with the information processing/play behavior effects (Jacobson et al, 1993).
    9) ANIMAL STUDIES
    a) Dose-related hyperactivity was seen in guinea pigs exposed prenatally to 3 to 5 g/kg/day ethanol, which persisted into adulthood (Catlin et al, 1993).
    b) Sexual orientation was altered in the male offspring of pregnant mice given oral doses of 2 or 4 g/kg ethanol twice per day during the final third of gestation: The males showed an increased preference for sexual partners of the same sex (Watabe & Endo, 1994). Whether this unusual finding has any relevance to human reproduction is unknown.
    H) LEUKEMIA
    1) Maternal drinking during pregnancy was associated with increased risk for acute myelogenous leukemia (AML) and lymphocytic leukemia in the offspring (odds ratios, 2.64 and 1.43, respectively). AML showed a dose-related effect. Paternal drinking was not a risk factor (Shu et al, 1996).
    I) PATENT DUCTUS ARTERIOSUS
    1) ANIMAL STUDIES
    a) Constriction of the ductus arteriosus was seen in fetal rats within 30 minutes of exposure of the dams to 20 mg/kg of ethanol on day 20 of gestation (Arishima et al, 1993).
    J) IMMUNE SYSTEM DISORDER
    1) ANIMAL STUDIES
    a) T-cell function in the offspring of Macaca nemestrina monkeys was depressed when the mothers received weekly oral doses of 1.8 g/kg ethanol during gestation, as measured by lower titers to tetanus toxoid after vaccination (Grossmann et al, 1993).
    K) NEURITIS
    1) ANIMAL STUDIES
    a) Ethanol produced nerve damage in dog pups when given orally to the pregnant females at the high dose of 500 mL per day throughout the pregnancy (HSDB , 2000). It also affected myelinization of the nerves in rats when present at 6.6% in the diet (Clayton & Clayton, 1982).
    L) ATOPIC DERMATITIS
    1) A study was conducted to determine the association between alcohol consumption during pregnancy and the development of atopic dermatitis (AD) in early infancy. A total of 24,341 mother-child pairs were observed prospectively. Information regarding maternal alcohol consumption was given during interviews conducted at 12 weeks gestation and 30 weeks gestation, and the diagnosis of AD was based on information obtained when the child was 18 months old. The results of the study showed that there is a direct correlation between the amount of maternal alcohol consumption during pregnancy and development of AD in early infancy (the first 2 months of life). The risk of AD increased significantly in high-risk children of mothers who consumed more than 4 drinks/week at 30 weeks gestation. High-risk children were defined as having 2 parents with allergic disease. The association between maternal alcohol consumption and the development of AD did not appear to extend beyond early infancy (children older than 2 months) (Linneberg et al, 2004).
    3.20.3) EFFECTS IN PREGNANCY
    A) STILLBIRTH
    1) Neonatal death resulted from excessive maternal treatment with ethanol in order to prevent premature labor in the 32nd week of an uncomplicated pregnancy. A severely depressed infant was delivered with no spontaneous respirations (1 min Apgar 2; 5 min Apgar 3). Hypothermia, hypoxia, metabolic acidosis, and progressive bradycardia preceded death of the neonate, despite substantial medical intervention (Jung et al, 1980).
    a) The mother had been prescribed vodka 30 mL orally 3 times/day for 2 days, and then 30 mL vodka orally per hour for 12 hours until the woman was hospitalized. During hospitalization, 10 mg morphine and 160 g ethanol were infused IV until the mother became unresponsive and unconscious.
    b) Blood ethanol levels postdelivery were as high as 715 mg/dL in the infant and 473 mg/dL in the mother; the therapeutic ethanol blood levels for prevention of premature delivery were reported as 90 to 160 mg/dL.
    2) ANIMAL STUDIES
    a) Ethanol may have subtle reproductive effects in experimental animals at low doses. Fetuses from pregnant mice maintained at a blood ethanol concentration of 0.03 mg/mL had increased prenatal mortality but no overt malformations (Ukita et al, 1993).
    B) ALTERED HORMONE LEVEL
    1) ANIMAL STUDIES
    a) In rats, prenatal exposure to ethanol depressed the postnatal surge of testosterone, which is required for normal sexual development in males (McGivern et al, 1993).
    C) DRUG INTERACTION
    1) ANIMAL STUDIES
    a) Ethanol has also been reported to interact with other chemicals to affect reproduction in experimental animals. It was synergistic with marijuana in producing fetotoxicity in mice and rats (Abel, 1985). Ethanol interacted with ethoxyethanol, a common industrial solvent, to produce behavioral and neurochemical effects in the offspring of rats (Nelson, 1984). It interacted with xylene in producing embryotoxicity in rats but was not teratogenic (Ungvary, 1985).
    D) PREGNANCY CATEGORY
    ETHANOLD*
    [*Risk Factor X if used in large amounts or for prolonged periods.]
    Reference: Briggs et al, 1998.
    3.20.4) EFFECTS DURING BREAST-FEEDING
    A) HYPOTONIA
    1) HUMANS
    a) MOTOR DEVELOPMENT: One study found a significant, dose-related relationship between ethanol use by breastfeeding mothers and impaired motor development in the nursing infants, after controlling for more than 100 confounding variables. Breast milk ethanol concentrations were estimated and not directly measured(Little et al, 1989).
    2) ANIMAL STUDIES
    a) Delayed eye opening, decreased activity, ataxia, tremors, and slowness were reported in rat pups who nursed ethanol-fed dams. Ethanol was present in the blood of the rat pups (Hekmatpanah et al, 1994).
    B) MYELITIS
    1) ANIMAL STUDIES
    a) HISTOPATHOLOGY: Rat pups of dams fed ethanol had decreased brain weights at 15 days of age (but not at 30 or 60 days), reduced brain myelin formation, and degenerative changes in and delayed maturation of the Purkinje cells, as compared with controls (Hekmatpanah et al, 1994).
    C) BREAST MILK
    1) HUMANS
    a) Ethanol can be passed into the breast milk of nursing mothers (AMA, 1985). The amount of alcohol ingested by nursing infants was estimated to be only 0.5% to 3.3% of the maternal dose on a weight basis (1.6 to 9.9 mg/kg). Alcohol inhibits the breast milk letdown reflex mediated by oxytocin (Mennella & Beauchamp, 1992).
    3.20.5) FERTILITY
    A) FERTILITY DECREASED FEMALE
    1) A greater than 50% reduction in the probability of conception during a menstrual cycle was reported in women who consumed ethanol, indicating a negative association between ethanol consumption and fertility (Hakim et al, 1998).

Carcinogenicity

    3.21.1) IARC CATEGORY
    A) IARC Carcinogenicity Ratings for CAS64-17-5 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
    1) Not Listed
    3.21.2) SUMMARY/HUMAN
    A) Alcohol consumption has been associated with various cancers, including liver, esophageal, breast, prostate, and colorectal cancer.
    3.21.3) HUMAN STUDIES
    A) HEPATIC CARCINOMA
    1) Alcohol consumption has been associated with cancers of the esophagus and liver. Distilled liquors are more strongly linked with esophageal cancers than wine or beer (Tuyns et al, 1982; Hinds et al, 1980; Kon & Ikeda, 1979). This may be due to an irritative effect of alcohol on the digestive tract. Studies on the possible relationship between drinking and liver cancer have produced mixed results, some have shown an association (Tanaka et al, 1987; Austin et al, 1986; Hardell et al, 1984; Oshima et al, 1984; Kon & Ikeda, 1979); others have not (Trichopoulos et al, 1987; Lam et al, 1982). One Korean study found increased risk for esophageal, liver, and rectal cancers (Choi & Kahyo, 1991).
    B) BREAST CARCINOMA
    1) Dose-related increases in risk for breast cancer were seen in a group of 41,837 postmenopausal women who had also never used estrogen for non-contraceptive purposes (Gapstur et al, 1992). In a case-control study on 189 Greek women with ovarian cancer, consumption of more than 2 drinks per day was linked with increased risk (Polychronopoulou et al, 1993).
    2) Ethanol consumption of less than 60 g/day was associated with a linear increase in breast cancer incidence in a pooled analysis of cohort studies involving 322,647 women evaluated for up to 11 years (Smith-Warner et al, 1998).
    C) PULMONARY CARCINOMA
    1) There was an increase in upper respiratory cancer in workers manufacturing ethanol by the strong acid (sulfuric acid) process, which was thought to be due to diethyl sulfate (Lynch, 1979). A possible cocarcinogenic effect of ethanol cannot be excluded in this study, however (Soskolne, 1984). Ethanol has also been implicated in increasing the risk of cancer of the larynx, esophagus, mouth, and pharynx in smokers (Clayton & Clayton, 1982). Ethanol should be regarded as a possible human cocarcinogen.
    D) ESOPHAGEAL CARCINOMA
    1) Alcohol consumption has been associated with cancers of the esophagus and liver. Distilled liquors are more strongly linked with esophageal cancers than wine or beer (Tuyns et al, 1982; Hinds et al, 1980; Kon & Ikeda, 1979) . This may be due to an irritative effect of distilled alcohol on the digestive tract.
    E) PROSTATE CARCINOMA
    1) Alcohol use was linked with an incidence of prostate cancer in a dose-related fashion in a case-control study on 981 black and white men, compared with 1315 controls; significantly elevated risk was seen in those who had consumed 22 to 56 drinks per week (odds ratio [OR], 1.4) and 57 drinks per week (OR, 1.9). The risk was similar for blacks and whites and could not be explained by known confounders, including tobacco use (Hayes et al, 1996).
    F) COLORECTAL CARCINOMA
    1) A pooled analysis of 8 cohort studies was conducted, involving 489,979 men and women with no history of cancer, other than non-melanoma skin cancer, at baseline. Across all of the studies, 76% to 89% and 45% to 78% of men and women, respectively, consumed alcohol, with a mean alcohol intake, among men and women, of 12.1 g/day to 20.3 g/day and 3.5 g/day to 10.9 g/day, respectively (actual alcohol intake ranged from 0 g/day to more than 45 g/day). During the follow-up period of 6 to 16 years, a total of 4687 cases of colorectal cancer were documented. The overall pooled multivariate relative risk of colorectal cancer was 1.16 (confidence interval [CI], 0.99 to 1.36) following alcohol intake of 30 g/day to 44 g/day, and 1.41 (CI, 1.16 to 1.72) following alcohol intake of 45 g/day or greater (p less than 0.001). This finding suggests a positive association between colorectal cancer and alcohol consumption, mainly at high levels of alcohol consumption. There appeared to be no clear difference in relative risk among specific alcoholic beverages.
    a) There were several limitations of the analysis. Only 1 measure of alcohol consumption at baseline was taken, and the history of lifetime alcohol consumption was not documented; drinking patterns and duration of alcohol use were not examined, and there was no information on screening for colorectal cancer (Cho et al, 2004).
    3.21.4) ANIMAL STUDIES
    A) ROUTE OF EXPOSURE
    1) Ethanol was not carcinogenic when applied to the skin of mice but did increase the activity of other known carcinogens (Barauskaite S, 1983; Hills & Venable, 1982; Radike, 1977; Stenback, 1969). It has been called an equivocal tumorigenic agent when given orally (or rectally) to mice (HSDB).

Genotoxicity

    A) Ethanol caused DNA damage in a rat model and Saccharomyces cerevisiae, DNA repair in Escherichia coli, and DNA inhibition in human lymphocytes. It caused mutations in E coli, Salmonella typhimurium, Aspergillus nidulans, and S cerevisiae. Ethanol has been positive on cytogenetic analysis in human fibroblasts, leukocytes, and lymphocytes; in rats and mice; and in hamster embryo and ovary cells.
    B) A positive micronucleus test was observed in mice and in dog lymphocytes. The dominant lethal test was positive in mice; sperm morphology was observed in mice, and ethanol was positive for gene conversion/mitotic recombination in A nidulans.
    C) Ethanol has caused sister chromatid exchange in human lymphocytes, in hamster ovary cells, and in mice. It also caused sex chromosome loss/nondisjunction in A nidulans, in Drosophila melanogaster, and in mice.

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) Obtain an ethanol concentration (either blood or breath).
    B) A bedside dextrose is indicated for patients with an altered mental status.
    C) Consider a head CT for comatose patients or those with evidence of trauma.
    D) Monitor serum chemistries.
    E) Obtain arterial or venous blood gases, and serum and urine ketones for alcoholic ketoacidosis.
    4.1.2) SERUM/BLOOD
    A) BLOOD/SERUM CHEMISTRY
    1) Determine serum electrolytes, glucose, and ethanol levels. Hypoglycemia, hypokalemia, and metabolic acidosis (lactic or ketoacidosis) may occur.
    2) BUN, creatinine, liver transaminases, and CPK may be useful in identifying secondary effects, such as hepatotoxicity (chronic ethanol use), respiratory depression, or rhabdomyolysis (if seizures are present).
    3) BLOOD ETHANOL LEVEL Typically elevated to 100 to 300 mg% in acute intoxication; most fatalities occur with levels greater than 400 mg% (Gossel & Bricker, 1994; Osborn, 1994). Death may occur at lower blood ethanol levels.
    a) The lethal dose is variable, depending in part on chronic versus infrequent ethanol use (Haddad et al, 1998). Coingestion of sedative hypnotics, tranquilizers, anticonvulsants, antidepressants, opioids, or related drugs can compound the adverse effects of ethanol (Rall, 1990).
    b) Interpretation of postmortem blood alcohol concentration (BAC) may be dependent upon several factors. During putrefaction, alcohol may be lost due to evaporation or may be produced by microbial activity, or postmortem alcohol diffusion from the stomach contents may occur if the stomach alcohol concentration (SAC) is greater than the BAC. For correct interpretation of BAC and SAC, especially if putrefaction is present, several specimens should be collected for analysis of alcohol concentration, including the vitreous humor, bile, synovial fluid, cerebrospinal, chest, or intra-abdominal fluid, inner ear fluid, and/or urine. These body fluids are isolated and protected within various body cavities and are less likely to be subjected to alcohol diffusion or production via microbial activity (Athanaselis et al, 2005).
    4) OSMOLALITY: Serum or plasma osmolality allows estimation of blood ethanol level.
    a) A blood ethanol concentration of 150 mg% (32.5 mmol/L) increases osmolality by 21.6 milliosmoles/kg water.
    b) The following equation correlates well with BAC (Weiss & Thurnheer, 1988): BAL (g/L) = osmolal gap/27
    B) ACID/BASE
    1) Arterial blood gases may be useful.
    C) COAGULATION STUDIES
    1) International normalized ratio or prothrombin time may be useful in identifying hepatotoxicity.
    4.1.3) URINE
    A) URINARY LEVELS
    1) Qualitative determination of urinary ethanol is commonly included in a toxicology screen (Olson, 1994a).
    2) Urinary ethanol levels may be falsely elevated in patients with diabetes. Urine specimens from newly diagnosed diabetic patients with symptoms of genital candidiasis and glycosuria could spontaneously generate considerable quantities of ethanol, thereby concluding that urinary ethanol levels could not reliably reflect ethanol intake in certain diabetic patients (Alexander et al, 1988).
    B) OTHER
    1) Alcoholic ketoacidosis will usually produce urine weakly positive for ketones; however, measurable ketones may be absent in both urine and serum (Jatlow, 1980).
    4.1.4) OTHER
    A) OTHER
    1) RESPIRATORY FUNCTION
    a) CAPNOGRAPHY is a noninvasive method used to determine respiratory depression in adolescents with acute alcohol intoxication via monitoring of decreasing tidal volumes, as measured by end-tidal carbon dioxide (ETCO2) of less than 30 mmHg, and decreasing respiratory rates, as measured by ETCO2 greater than 50 mmHg (Langhan, 2013).

Radiographic Studies

    A) HEAD CT
    1) Comatose patients may require a head CT scan to rule out intracranial injury.
    B) CHEST RADIOGRAPH
    1) Chest x-ray is indicated if aspiration is suspected.

Methods

    A) MULTIPLE ANALYTICAL METHODS
    1) SUMMARY: Ethanol levels may be determined from blood, serum, plasma, urine, and breath analysis. Salivary determinations are not reliable. Adipose tissue fatty acid ethyl ethers may be measured to determine the chronicity of ethanol use.
    2) BLOOD
    a) Chemical reduction, enzymatic, spectrophotometric, and gas chromatographic methods are available. Whole blood, serum, or plasma may be used in most assays.
    b) The QED A350 Saliva Alcohol Test was used to measure ethanol levels in the serum and was shown to be 100% sensitive and 82% specific in detecting a blood ethanol level of greater than 100 mg/dL (Keim et al, 1999).
    3) EMIT IMMUNOASSAYS: Qualitative Enzyme Multiplied Immunoassay Technique (EMIT(R)) homogeneous enzyme immunoassays are available for the measurement of ethyl alcohol (ethanol) in urine and in serum or plasma. The detection limit (sensitivity) is 0.05% (50 mg/dL) of ethanol for both the urine and the serum assays. In clinical studies, this method compared favorably with gas-liquid chromatography.
    4) URINE: It has been suggested that a urine ethanol concentration at autopsy is necessary to exclude the possibility that any ethanol in the blood was not generated postmortem (Heatley & Crane, 1989).
    5) SALIVA: A colorimetric saliva dipstick ethanol assay (Alco-Screen, Chem-Elec, North Webtser, IN) was found NOT to be of value in estimating serum ethanol concentrations. There was poor correlation between serum ethanol and test results, and a high number of false-negatives were noted. The authors deemed the test unacceptable for emergency department use (Rodenberg et al, 1990).
    6) BREATH TESTS: Breath tests have been found to correlate well with serum levels. Smokeless tobacco, white spirit vapors, and toluene do not interfere with results (Tominack & Spyker, 1987; Gill et al, 1991a; Gill et al, 1991b). Metered dose inhalers may cause transiently elevated breath alcohol levels for 2 minutes or less(Gomez et al, 1992).
    B) OTHER
    1) CORRELATION WITH SERUM LEVELS: Breath tests have been found to correlate well with serum levels (Jones, 1991; Falkensson et al, 1989) .
    2) CASE REPORT: Ethanol analysis in 6 volunteers using a modified breathalyzer device was compared with blood ethanol levels (Falkensson et al, 1989). The Alcolmeter SD-2, when used with a mouth tube or mouth cup apparatus, correlated highly with blood ethanol as measured by gas chromatography.
    a) This method detects and cannot distinguish between ethanol, methanol, and 1- and 2-propanol; it does not detect ethylene glycol. It can be used on unconscious subjects for bedside diagnosis.
    3) CASE REPORT: It was found that the Intoximeter 3000 and blood alcohol levels of a single adult male subject who had consumed 134 g ethanol over 3 hours had good correlation between the 2 measurement methods (Jones, 1991).
    4) INTERFERENCE: Smokeless tobacco (Tominack & Spyker, 1987), white spirit vapors (Gill et al, 1991a), and toluene (Gill et al, 1991b) do not interfere with results. Metered dose inhalers may cause transiently elevated breath alcohol levels for 2 minutes or less(Gomez et al, 1992).
    5) SMOKELESS TOBACCO: Organic matrix dental adhesive and mentholated smokeless tobacco did NOT falsely elevate the ethanol breathalyzer, Alco Sensor III fuel cell (Tominack & Spyker, 1987).
    6) WHITE SPIRIT VAPORS: Seven volunteers were exposed to white spirit vapor and then tested with a breathalyzer (Lion Intoximeter 3000). Alcohol detection responses did NOT exceed a reading of 1 mcg/100 mL for breath samples more than 10 minutes postexposure (Gill et al, 1991a).
    7) METERED DOSE INHALERS: Commonly used to administer inhaled medications, these inhalers contain up to 38% ethanol. The effect of various inhalers and a measured dose of ethanol on breath alcohol testing were compared. It was found that some inhalers caused transient (2 minutes or less) elevations of breath alcohol levels well above legal levels for intoxication (Gomez et al, 1992).
    8) HAND SANITIZERS: The use of alcohol-based hand sanitizers by the operator of a standard hospital breathalyzer may cause false-positive readings.
    a) A prospective study involved 75 participants who were divided equally in 3 groups. Group 1 used 1.5 mL of hand sanitizer (1 "pump") and allowed their hands to dry before operating the breathalyzer machine, group 2 used 1.5 mL of hand sanitizer and did not allow their hands to dry before operating the breathalyzer machine, and group 3 used 3 mL of hand sanitizer and also did not allow their hands to dry. The initial breathalyzer reading of all participants was 0.000 g/dL; however, following hand sanitizer use, the median readings for groups 1, 2, and 3 were 0.004 g/dL (interquartile range [IQR] 0.001 to 0.008 g/dL), 0.051 g/dL (IQR 0.043 to 0.064 g/dL), and 0.119 g/dL (IQR 0.089 to 0.134 g/dL), respectively (Ali et al, 2013).
    9) FATTY ACID ETHYL ETHERS: Can be measured in the adipose tissue and can provide an indication of whether the subject was a chronic alcoholic, intoxicated at time of death, or not intoxicated or alcoholic regardless of blood ethanol level. Chronic alcoholics had a mean fatty acid ethyl ester concentration of 300 nanometers (nm)/g (+/- 46 nm/g); nonalcoholics who were not intoxicated had mean concentrations of 43 nm/g (+/- 13 nm/g) (Laposata et al, 1989).

Life Support

    A) Support respiratory and cardiovascular function.

Patient Disposition

    6.3.1) DISPOSITION/ORAL EXPOSURE
    6.3.1.1) ADMISSION CRITERIA/ORAL
    A) Admit adult patients with prolonged mental status depression, those requiring airway protection or ventilatory support, those with alcoholic ketoacidosis that does not rapidly respond to intravenous hydration and dextrose, and those with other significant complications of chronic alcoholism (bleeding, encephalopathy, status epilepticus, acid base or electrolyte disturbances, hypoglycemia, trauma, severe withdrawal).
    B) Refer patients for treatment for chronic alcoholism.
    C) Admit children with significant CNS depression, seizures, acid-base disturbances, or hypoglycemia.
    6.3.1.2) HOME CRITERIA/ORAL
    A) Patients who are minimally intoxicated with no use of coingestants can be observed at home if there is another responsible, nonintoxicated adult. Symptomatic children or children with ingestions that are expected to cause more than minimal symptoms should be referred to a healthcare facility. In addition, consider sending a child to the emergency department if a calculated blood alcohol level is greater than 50 mg/dL (an estimated ingestion of greater than 0.5 mL/kg absolute ethanol) or if concerned about the home situation.
    B) One study reported that children with a history of ingestion of up to 60 mL of colognes, perfumes, or after-shaves were unlikely to develop symptoms and could be safely observed at home by a responsible adult, provided that follow-up could be easily obtained (this was a study of 123 children younger than 6 years) (Scherger et al, 1988).
    1) Another study disagrees with the above conclusions and asserts that ingestion of ethanol-containing products by small children must be evaluated according to a calculation of maximum possible ingested dose per kg body weight. For example, a lethal dose of a perfume containing 90% ethanol by a 10 kg, 12-month-old child could be as little as 42.2 mL (Silverman, 1990).
    6.3.1.3) CONSULT CRITERIA/ORAL
    A) Consult a poison center or medical toxicologist for assistance in managing severe poisonings.
    6.3.1.5) OBSERVATION CRITERIA/ORAL
    A) Patients should be observed until they are not clinically intoxicated. If they are minimally intoxicated; there is a responsible, nonintoxicated adult who can provide care; and there is no evidence of trauma or other medical problems, then they can potentially be discharged, depending on the circumstances. Refer patients with chronic alcoholism or high-risk drinking for detoxification and rehabilitation.

Monitoring

    A) Obtain an ethanol concentration (either blood or breath).
    B) A bedside dextrose is indicated for patients with an altered mental status.
    C) Consider a head CT for comatose patients or those with evidence of trauma.
    D) Monitor serum chemistries.
    E) Obtain arterial or venous blood gases, and serum and urine ketones for alcoholic ketoacidosis.

Oral Exposure

    6.5.1) PREVENTION OF ABSORPTION/PREHOSPITAL
    A) ACTIVATED CHARCOAL
    1) Ethanol absorption is not affected by activated charcoal.
    2) STUDIES
    a) In several crossover human studies, administration of from 20 g of activated charcoal to 60 g of superactivated charcoal, given 5 to 30 minutes before or after an ethanol load (resulting in blood ethanol levels of 100 to 130 mg%) had no effect on ethanol absorption (Minocha et al, 1986; Hulten et al, 1985; Olkkola, 1985; Neuvonen et al, 1984).
    b) Two human studies indicate that ethanol only slightly decreases the effectiveness of activated charcoal in preventing aspirin or quinidine sulfate absorption (Cooney, 1995). Results of a study conducted in mice indicated that ethanol may decrease the adsorptive capacity of charcoal for strychnine (Olkkola, 1985).
    6.5.2) PREVENTION OF ABSORPTION
    A) SUMMARY
    1) Treatment is supportive and symptomatic. Position patient to prevent aspiration. Aspiration of gastric contents with a nasogastric tube may be useful in select patients (Pollack et al, 1992). Activated charcoal is NOT useful (Cooney, 1995).
    B) GASTRIC ASPIRATION
    1) Consider insertion of a nasogastric tube to aspirate gastric contents in patients with very recent, large ingestions. This should NOT be performed routinely in all intoxicated patients.
    6.5.3) TREATMENT
    A) SUPPORT
    1) Position patient to prevent aspiration. Thiamine, glucose, and naloxone should be given routinely. Phenytoin for prophylaxis of alcohol withdrawal seizures is NOT indicated.
    B) AIRWAY MANAGEMENT
    1) Place patient in semilateral decubitus position with head forward and mouth down to avoid aspiration of vomitus. Intubate if clinically indicated for airway protection or ventilatory support.
    C) FLUID/ELECTROLYTE BALANCE REGULATION
    1) An IV line should be started. Hydrate with 0.9% NaCl with 5% dextrose as clinically indicated.
    2) CROSSOVER STUDY: A group of volunteers ingested a predetermined dose of ethanol without receiving 0.9% NS therapy; other volunteers did receive 0.9% NS therapy immediately following ethanol ingestion. No difference in the rates of ethanol clearance with or without IV fluid intervention was observed. The findings suggested that IV fluid therapy does NOT accelerate ethanol clearance in intoxicated patients (Li et al, 1999).
    D) DEXTROSE
    1) INDICATIONS: If rapidly determined bedside glucose level is less than 60 mg/dL, or if rapid determination is not available.
    2) ADULT 25 g (50 mL of 50% dextrose solution) IV; may repeat as needed.
    3) PEDIATRIC 0.5 to 1 g/kg as 25% dextrose solution or 10% dextrose solution (2 to 4 mL/kg).
    4) PRECAUTIONS: Glucose administration should be PRECEDED by 100 mg of thiamine IV or IM if chronic alcoholism or malnutrition is suspected, to prevent the development of Wernicke's encephalopathy.
    E) THIAMINE
    1) DOSE/ROUTE 100 mg IV or IM in patients with chronic ethanol abuse.
    2) WARNING: Thiamine administration should PRECEDE IV glucose bolus.
    F) NALOXONE
    1) INDICATIONS: Although not predictably or consistently effective, should be given to any patient with an abnormal mental status after overdose.
    2) DOSE 2 mg IV, may repeat as needed.
    3) EFFICACY
    a) Naloxone may antagonize the depressant effect following acute ethanol overdose (Rae, 1986; Lyon & Antony, 1982; Sorensen & Mattisson, 1978), but this effect does not appear to be predictable or consistent in humans (Mattila et al, 1981; Jeffreys et al, 1980) or animals (Lignian et al, 1982).
    1) It has been speculated that individuals with genetically determined chlorpropamide alcohol flush, representing 6% to 10% of Caucasians, are more likely to respond to naloxone (Baraniuk et al, 1987).
    G) BENZODIAZEPINE
    1) Useful in alcohol withdrawal; may provide some protection from alcohol withdrawal seizures. Lorazepam has been recommended for patients older than 60 years or for persons who have hepatic dysfunction, as indicated by elevated prothrombin time or international normalized ratio (INR), increased bilirubin, abnormal biopsy, or other measures (Mayo-Smith, 1997; Hoey et al, 1994).
    2) DIAZEPAM
    a) ADULT DOSE: Initially 5 to 10 mg IV, OR 0.15 mg/kg IV up to 10 mg per dose up to a rate of 5 mg/minute; may be repeated every 5 to 20 minutes as needed (Brophy et al, 2012; Prod Info diazepam IM, IV injection, 2008; Manno, 2003).
    b) PEDIATRIC DOSE: 0.1 to 0.5 mg/kg IV over 2 to 5 minutes; up to a maximum of 10 mg/dose. May repeat dose every 5 to 10 minutes as needed (Loddenkemper & Goodkin, 2011; Hegenbarth & American Academy of Pediatrics Committee on Drugs, 2008).
    c) Monitor for hypotension, respiratory depression, and the need for endotracheal intubation. Consider a second agent if seizures persist or recur after repeated doses of diazepam .
    3) NO INTRAVENOUS ACCESS
    a) DIAZEPAM may be given rectally or intramuscularly (Manno, 2003). RECTAL DOSE: CHILD: Greater than 12 years: 0.2 mg/kg; 6 to 11 years: 0.3 mg/kg; 2 to 5 years: 0.5 mg/kg (Brophy et al, 2012).
    b) MIDAZOLAM has been used intramuscularly and intranasally, particularly in children when intravenous access has not been established. ADULT DOSE: 0.2 mg/kg IM, up to a maximum dose of 10 mg (Brophy et al, 2012). PEDIATRIC DOSE: INTRAMUSCULAR: 0.2 mg/kg IM, up to a maximum dose of 7 mg (Chamberlain et al, 1997) OR 10 mg IM (weight greater than 40 kg); 5 mg IM (weight 13 to 40 kg); INTRANASAL: 0.2 to 0.5 mg/kg up to a maximum of 10 mg/dose (Loddenkemper & Goodkin, 2011; Brophy et al, 2012). BUCCAL midazolam, 10 mg, has been used in adolescents and older children (5-years-old or more) to control seizures when intravenous access was not established (Scott et al, 1999).
    4) LORAZEPAM
    a) MAXIMUM RATE: The rate of intravenous administration of lorazepam should not exceed 2 mg/min (Brophy et al, 2012; Prod Info lorazepam IM, IV injection, 2008).
    b) ADULT DOSE: 2 to 4 mg IV initially; repeat every 5 to 10 minutes as needed, if seizures persist (Manno, 2003; Brophy et al, 2012).
    c) PEDIATRIC DOSE: 0.05 to 0.1 mg/kg IV over 2 to 5 minutes, up to a maximum of 4 mg/dose; may repeat in 5 to 15 minutes as needed, if seizures continue (Brophy et al, 2012; Loddenkemper & Goodkin, 2011; Hegenbarth & American Academy of Pediatrics Committee on Drugs, 2008; Sreenath et al, 2009; Chin et al, 2008).
    5) CASE STUDY: A prospective, double-blind study was conducted to determine the efficacy of lorazepam in prevention of recurrent seizures related to alcohol abuse. The patients, who presented with witnessed generalized seizure, were assigned to randomly receive either 2 mg of lorazepam in 2 mL of normal saline IV or 4 mL of normal saline IV alone Then they were observed for 6 hours for the occurrence of a second seizure. Three of 100 patients (3%) of the lorazepam group had a second seizure, as compared with 21 of 86 patients (24%) in the placebo group, indicating that treatment with intravenous lorazepam is associated with a significant reduction in the risk of alcohol-related recurrent seizures (D'Onofrio et al, 1999).
    6) PROPOFOL infusions have been successfully used in cases of ethanol withdrawal, characterized by the occurrence of delirium tremens, refractory to high doses of benzodiazepines (McCowan & Marik, 2000).
    H) PHENYTOIN
    1) Phenytoin is NOT INDICATED for alcohol withdrawal seizure prophylaxis.
    2) STUDIES
    a) A prospective, randomized, placebo-controlled, double-blind study of 55 patients who had seized from alcohol withdrawal tested the efficacy of phenytoin in preventing further withdrawal seizures (Chance, 1991). In this study, phenytoin did not prevent further withdrawal seizures any more than did placebo.
    1) Phenytoin was dosed at 15 mg/kg up to a maximum of 1000 mg for a 70 kg patient and at a rate of no more than 37 mg/min. Six of 28 (21%) patients dosed with phenytoin had recurrent seizures, compared with 5 of 27 (19%) placebo-treated patients.
    b) Another study involving 100 adults reported that there was no significant difference in seizure activity during ethanol withdrawal among phenytoin-treated (15 mg/kg; mean phenytoin blood level of 16 mcg/mL) and placebo-treated patients (Rathlev et al, 1994). The period of observation posttreatment was 6 hours.
    I) FLUMAZENIL
    1) Flumazenil, a benzodiazepine antagonist, has been found to occasionally improve the mental status of ethanol-intoxicated patients when administered at high doses (2 to 5 mg in adults).
    2) STUDIES
    a) Eighteen ethanol-overdose patients were dosed in a double-blind fashion with either placebo or 1 mg flumazenil. Improvement in conscious state, as measured by Glasgow Coma Scale, was no greater for flumazenil-dosed patients than for those who got placebo (Lheureux & Askenasi, 1991).
    1) Eleven of the above patients were then given a higher dose (2 to 5 mg) of flumazenil in an uncontrolled trial, and 5 improved in state of consciousness.
    b) Eight adult male volunteers with a mean blood ethanol level of 1.6 g/L received either placebo or flumazenil 5 mg and were evaluated with psychomotor and cognitive function tests at 15 and 75 minutes post-dosing (Clausen et al, 1990).
    1) No significant difference was found in these subjects between placebo and flumazenil. The authors concluded that flumazenil had no influence on psychomotor function in acute ethanol toxicity.
    c) ANIMALS: Mice were habituated to oral ethanol for 10 days and then were given a single injection of flumazenil (10 mg/kg) 14 hours prior to ethanol withdrawal.
    1) Mice who had received flumazenil experienced significantly reduced seizure severity during withdrawal from ethanol (Buck et al, 1991).
    3) CONTRAINDICATIONS
    a) Flumazenil should not be used in patients with serious cyclic antidepressant poisoning, as manifested by motor abnormalities (twitching, rigidity, seizure), dysrhythmias (wide QRS, ventricular dysrhythmia, heart block), anticholinergic signs (mydriasis, dry mucosa, hypoperistalsis), or cardiovascular collapse at presentation (Prod Info ROMAZICON(R) IV injection, 2004).
    b) Flumazenil should not be used in patients who are benzodiazepine-dependent or who have been given benzodiazepines for control of a life-threatening condition (Thomson et al, 2006; Prod Info ROMAZICON(R) IV injection, 2004).
    c) There is no known benefit of treatment with flumazenil in a mixed-drug overdose patient who is in critical condition. Flumazenil should NOT be used in cases where seizures are likely, from any cause (Thomson et al, 2006; Prod Info ROMAZICON(R) IV injection, 2004) .
    J) EXPERIMENTAL THERAPY
    1) FRUCTOSE has been advocated as an accelerator of ethanol metabolism and has been thought by some to improve mental status (Amene, 1976; Brown et al, 1972). It is administered by IV drip (10% in 1000 mL of water) or given orally in large dosages (200 g or more).
    a) Fructose can cause nausea and vomiting, intensify lactic acidosis, and reduce blood volume through osmotic diuresis.
    b) It is contraindicated in patients with advanced liver disease, uncontrolled diabetes mellitus, and hyperuricemic states.
    2) ANTIOXIDANTS: A preparation of vitamin E, beta carotene, vitamin C, and selenium did not significantly alter serum aspartate aminotransferase concentrations or presumed markers of free radicals in alcoholic patients, as compared with controls. Antioxidant deficiencies were reversed in the alcoholics by administration of the antioxidants (Butcher et al, 1993).
    3) PYRIDOXINE (VITAMIN B6): A preliminary study found no effect of pyridoxine (1 g IV in 10 mL saline) on ethanol-induced CNS depression, as compared with saline-only treated controls (Mardel et al, 1994).
    4) PICAMILON, a GABA receptor agonist, was administered as a loading dose (5 mg/kg IV), followed by continuous infusion (1.6 mg/kg/hr) for up to 4 hours in patients presenting with acute ethanol withdrawal. Benzodiazepines and supportive treatment were also provided to the Picamilon group (n=32) and to a control group (n=18).
    a) Picamilon-treated cases required lower benzodiazepine doses, had improved trembling test scores, no apparent complications, mild sedation, and significantly reduced systolic blood pressure and systemic vascular resistance, as compared with controls (Afanasiev et al, 1995).
    5) METADOXINE: This investigational drug has been shown in a multicenter trial to be effective in normalizing liver function tests and accelerating fatty liver recovery in alcoholic patients. These patients were given 1500 mg/day orally of metadoxine for 3 months, with ultrasonography performed before and after treatment. Biochemical changes were similar in both abstinent and non-abstinent patients. After therapy, 28% of the metadoxine group had ultrasonographic signs of steatosis, as compared with 70% of the placebo group (Caballeria et al, 1998).

Eye Exposure

    6.8.1) DECONTAMINATION
    A) EYE IRRIGATION, ROUTINE: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, an ophthalmologic examination should be performed (Peate, 2007; Naradzay & Barish, 2006).

Enhanced Elimination

    A) HEMODIALYSIS
    1) SUMMARY: Hemodialysis can eliminate ethanol but is rarely indicated. Consider in patients with severe intoxication (eg, hypotension) not responding to supportive care.
    a) It can eliminate ethanol 3 to 4 times more rapidly than liver metabolism. May be useful in patients with excessive blood levels, impaired hepatic function, and in those whose condition deteriorates in spite of maximal supportive measures.
    2) CASE REPORT: A nonalcoholic patient who had ingested 10 pints of beer and one-half bottle of gin was successfully treated by hemodialysis after supportive measures were ineffective. The blood ethanol concentration dropped an average of 62 mg% per hour during hemodialysis, or from 440 mg% (onset of hemodialysis) to less than 100 mg% at 12 hours of dialysis (Elliott & Hunter, 1974).
    3) CASE REPORT: A 64-year-old woman presented with coma and shock (blood pressure of 50/30 mmHg) following severe ethanol intoxication. Her initial blood ethanol level was 628 mg/dL. Despite 4 hours of supportive treatment, the patient remained comatose, her blood pressure increased to 107/70 mmHg, and her blood ethanol level had only decreased by 17%, to 523 mg/dL. Hemodialysis was then initiated with continued infusions of vasopressors and inotropic agents. After 4 hours of dialysis, the patient became responsive and was able to follow commands. Her blood pressure normalized, and her blood ethanol concentration decreased to 100 mg/dL (Atassi et al, 1999).
    4) CASE REPORT: A 52-year-old woman presented to the emergency department comatose, apneic, and hypothermic after ingesting 1 L of methylated spirits (consisting of 95% ethanol and small amounts of fluorescein, denatonium benzoate, and methyl isobutyl ketone). Her initial blood ethanol level was 1.127 g/dL (245 mmol/L). The patient was mechanically ventilated and resuscitated, and hemodialysis was initiated. Two hours later (while on dialysis), the patient's blood ethanol level decreased to 0.76 g/dL and continued to decrease over the next 19 hours to 0.044 g/dL. The patient's clinical status improved, and she was discharged approximately 8 days post-admission without neurologic sequelae (Sanap & Chapman, 2003).
    5) CASE REPORT (CHILD): A 3-year-old child with cerebral palsy was found cold, pale, and unresponsive (Glasgow Coma score of 3) by emergency personnel and presented to the emergency department with hypotension (56/25 mmHg), tachycardia (130 beats/min) and hypothermia (33.9 degrees C), with pinpoint pupils. Arterial blood gas analysis revealed lactic acidosis (pH 7.15, pCO2 43, HCO3 14.3 mmol/L, lactate 5.3 mmol/L). Serum ethanol concentration was 958 mg/dL. Despite supportive care, the patient's hypotension (65/48 mmHg) and acidosis persisted. Hemodialysis was performed approximately 5 hours post-presentation for a period of 4 hours. Immediately following hemodialysis, the patient's serum ethanol concentration decreased to 70 mg/dL. Her blood pressure stabilized, the acidosis resolved, and she became increasingly responsive (McGinnity de Laveaga & Caravati, 2015).

Case Reports

    A) PEDIATRIC
    1) Acute ethanol intoxication has been reported in a 33-month-old child. The child was thought to ingest 11 ounces of mouthwash (48.2 g of absolute ethanol) approximately 2 hours before being found in a stuporous state. Approximately 3.5 after ingestion, blood ethanol level was 306 mg%. The patient was treated by nasogastric lavage with normal saline, warming by radiant heater, administration of IV fluids, and supplemental bicarbonate. Eight hours postingestion, the blood ethanol level was 128 mg%, and by 18 hours after admission, the patient was responding appropriately and had normal blood gases and electrolytes (Weller-Fahy et al, 1980).

Summary

    A) TOXICITY: Ethanol levels that cause clinical intoxication can vary widely, depending on an individual's tolerance to ethanol. The legal driving limit in most of the states in the US is 80 mg/dL. In casual drinkers, coma likely occurs at a level of approximately 200 mg/dL, and death may occur at an approximate level of 450 mg/dL.
    B) A dose of about 1 mL/kg (1 g/kg) of absolute ethanol (95% to 99% ethanol) generally results in blood levels of 100 to 150 mg/dL (21 to 32 mmol/L), which would be expected to cause mild to moderate intoxication in most adults. However, a dose of 0.5 mL/kg absolute ethanol (an estimated blood alcohol level of 50 to 75 mg/dL) may cause significant intoxication in young children.
    C) INTOXICATION: Blood ethanol concentrations between 150 and 300 mg/dL (32.6 to 65.2 mmol/L) will generally cause obvious signs and symptoms.
    D) DEATH Generally reported at 5 to 6 g/kg in the non-tolerant adult and at 3 g/kg in children. Usually associated with blood ethanol levels greater than 400 mg/dL (86.8 mmol/L), although levels as low as 250 mg/dL have proven fatal. Cases of ethanol ingestion complicated by aspiration of gastric contents, coingestants, preexisting disease, or other factors may cause death at lower blood ethanol levels.
    E) RECOVERY Reported in patients with blood ethanol levels greater than 1510 mg/dL (327.8 mmol/L). Supportive care was provided; a history of chronic ethanol abuse (and thus tolerance) was present in at least 1 case.

Minimum Lethal Exposure

    A) ADULT
    1) Non-tolerant adult: 5 to 6 g/kg of body weight via oral route (Osborn, 1994), which is equivalent to approximately 33 beers (Harbison, 1998).
    2) CASE REPORT: A 36-year-old man, with a history of schizophrenia, presented to the emergency department (ED) with ethanol intoxication. The patient was uncooperative with slurred speech and nystagmus. A breath ethanol reading was 278 mg/dL. Four hours later, with supportive care, the patient was calm with a steady gait and was discharged. Thirty minutes later, the patient was found unresponsive and pulseless in the bathroom at the ED, with an empty 354-mL hand sanitizer containing 62% ethanol and less than 5% isopropanol. Following resuscitation, the patient developed spontaneous circulation with normal sinus rhythm, but never regained consciousness. His serum ethanol concentration was 526 mg/dL. A brain MRI showed extensive bilateral cortical infarction, cerebral edema, and sulcal effacement, indicating anoxic brain injury. The patient died on hospital day 7 following withdrawal of care. Based on his post-resuscitation serum ethanol concentration, it is suspected that the patient had ingested the majority of the contents of the hand sanitizer container (Schneir & Clark, 2013).
    B) PEDIATRIC
    1) Child: 3 g/kg (1 mL = 0.789 g) of body weight via oral route (Osborn, 1994; Ellenhorn & Barceloux, 1988).
    C) LIMITATIONS
    1) There is wide variability in toxicity, with factors such as hypoglycemia, coingestants, hypothermia, other medical conditions, age, aspiration of vomitus, a past history of chronic vs infrequent ethanol use, and the availability of supportive care influencing each overdose situation (Olson, 1994; Ellenhorn & Barceloux, 1988; Johnson, 1985; Weyman et al, 1974) .

Maximum Tolerated Exposure

    A) ADULT
    1) Very few adverse effects have been reported from inhalation and dermal exposures in industrial settings. Occupational exposures to ethanol are not of the same magnitude as chronic ingestion of alcoholic beverages (Harbison, 1998).
    2) Human epidemiological and animal studies have not found any association between inhalation of ethanol vapors and abnormal fetal development (Harbison, 1998).
    3) Concentrations of 1000 to 5000 parts per million (ppm) produce some symptoms of irritation. Exposure at 5000 to 10,000 ppm has caused transient but strong irritation of the eye and nose and has produced cough. At 15,000 ppm, effects were continuous lacrimation and cough. A level of 20,000 ppm (40 mg/L) was judged as impossible to tolerate. Above this level, the atmosphere was described as suffocating even for brief exposures (ACGIH, 2001; Bingham et al, 2001; Hathaway et al, 1996).
    B) PEDIATRIC
    1) DOSE of 60 to 105 mL (50% to 99% ethanol):
    a) All but 1 out of 119 children were asymptomatic following estimated ingestion of up to 60 mL of cologne, perfume, or aftershave products (50% to 99% ethanol). Slurred speech and ataxia developed in 2 out of 4 children who ingested an estimated 60 to 105 mL of ethanol (Scherger et al, 1988).
    2) DOSE of 48.2 to 180 g:
    a) Survival following an estimated ingestion of 180 g (Gibson et al, 1985) and 48.2 g (Weller-Fahy et al, 1980) of ethanol by two 3-year-olds have been reported. Supportive care was provided in both cases, and vomiting occurred within 15 minutes of the 180 g ingestion.
    3) HAND SANITIZERS: In a retrospective review of 647 pediatric (age range, 1 month to 5 years; mean age, 1.89 years) exposures to ethanol-based hand sanitizers (599 ingestions, 105 dermal, 29 ocular, and 2 inhalational), 31 (4.8%) patients did not develop any symptoms; 26 (4%) patients had only a minor effect; 372 (57.5%) were coded as nontoxic (no effects were expected) and 10 (1.6%) were coded as minimal clinical effects possible. No moderate or severe effects were observed. Reported effects were dermal erythema (n=4), oral irritation (n=2), vomiting (n=5), ocular irritation (n=9), lacrimation (n=1), conjunctivitis (n=1), cough (n=4), and miscellaneous other (n=2) (Mrvos & Krenzelok, 2009).
    4) CASE REPORT/HAND SANITIZER: A 3-year-old child presented to the emergency department with loss of balance, vomiting, drowsiness, and unresponsiveness to painful stimuli following a suspected ingestion of an alcohol-based hand sanitizer, containing 62% ethanol. In addition, the patient also developed nystagmus, mydriasis, hypotension (108/56 mmHg), tachycardia (108 bpm), and hypothermia (94.7 degrees F). An initial blood ethanol level, obtained approximately 1 hour post-presentation, was 212 mg/dL. With supportive care, the patient's condition improved with a decrease in her blood ethanol level to 45 mg/dL, 6 hours after the first level, and undetectable 8 hours later (Ruck et al, 2010). In order for the patient to initially present with a blood ethanol level of 212 mg/dL, it is believed that she ingested approximately 45 mL of the hand sanitizer.
    5) CASE REPORT/HAND SANITIZER: A 4-year-old child became "floppy" but responsive after ingesting approximately 6 ounces of an ethanol-based liquid hand sanitizer. The patient's blood ethanol level, obtained approximately 60 to 90 minutes post-ingestion, was 221 mg/dL. The patient recovered with supportive care (Reed et al, 2010).
    6) CASE REPORT (INFANT): A 29-day old 3.5 kg infant was brought to the emergency department because of suspected ethanol intoxication due to reported ingestion of soy formula that was mixed with 1 to 3 ounces of gin instead of water. At presentation, approximately 1.5 hours post-ingestion, the patient had a weak cry and cough, with a variable tone, described as "flat", "floppy", and "normal". Her initial heart rate was 181 beats/min, blood pressure of 85/67 mmHg and respiratory rate of 47 breaths/min; oxygenation was normal on room air. Physical examination was normal. Laboratory data revealed an initial blood alcohol concentration, obtained approximately 2 hours post-ethanol ingestion, was 301 mg/dL. All other laboratory parameters, including serum electrolytes, renal function tests, and glucose were within normal limits. With supportive care, including continuous administration of IV fluids containing 5% dextrose and 0.45% sodium chloride at 6 mL/kg/hour, the patient was awake and alert, and feeding normally. Continued observation revealed a slight increase in a liver enzyme level (AST 87 units/L) approximately 13 hours post ethanol-ingestion, but resolved 12 hours later. All other cardiovascular, neurologic, respiratory, and glycemic parameters remained normal, and the patient was discharged 3 days post-admission (Fong & Muller, 2014).
    7) CASE REPORT (INFANT): A 15-day-old infant presented to the emergency department with flushed skin, hypoactive, and somnolent approximately 3 hours after drinking formula milk. At presentation, the patient was hypotensive (55/29 mmHg) and tachycardic (214 beats/min), and arterial blood gases indicated metabolic acidosis (pH 7.186, HCO3 16.7 mmol/L, pCO2 45.8 mmHg, base excess -10.1 mmol/L). The patient's serum ethanol concentration, obtained at admission, was 43 mg/dL. With supportive care, including IV fluid administration, the patient gradually recovered within 12 hours post-admission. An interview with the parents, 24 hours post-admission, revealed that the infant's formula had been inadvertently mixed with 10 mL of sake (Japanese wine prepared from fermented rice). Follow up of the patient over the next 12 months showed no evidence of psychomotor sequelae (Zaitsu et al, 2013).
    8) CASE REPORT (ADOLESCENT): A 14-year-old boy presented to the emergency department with an altered mental status and an inability to walk on his own. Examination of the patient demonstrated a Glasgow Coma score of 6 and an absence of a gag reflex, necessitating intubation. Arterial blood gas analysis revealed metabolic acidosis, and laboratory data revealed a serum ethanol concentration of 233 mg/dL. Other toxicologic screening was negative for drugs of abuse and acetaminophen level was normal. Following supportive care, he was extubated and referred to psychiatry for consultation. Interview of the patient's friends indicated that he had ingested 24 ounces of lemon cooking extract. It was determined that lemon extract has a similar alcohol content as bourbon and absinthe (Dayton et al, 2015).

Serum Plasma Blood Concentrations

    7.5.2) TOXIC CONCENTRATIONS
    A) TOXIC CONCENTRATION LEVELS
    1) CASE REPORTS
    a) SUMMARY
    1) Most fatalities occur at blood ethanol levels greater than 400 mg/dL (86.8 mmol/L) (Osborn, 1994). Chronic ethanol abusers may survive high blood ethanol levels that are typically lethal to other individuals (Ellenhorn & Barceloux, 1988). Other factors, such as aspiration of vomitus, advanced age, and/or preexisting disease, may result in death at lower blood alcohol levels (Johnson, 1985).
    b) ADULT
    1) Blood alcohol levels above 250 mg/dL (postmortem) were associated with death in 109 uncomplicated adult cases (Johnson, 1985).
    a) Blood alcohol levels of less than 150 mg/dL (postmortem) were associated with death in 6 elderly persons who had significant diseases and/or had evidence of asphyxiation, possibly due to aspiration of vomitus (Johnson, 1985).
    b) A prison inmate's blood alcohol level was 335 mg/dL after drinking an unknown amount of hand sanitizer that contained 62% ethanol by weight (more than 70% ethanol by volume) (Doyon & Welsh, 2007).
    c) MAXIMUM SURVIVED BLOOD ETHANOL LEVELS (ADULTS)
    1) Remarkable recovery (treatment given) has been reported with levels of:
    a) 1510 mg/dL (327.8 mmol/L) in a case with a history of chronic ethanol abuse (Johnson et al, 1982);
    b) 1127 mg/dL (244.5 mmol/L) in a case with no history of chronic ethanol abuse; the person had ingested 2.5 bottles of whiskey (Berild & Hasselbalch, 1981);
    c) 780 mg/dL (169.3 mmol/L); status of ethanol use (eg, chronic abuser or infrequent user) is not known (Hammond et al, 1973); and
    d) 650 mg/dL (141.1 mmol/L) (Poklis & Pearson, 1977).
    e) A blood ethanol level of 1127 mg/dL (245 mmol/L) was reported in a 52-year-old woman who was comatose, apneic, and hypothermic, after drinking 1 L of methylated spirits (consisting of 95% ethanol and small amounts of fluorescein, denatonium benzoate, and methyl isobutyl ketone). The patient recovered following early resuscitation and dialysis (Sanap & Chapman, 2003).
    d) MAXIMUM SURVIVED BLOOD ETHANOL LEVELS (PEDIATRIC)
    1) 740 mg/dL in a 4-year-old; supportive care and peritoneal dialysis were provided (Dickerman et al, 1968).
    2) 575 mg/dL in an 18-month-old child who ingested an estimated 30 to 60 mL vodka; supportive care was provided (Ragan et al, 1979).
    3) 400 mg/dL (86.8 mmol/L) in a 12.5 kg, 3-year-old child; supportive care was provided (Gibson et al, 1985).
    e) PERCUTANEOUS EXPOSURE
    1) 800 mg/dL in a 28-month-old, 11 kg child following application of 70% ethanol wraps to part of 1 arm for less than 24 hours; the child was comatose and hypoglycemic, and supportive care was provided (Puschel, 1981).
    2) 362 mg/dL in a previously healthy 1-month-old, 3.6 kg infant following 3-day application of gauze soaked with 95% ethanol and 5% methanol to the umbilical stump; supportive care was provided (Da Dalt et al, 1991).
    3) CASE REPORT: A 45-year-old woman was found dead in a bathtub containing 40.5% (volume per volume) of ethanol. The patient believed that ethanol immersion would prevent the occurrence of severe acute respiratory syndrome (SARS); she was found approximately 12 hours following immersion. Her blood alcohol concentration (BAC was 1350 mg/dL. There was no significant fluid found in her stomach. According to the formula of BAC = ethanol (mg)/[volume of distribution (L/kg) x body weight (kg) x 10], it was believed that she had percutaneously absorbed approximately 1500 mL of 40% ethanol (Wu et al, 2005).
    f) ACUTE INTOXICATION
    1) Blood ethanol concentrations of 150 to 300 mg/dL (32.5 to 65.1 mmol/L) are generally associated with obvious signs and symptoms of acute intoxication (Gossel & Bricker, 1994; Osborn, 1994).
    2) A blood ethanol level of 100 mg/dL will usually result from ingestion of 3 to 4 ethanol beverages containing a total dose of about 0.7 g of ethanol per kg and may be sufficient in some states to be considered legally drunk (Olson, 1994a).
    g) ASYMPTOMATIC PATIENTS
    1) In one study, blood ethanol concentrations of 120 to 540 mg/dL (26.0 to 117.2 mmol/L; average, 268 mg/dL) were present in 76 patients judged to be sober in an emergency department but who had a history of recent ethanol ingestion (Urso et al, 1981).

Workplace Standards

    A) ACGIH TLV Values for CAS64-17-5 (American Conference of Governmental Industrial Hygienists, 2010):
    1) Editor's Note: The listed values are recommendations or guidelines developed by ACGIH(R) to assist in the control of health hazards. They should only be used, interpreted and applied by individuals trained in industrial hygiene. Before applying these values, it is imperative to read the introduction to each section in the current TLVs(R) and BEI(R) Book and become familiar with the constraints and limitations to their use. Always consult the Documentation of the TLVs(R) and BEIs(R) before applying these recommendations and guidelines.
    a) Adopted Value
    1) Ethanol
    a) TLV:
    1) TLV-TWA:
    2) TLV-STEL: 1000 ppm
    3) TLV-Ceiling:
    b) Notations and Endnotes:
    1) Carcinogenicity Category: A3
    2) Codes: Not Listed
    3) Definitions:
    a) A3: Confirmed Animal Carcinogen with Unknown Relevance to Humans: The agent is carcinogenic in experimental animals at a relatively high dose, by route(s) of administration, at site(s), of histologic type(s), or by mechanism(s) that may not be relevant to worker exposure. Available epidemiologic studies do not confirm an increased risk of cancer in exposed humans. Available evidence does not suggest that the agent is likely to cause cancer in humans except under uncommon or unlikely routes or levels of exposure.
    c) TLV Basis - Critical Effect(s): URT irr
    d) Molecular Weight: 46.07
    1) For gases and vapors, to convert the TLV from ppm to mg/m(3):
    a) [(TLV in ppm)(gram molecular weight of substance)]/24.45
    2) For gases and vapors, to convert the TLV from mg/m(3) to ppm:
    a) [(TLV in mg/m(3))(24.45)]/gram molecular weight of substance
    e) Additional information:

    B) NIOSH REL and IDLH Values for CAS64-17-5 (National Institute for Occupational Safety and Health, 2007):
    1) Listed as: Ethyl alcohol
    2) REL:
    a) TWA: 1000 ppm (1900 mg/m(3))
    b) STEL:
    c) Ceiling:
    d) Carcinogen Listing: (Not Listed) Not Listed
    e) Skin Designation: Not Listed
    f) Note(s):
    3) IDLH:
    a) IDLH: 3300 ppm
    b) Note(s): [10%LEL]
    1) [10%LEL]: The 10%LEL designation is provided where the IDLH was based on 10% of the lower explosive limit. This is used for safety purposes in some cases even though toxicity is not indicative of irreversible health effects or impairment of escape exists only at higher concentrations.

    C) Carcinogenicity Ratings for CAS64-17-5 :
    1) ACGIH (American Conference of Governmental Industrial Hygienists, 2010): A3 ; Listed as: Ethanol
    a) A3 :Confirmed Animal Carcinogen with Unknown Relevance to Humans: The agent is carcinogenic in experimental animals at a relatively high dose, by route(s) of administration, at site(s), of histologic type(s), or by mechanism(s) that may not be relevant to worker exposure. Available epidemiologic studies do not confirm an increased risk of cancer in exposed humans. Available evidence does not suggest that the agent is likely to cause cancer in humans except under uncommon or unlikely routes or levels of exposure.
    2) EPA (U.S. Environmental Protection Agency, 2011): Not Listed
    3) IARC (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004): Not Listed
    4) NIOSH (National Institute for Occupational Safety and Health, 2007): Not Listed ; Listed as: Ethyl alcohol
    5) MAK (DFG, 2002): Category 5 ; Listed as: Ethanol
    a) Category 5 : Substances with carcinogenic and genotoxic effects, the potency of which is considered to be so low that, provided the MAK and BAT values are observed, no significant contribution to human cancer risk is to be expected. The classification is supported by information on the mode of action, dose dependence and toxicokinetic data pertinent to species comparison.
    6) NTP (U.S. Department of Health and Human Services, Public Health Service, National Toxicology Project ): Not Listed

    D) OSHA PEL Values for CAS64-17-5 (U.S. Occupational Safety, and Health Administration (OSHA), 2010):
    1) Listed as: Ethyl alcohol (Ethanol)
    2) Table Z-1 for Ethyl alcohol (Ethanol):
    a) 8-hour TWA:
    1) ppm: 1000
    a) Parts of vapor or gas per million parts of contaminated air by volume at 25 degrees C and 760 torr.
    2) mg/m3: 1900
    a) Milligrams of substances per cubic meter of air. When entry is in this column only, the value is exact; when listed with a ppm entry, it is approximate.
    3) Ceiling Value:
    4) Skin Designation: No
    5) Notation(s): Not Listed

Toxicity Information

    7.7.1) TOXICITY VALUES
    A) References: OHM/TADS, 2002 RTECS, 2002
    1) LD50- (INTRAPERITONEAL)MOUSE:
    a) 528 mg/kg
    2) LD50- (ORAL)MOUSE:
    a) 220 mg/kg (OHM/TADS , 2002a)
    b) 3450 mg/kg
    3) LD50- (SUBCUTANEOUS)MOUSE:
    a) 8285 mg/kg
    4) LD50- (INTRAARTERIAL)RAT:
    a) 11 mg/kg -- chronic pulmonary edema; dyspnea
    5) LD50- (INTRAPERITONEAL)RAT:
    a) 1225 mg/kg (OHM/TADS , 2002a)
    b) 3600 mcg/kg
    c) 5000 mg/kg (OHM/TADS , 2002a)
    6) LD50- (ORAL)RAT:
    a) 7060 mg/kg -- respiratory changes
    b) 7800 mg/kg (OHM/TADS , 2002a)
    c) 13,700 mg/kg (OHM/TADS , 2002a)
    7) TCLo- (INHALATION)RAT:
    a) female, 20,000 ppm for 7H at 1 to 22D of pregnancy -- developmental abnormalities

Toxicologic Mechanism

    A) CNS EFFECTS
    1) Ethanol is a CNS depressant that causes stupor, coma, and eventually death if ingested in excessive quantities.
    2) A comprehensive review article on ethanol and its action on neurotransmitters, their receptors, and their metabolism in the brain was published (Deitrich et al, 1989).
    3) Wernicke encephalopathy has been associated with thiamine deficiency in alcoholics. Other forms of brain damage in alcoholics may be due to toxic effects of acetaldehyde, fatty acid ethyl esters, malnutrition, and/or vitamin deficiencies (Charness, 1993).
    B) HYPOGLYCEMIA
    1) In normal adults, ethanol-induced hypoglycemia requires a significant fasting state to exhaust the dietary and hepatic (glycogenolysis) sources of glucose. Hypoglycemia develops more readily in children and alcoholics.
    2) When dietary and hepatic sources of glucose are depleted, gluconeogenesis must maintain euglycemia. However, during the oxidation of ethanol, there is an increase in the NADH/NAD ratio, which creates an increase in the conversion of pyruvate to lactate. The lack of the key intermediate, pyruvate, halts gluconeogenesis, and hypoglycemia ensues (Hoffman & Goldfrank, 1989).
    C) HYPOTHERMIA
    1) Hypothermia may result from peripheral vasodilation, CNS depression, interference with the thermoregulator mechanism, and/or impaired behavioral response to a cold environment (Szpak et al, 1995; Delaney et al, 1994; Goldfrank et al, 1994; Weyman et al, 1974).
    D) ACIDOSIS
    1) Ethanol-induced ketoacidosis requires a relative fasting state. In the absence of dietary and hepatic sources of glucose, free fatty acids are mobilized from adipose tissue. As the only available source of glucose and as a result of an increase in the NADH/NAD ratio from ethanol oxidation, fatty acids are oxidized to acetoacetate and beta-hydroxybutyrate (ketogenesis). Ketogenesis, coupled with volume depletion, decreased ketone elimination, and lactic acid production, leads to acidosis (Hoffman & Goldfrank, 1989).
    E) INCREASED OSMOLAL GAP
    1) Endogenous elevations of glycerol, acetone, and acetone metabolites, in addition to ethanol, may contribute to the increased osmolal gap reported in some patients with alcoholic metabolic acidosis (Braden et al, 1993).
    F) CARDIOVASCULAR EFFECTS
    1) CARDIOMYOPATHY
    a) ALTERED PROTEIN SYNTHESIS: Based on animal studies, it has been postulated that cardiac dysfunction from ethanol abuse may be due to depressed myocardial protein synthesis (Preedy et al, 1994; Siddiq et al, 1994; Siddiq et al, 1993), secondary to disturbed intracellular calcium homeostasis (Siddiq et al, 1994), nutritional deficits, catecholamines, and other neurohormones (Preedy et al, 1994), or acetaldehyde (Siddiq et al, 1994).
    b) FREE RADICALS: Reactive free radicals and fatty acid esters theoretically may alter myocardial structure and function (Preedy et al, 1994).
    c) IMPAIRED OXIDATIVE METABOLISM: Decreased oxidative metabolism in cardiac tissue of ethanol-fed animals has been reported (Thomas et al, 1994) and may relate to impaired synthesis of myocardial proteins (Siddiq et al, 1994).
    d) TOXIC METABOLITES: The ethanol metabolite, acetaldehyde, is unlikely to have major direct effects on cardiac muscle function in vivo, but it may stimulate the release of catecholamines, which can influence cardiac function (Thomas et al, 1994).
    2) ANGINA
    a) Due to the delayed onset of angina after ethanol ingestion, it has been proposed that angina occurs indirectly as a result of an ethanol metabolite (ie, acetaldehyde) or of ethanol-stimulated production or decrease of other substances in the body (Oda et al, 1994; Preedy et al, 1994) .
    1) Four individuals with histories of ethanol-induced variant angina and significant coronary artery stenosis developed coronary spasm after alcohol challenge. These cases had statistically significant increased thromboxane, decreased 6-ketoprostaglandin F1-alpha, and decreased cyclic guanosine monophosphate, as compared with controls (Oda et al, 1994).
    2) Study results suggest that ethanol-induced magnesium deficiency may predispose some individuals to ethanol-induced angina (Miwa et al, 1994).
    G) HEPATOTOXICITY
    1) ALTERED LIPID METABOLISM
    a) Ethanol ingestion produces hepatic lipid accumulation ("fatty liver"). The following mechanisms contribute to this (Myerson & Rubin, 1992):
    1) Decreased lipid oxidation by the liver
    2) Decreased hepatic clearance of lipoprotein
    3) Enhanced hepatic lipogenesis
    4) Enhanced uptake of circulating lipids
    5) Increased mobilization of peripheral fat
    b) Ethanol is hepatotoxic due to NADH production in its alcohol dehydrogenase pathway. This excessive NADH affects the metabolism of lipids, carbohydrates, proteins, and purines (Lieber & DeCarli, 1991).
    2) CHEMICAL INTERACTIONS
    a) Ethanol may potentiate the hepatotoxicity of some chemicals and/or alter their clearance due to combined hepatotoxicity of ethanol and these chemicals; increased bioactivation induced by ethanol; and other ethanol-induced effects on hepatic enzymes involved in detoxification, bioactivation, or cellular protection, as shown in animals and in vitro (Odeleye et al, 1993; Hasumura et al, 1974; Rubin et al, 1970).
    b) Fasting and effects of chronic ethanol use may increase hepatotoxicity associated with excessive acetaminophen dosing in alcoholics, possibly as a result of reduced hepatic protective enzymes (eg, glutathione) and increased bioactivation of acetaminophen (Whitcomb & Block, 1994).

Physical Characteristics

    A) Ethanol is a volatile, mobile, hygroscopic, colorless, flammable liquid with a fragrant, weak, ethereal, vinous odor and burning taste (Ashford, 1994; Budavari, 2000; (HSDB, 2002); Lewis, 2000; Sittig, 1991).

Molecular Weight

    A) 46.07

Other

    A) ODOR THRESHOLD
    1) 5-10 ppm (Sittig, 1991)
    2) 10 ppm ((CHRIS, 2002))
    3) 0.3420 mg/m(3) (Harbison, 1998)
    4) 2.40X10(+13) molecules/cm(3) in air; purity not specified ((HSDB, 2002))
    5) 3.30X10(+13) molecules/cm(3) in air; purity not specified ((HSDB, 2002))
    6) 84 ppm (Tolerance) (ACGIH, 2001)
    7) 4.40X10(+3) ppm (Detection) in air; purity not specified ((HSDB, 2002))
    8) 1.00x10(-1) mg/L gas (Detection) in air; purity not specified ((HSDB, 2002))
    9) 1.00X10(+1) ppm (Recognition) in air; chemically pure ((HSDB, 2002))

General Bibliography

    1) 40 CFR 372.28: Environmental Protection Agency - Toxic Chemical Release Reporting, Community Right-To-Know, Lower thresholds for chemicals of special concern. National Archives and Records Administration (NARA) and the Government Printing Office (GPO). Washington, DC. Final rules current as of Apr 3, 2006.
    2) 40 CFR 372.65: Environmental Protection Agency - Toxic Chemical Release Reporting, Community Right-To-Know, Chemicals and Chemical Categories to which this part applies. National Archives and Records Association (NARA) and the Government Printing Office (GPO), Washington, DC. Final rules current as of Apr 3, 2006.
    3) 49 CFR 172.101 - App. B: Department of Transportation - Table of Hazardous Materials, Appendix B: List of Marine Pollutants. National Archives and Records Administration (NARA) and the Government Printing Office (GPO), Washington, DC. Final rules current as of Aug 29, 2005.
    4) 49 CFR 172.101: Department of Transportation - Table of Hazardous Materials. National Archives and Records Administration (NARA) and the Government Printing Office (GPO), Washington, DC. Final rules current as of Aug 11, 2005.
    5) 62 FR 58840: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 1997.
    6) 65 FR 14186: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2000.
    7) 65 FR 39264: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2000.
    8) 65 FR 77866: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2000.
    9) 66 FR 21940: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2001.
    10) 67 FR 7164: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2002.
    11) 68 FR 42710: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2003.
    12) 69 FR 54144: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2004.
    13) AAPCC: American Association of Poison Control Centers Emergency Alert. American Association of Poison Control Centers, 1991.
    14) AAR: Emergency Handling of Hazardous Materials in Surface Transportation, Bureau of Explosives, Association of American Railroads, Washington, DC, 1996.
    15) AAR: Emergency Handling of Hazardous Materials in Surface Transportation, Bureau of Explosives, Association of American Railroads, Washington, DC, 2000.
    16) ACGIH: Documentation of the Threshold Limit Values and Biological Exposure Indices, 6th ed, Am Conference of Govt Ind Hyg, Inc, Cincinnati, OH, 2001.
    17) AIHA: 2006 Emergency Response Planning Guidelines and Workplace Environmental Exposure Level Guides Handbook, American Industrial Hygiene Association, Fairfax, VA, 2006.
    18) AMA: Council on Scientific Affairs: Effects of Toxic Chemicals on the Reproductive System, American Medical Association, Chicago, IL, 1985.
    19) Abel EL & Sokol RJ: A revised conservative estimate of the incidence of FAS and its economic impact. Alcohol Clin Exp Res 1991; 15:514-524.
    20) Abel EL: Drug Alcohol Depend 1984; 14:1-10.
    21) Abel EL: Rat offspring sired by males treated with alcohol. Alcohol 1993; 10:237-242.
    22) Abel EL: Teratology 1985; 31:35-40.
    23) Adinoff B, Risher-Flowers D, & De Jong J: Disturbances of hypothalamic- pituitary-adrenal axis functioning during ethanol withdrawal in six men. Am J Psychiat 1991; 148:1023-1025.
    24) Afanasiev V, Green GB, & Priputina L: Controlled trial of picamilon for treatment of ethanol withdrawal (Abstract). J Toxicol Clin Toxicol 1995; 33:531-532.
    25) Alexander WD, Wills PD, & Eldred N: Urinary ethanol and diabetes mellitus. Diabet Med 1988; 5(5):463-464.
    26) Ali SS, Wilson MP, Castillo EM, et al: Common hand sanitizer may distort readings of breathalyzer tests in the absence of acute intoxication. Acad Emerg Med 2013; 20(2):212-215.
    27) Alldredge BK & Lowenstein DH: Status epilepticus related to alcohol abuse.. Epilepsia 1993; 34:1033-1037.
    28) Amene PC: Intravenous fructose for acute alcoholism: A double-blind study. JACEP 1976; 5:253-256.
    29) American Conference of Governmental Industrial Hygienists : ACGIH 2010 Threshold Limit Values (TLVs(R)) for Chemical Substances and Physical Agents and Biological Exposure Indices (BEIs(R)), American Conference of Governmental Industrial Hygienists, Cincinnati, OH, 2010.
    30) Ando H, Abe H, & Hisanou R: Ethanol-induced myocardial ischemia: close relation between blood acetaldehyde level and myocardial ischemia. Clin Cardiol 1993; 16:443-446.
    31) Andrews LS & Snyder R: Toxic effects of solvents and vapors, in: Amdur MO, Doull J & Klaassen CD (Eds), Casarett and Doull's The Basic Science of Poisons, 4th ed, Pergamon Press, New York, NY, 1991, pp 681-700.
    32) Anon: MRI Proj No 4867-T. Contract No NOI-CN-95419. Div Cancer Control Rehab, National Cancer Institute, 1980.
    33) Anon: NIOSH Contract No 210-78-0009, NTIS PB83-238-527, National Institute of Occupational Health and Safety, Washington, DC, 1980b, pp 103.
    34) Anon: Neurogenic nystagmus, in Duke-Elder (ed): System of Ophthalmology, CV Mosby, St Louis, MO, 1971, pp 861.
    35) Ansell-Edmont: SpecWare Chemical Application and Recommendation Guide. Ansell-Edmont. Coshocton, OH. 2001. Available from URL: http://www.ansellpro.com/specware. As accessed 10/31/2001.
    36) Arishima K, Yamamoto M, & Takizawa T: Effect of acute maternal alcohol consumption on the fetal ductus arteriosus in the rat. Biol Neonate 1993; 63:40-43.
    37) Ashford R: Ashford's Dictionary of Industrial Chemicals, Wavelength Publications Ltd, London, England, 1994.
    38) Ashford RD: Ashford's Dictionary of Industrial Chemicals, Wavelength Publications, London, United Kingdom, 1994a.
    39) Atassi WA, Noghnogh AA, & Hariman R: Hemodialysis as a treatment of severe ethanol poisoning. Intl J Artif Organs 1999; 22:18-20.
    40) Athanaselis S, Stefanidou M, & Koutselinis A: Interpretation of postmortem alcohol concentrations. Forens Sci Intl 2005; 149:289-291.
    41) Austin H, Delzell E, & Grufferman S: Cancer Res 1986; 46:962-966.
    42) Ayres JG: Alcohol-induced bronchial asthma (letter). J Allergy Clin Immunol 1997; 860.
    43) Balmer MG: Am Ind Hyg Assoc J 1976; 37:345-352.
    44) Baraniuk JN, Murray RB, & Mabbee WG: Naloxone, ethanol, and the chlorpropamide alcohol flush. Alcohol Clin Exp Res 1987; 11:518-520.
    45) Barauskaite S: Iss Viniti 5690-83, 1983.
    46) Barrett MJ & Babl FE: Alcohol-based hand sanitiser: a potentially fatal toy. Med J Aust 2015; 203(1):43-44.
    47) Baselt RC & Cravey RH: Ethanol, in: Baselt RC & Cravey RH (Eds): Disposition of Toxic Drugs and Chemicals in Man, Chemical Toxicology Institute, Foster City, CA, 1995.
    48) Baselt RC: Biological Monitoring Methods for Industrial Chemicals, 3rd ed, Chemical Toxicology Institute, Foster City, CA, 1997.
    49) Baselt RC: Disposition of Toxic Drugs and Chemical in Man, 5th ed, Chemical Toxicology Institute, Foster City, CA, 2000a.
    50) Baselt RC: Disposition of Toxic Drugs and Chemicals in Man, 5th ed, Chemical Toxicology Institute, Foster City, CA, 2000.
    51) Bata Shoe Company: Industrial Footwear Catalog, Bata Shoe Company, Belcamp, MD, 1995.
    52) Battisti L, Degani D, & Rugolotto S: Fetal alcohol syndrome and malignant disease: a case report. Am J Pediatr Hematol Oncol 1993; 15:136-137.
    53) Bauer U & Strass M: Hehandlung von Magen und Zwolffingerdam-Geschwuren mit Carbenoxolone-Natrium. Med Welt 1972; 23:985.
    54) Baxter PJ, Adams PH, & Aw TC: Hunter's Diseases of Occupations, 9th ed, Oxford Univ Press, Inc, New York, NY, 2000.
    55) Bennett RH, Cherek DR, & Spiga R: Acute and chronic alcohol tolerance in humans - effects of dose and consecutive days of exposure. Alcohol Clin Exp Res 1993; 17:740-745.
    56) Berild D & Hasselbalch H: Survival after a blood alcohol of 1127 mg/dl. Lancet 1981; 2:363.
    57) Berliner EG: Gig Aspekty Okhr Zdorovya Naseleniya 1977; 61.
    58) Bertolet BD, Freund G, & Martin CA: Unrecognized left ventricular dysfunction in an apparently healthy alcohol abuse population. Drug Alcohol Depend 1991; 28:113-119.
    59) Best Manufacturing: ChemRest Chemical Resistance Guide. Best Manufacturing. Menlo, GA. 2002. Available from URL: http://www.chemrest.com. As accessed 10/8/2002.
    60) Best Manufacturing: Degradation and Permeation Data. Best Manufacturing. Menlo, GA. 2004. Available from URL: http://www.chemrest.com/DomesticPrep2/. As accessed 04/09/2004.
    61) Bingham E, Cohrssen B, & Powell CH: Patty's Toxicology Vol. 6, 5th ed, John Wiley & Sons, Inc, New York, NY, 2001a.
    62) Bingham E, Cohrssen B, & Powell CH: Patty's Toxicology, Vol <6>. 5th ed, John Wiley & Sons, New York, NY, 2001.
    63) Block RS, Weaver DW, & Bowman DL: Acute alcohol intoxication: significance of the amylase level. Ann Emerg Med 1983; 12:294-296.
    64) Boggan WO, Monroe B, & Turner WR Jr: Effect of prenatal ethanol administration on the urogenital system of mice. Alcohol Clin Exp Res 1989; 13:206-208.
    65) Bonev G: Khig Zdraveopaz 1974; 17:533-536.
    66) Boss Manufacturing Company: Work Gloves, Boss Manufacturing Company, Kewanee, IL, 1998.
    67) Bottiger LE: Alcohol and the blood. Scand J Haematol 1973; 10:321-326.
    68) Boyd TA, Ernhart CB, & Greene TH: Prenatal alcohol exposure and sustained attention in the preschool years. Neurotoxicol Teratol 1991; 13:49-55.
    69) Braden GL, Strayhorn CH, & Germain MJ: Increased osmolol gap in alcoholic acidosis. Arch Intern Med 1993; 153:2377-2380.
    70) Brennan DF, Betzelos S, & Reed R: Ethanol elimination rates in an ED population. Am J Emerg Med 1995; 13:276-280.
    71) Brophy GM, Bell R, Claassen J, et al: Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17(1):3-23.
    72) Brown RT, Coles CD, & Smith IE: Effects of prenatal alcohol exposure at school age. II. Attention and behavior. Neurotoxicol Teratol 1991; 13:369-376.
    73) Brown SS, Forrest JA, & Roscoe P: A controlled trial of fructose in the treatment of acute alcohol intoxication. Lancet 1972; 2:898-900.
    74) Buck KJ, Heim H, & Harris RA: Reversal of alcohol dependence and tolerance by a single administration of flumazenil. J Pharmacol Exp Ther 1991; 257:984-989.
    75) Budavari S: The Merck Index, 12th ed, Merck & Co, Inc, Whitehouse Station, NJ, 1996, pp 641-642.
    76) Budavari S: The Merck Index, 12th ed. on CD-ROM. Version 12:3a. Chapman & Hall/CRCnetBASE. Whitehouse Station, NJ. 2000.
    77) Butcher GP, Rhodes JM, & Walker R: The effect of antioxidant supplementation on a serum marker of free radical activity and abnormal serum biochemistry in alcoholic patients admitted for detoxification. J Hepatol 1993; 19:105-109.
    78) CHRIS: CHRIS Hazardous Chemical Data. U.S. Department of Transportation, U.S. Coast Guard. Washington, DC, US (Internet Version). Edition expires 2002; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    79) Caballeria J, Pares A, & Bru C: Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo- control trial. J Hepatol 1998; 28:54-60.
    80) Calvino J, Bravo J, Millan B, et al: Flank pain and acute renal failure after binge drinking: a growing concern?. Ren Fail 2013; 35(3):421-424.
    81) Cameron AM: Arch Toxicol 1985; Suppl 8:422-424.
    82) Catlin MC, Abdollah S, & Brien JF: Dose-dependent effects of prenatal ethanol exposure in the guinea pig. Alcohol 1993; 10:109-115.
    83) Chamberlain JM, Altieri MA, & Futterman C: A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Ped Emerg Care 1997; 13:92-94.
    84) Chance JF: Emergency department treatment of alcohol withdrawal seizures with phenytoin. Ann Emerg Med 1991; 20:520-522.
    85) Charness ME: Brain lesions in alcoholics. Alcohol Clin Exp Res 1993; 17:2-11.
    86) ChemFab Corporation: Chemical Permeation Guide Challenge Protective Clothing Fabrics, ChemFab Corporation, Merrimack, NH, 1993.
    87) Chemsoft(R) : Electronic EPA, NIOSH, & OSHA Methods(TM). Windowchem(TM) Software. Fairfield, CA. 2000.
    88) Chin RF , Neville BG , Peckham C , et al: Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008; 7(8):696-703.
    89) Cho E, Smith-Warner SA, Ritz J, et al: Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 2004; 140:603-613.
    90) Choi SY & Kahyo H: Internat J Cancer 1991; 49:381-386.
    91) Cicero TJ & Bell RD: Adv Exp Med Biol 1980; 132:211-217.
    92) Cicero TJ, Nock B, & O'Connor LH: Acute paternal alcohol exposure impairs fertility and fetal outcome. Life Sci 1994; 55:PL33-PL36.
    93) Cina SJ, Russell RA, & Conradi SE: Sudden death due to metronidazole/ethanol interaction. Am J Forens Med Pathol 1996; 17:343-346.
    94) Clark CR: Adv Mod Environ Toxicol 1984; 6:109-122.
    95) Clausen TG, Wolff J, & Carl P: The effect of the benzodiazepine antagonist, flumazenil, on psychometric performance in acute ethanol intoxication in man. Eur J Clin Pharmacol 1990; 38:233-236.
    96) Clayton DE & Busse W: Anaphylaxis to wine. Clin Allerg 1980; 10:341-343.
    97) Clayton GD & Clayton FE: Patty's Industrial Hygiene and Toxicology, Vol 2C, Toxicology, 3rd ed, John Wiley & Sons, New York, NY, 1982, pp 4541-4556.
    98) Clayton GD & Clayton FE: Patty's Industrial Hygiene and Toxicology, Vol 2C. Toxicology, 4th ed, John Wiley & Sons, New York, NY, 1994.
    99) Coles CD, Brown RT, & Smith IE: Effects of prenatal alcohol exposure at school age. I. Physical and cognitive development. Neurotoxicol Teratol 1991; 13:357-367.
    100) Comasec Safety, Inc.: Chemical Resistance to Permeation Chart. Comasec Safety, Inc.. Enfield, CT. 2003. Available from URL: http://www.comasec.com/webcomasec/english/catalogue/mtabgb.html. As accessed 4/28/2003.
    101) Comasec Safety, Inc.: Product Literature, Comasec Safety, Inc., Enfield, CT, 2003a.
    102) Cooney DO: Major classes of drugs and chemicals, in: Cooney DO (Ed): Activated Charcoal in Medical Applications, Marcel Dekker, Inc, New York, NY, 1995.
    103) Council on Scientific Affairs: Alcohol and the Driver. JAMA 1986; 255:522-527.
    104) Cox NH & Mustchin CP: Prolonged spontaneous and alcohol-induced flushing due to the solvent dimethylformamide. Contact Dermatitis 1991; 24:69-70.
    105) Cummins LH: Hypoglycemia and convulsions in children following alcohol ingestion. J Pediatr 1961; 23-26.
    106) D'Onofrio G, Rathley NK, & Ulrich AS: Lorazepam for the prevention of recurrent seizures related to alcohol. N Eng J Med 1999; 340:915-919.
    107) DFG: List of MAK and BAT Values 2002, Report No. 38, Deutsche Forschungsgemeinschaft, Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, Wiley-VCH, Weinheim, Federal Republic of Germany, 2002.
    108) Da Dalt L, Dall'Amico R, & Laverda AM: Percutaneous ethyl alcohol intoxication in a one-month-old infant. Pediatr Emerg Care 1991; 7:343-344.
    109) Dagradi AE: Esophageal varices, splenic pulp pressure and "directional" flow patterns in alcoholic liver cirrhosis: a correlative study. Am J Gastroenterol 1973; 59:15-22.
    110) Daryanani HE, Santolaria FJ, & Gonzalez Reimers E: Alcoholic withdrawal syndrome and seizures. Alcohol Alcohol 1994; 29:323-328.
    111) Dasilva VA, McLean AEM, & Beales D: Ethanol elimination by rats as a function of reproductive state, gender and nutritional status. Braz J Med Biol Res 1996; 29:651-657.
    112) Day NL, Richardson GA, & Geva D: Alcohol, marijuana, and tobacco: effects of prenatal exposure on offspring growth and morphology at age six. Alcohol Clin Exp Res 1994; 18:786-794.
    113) Dayton J, Caravati M, & Smith S: The Grocery Baking Aisle and Non-beverage Alcohol Abuse (abstracts). Clin Toxicol (Phila) 2015; 5(7):674.
    114) De Keyser J: Spasmodic torticollis occurring during alcohol withdrawal. Neurol 1993; 43:623-624.
    115) Deitrich RA, Dunwiddie T, & Harris RA: Mechanism of action of ethanol: initial central nervous system actions. Pharmacol Rev 1989; 41:489-537.
    116) Delaney KA, Vassallo SU, & Goldfrank LR: Thermoregulatory principles, in: Goldfrank LR, Flomenbaum NE, Lewin NA et al (Eds): Goldfrank's Toxicologic Emergencies, 5th ed, Appleton & Lange, Norwalk, CT, 1994, pp 151-159.
    117) Dickerman JD, Bishop W, & Marks JF: Acute ethanol intoxication in a child. Pediatrics 1968; 42:837-840.
    118) Diez A, Puig J, & Serrano S: Alcohol-induced bone disease in the absence of severe chronic liver damage. J Bone Miner Res 1994; 9:825-831.
    119) Doyon S & Welsh C: Intoxication of a prison inmate with an ethyl alcohol-based hand sanitizer. N Engl J Med 2007; 356(5):529-530.
    120) DuPont: DuPont Suit Smart: Interactive Tool for the Selection of Protective Apparel. DuPont. Wilmington, DE. 2002. Available from URL: http://personalprotection.dupont.com/protectiveapparel/suitsmart/smartsuit2/na_english.asp. As accessed 10/31/2002.
    121) DuPont: Permeation Guide for DuPont Tychem Protective Fabrics. DuPont. Wilmington, DE. 2003. Available from URL: http://personalprotection.dupont.com/en/pdf/tyvektychem/pgcomplete20030128.pdf. As accessed 4/26/2004.
    122) DuPont: Permeation Test Results. DuPont. Wilmington, DE. 2002a. Available from URL: http://www.tyvekprotectiveapprl.com/databases/default.htm. As accessed 7/31/2002.
    123) Dukes NMA: Meyler's Side Effects of Drugs, Ann 5, Excerpta Medica, New York, NY, 1981.
    124) EPA: Search results for Toxic Substances Control Act (TSCA) Inventory Chemicals. US Environmental Protection Agency, Substance Registry System, U.S. EPA's Office of Pollution Prevention and Toxics. Washington, DC. 2005. Available from URL: http://www.epa.gov/srs/.
    125) ERG: Emergency Response Guidebook. A Guidebook for First Responders During the Initial Phase of a Dangerous Goods/Hazardous Materials Incident, U.S. Department of Transportation, Research and Special Programs Administration, Washington, DC, 2004.
    126) Edwards HG & Dow-Edwards DL: Craniofacial alterations in adult rats prenatally exposed to ethanol. Teratology 1991; 44:373-378.
    127) Edwards WM & Hoyt R: Alcoholic ketoacidosis. S Med J 1973; 66:281-282.
    128) Eilam O & Heyman SN: Wenckebach-type atrioventricular block in severe alcohol intoxication (Letter). Ann Emerg Med 1991; 1170.
    129) Eliason MJ & Williams JK: Fetal alcohol syndrome and the neonate. J Perinat Neonatal Nurs 1990; 3:64-72.
    130) Ellenhorn MJ & Barceloux DG: Ethanol, in: Ellenhorn MJ & Barceloux DG (Eds): Medical Toxicology: Diagnosis and Treatment of Human Poisoning, Elsevier, New York, NY, 1988.
    131) Elliott RW & Hunter PR: Acute ethanol poisoning treated by haemodialysis. Postgrad Med J 1974; 50:515-517.
    132) Eriksson CJP, Fukunaga T, & Sarkola T: Estrogen-related acetaldehyde elevation in women during alcohol intoxication. Alcoholism Clin Exp Res 1996; 20:1192-1195.
    133) Ernhart CB: Alcohol Clin Exp Res 1985; 9:447-453.
    134) Estruch R, Nicolas JM, & Villegas E: Relationship between ethanol-related diseases and nutritional status in chronically alcoholic men. Alcohol Alcohol 1993; 28:543-550.
    135) Ettinger PO, CF, & De La Cruz C Jr: Wu. Am Heart J 1978; 95:555-562.
    136) Falkensson M, Jones W, & Sorbo B: Bedside diagnosis of alcohol intoxication with a pocket-size breath-alcohol device: sampling from unconscious subjects and specificity for ethanol. Clin Chem 1989; 35:918-921.
    137) Ferko AP & Bobyock E: Toxicol Appl Pharmacol 1977; 40:269-276.
    138) Fett DL & Vukov LF: An unusual case of severe griseofulvin-alcohol interaction. Am J Emerg Med 1994; 24:95-97.
    139) Field JB, Williams HE, & Mortimore GE: Studies on the mechanism of ethanol-induced hypoglycemia. J Clin Invest 1963; 42:497-506.
    140) Fields JZ, Turk A, & Durkin M: Increased gastrointestinal symptoms in chronic alcoholics. Am J Gastrointerol 1994; 89:382-386.
    141) Filley CM & Kelly JP: Alcohol- and drug-related neurotoxicity. Curr Opin Neurol Neurosurg 1993; 6:443-447.
    142) Fisher HR, Simson RI, & Kapur BM: Calculation of blood alcohol concentration (BAC) by sex, weight, number of drinks and time. Canad J Public Health 1987; 78:300-304.
    143) Fisher SE: Ethanol alters hormone production in cultured human placental trophoblasts. Alcohol Clin Exp Res 1993; 17:816-821.
    144) Flannery MT, Altus P, & Taub LD: Alcohol withdrawal with an unusual presentation. S Med J 1991; 84:1408-1409.
    145) Fong HF & Muller AA: An unexpected clinical course in a 29-day-old infant with ethanol exposure. Pediatr Emerg Care 2014; 30(2):111-113.
    146) French SW & Morris JR: Res Commun Chem Pathol Pharmacol 1972; 4:221-233.
    147) Froster UG & Baird PA: Congenital defects of the limbs and alcohol exposure in pregnancy - data from a population based study. Am J Med Genet 1992; 44:782-785.
    148) Fujiwara T, Watanabe M, & Matsuda K: Complex partial status epilepticus provoked by ingestion of alcohol: a case report. Epilepsia 1991; 32:650-656.
    149) Galea P & Goel K: The fetal alcohol syndrome. Scot Med J 1989; 34:505.
    150) Gapstur SM, Potter JD, & Sellers TA: Increased risk of breast cancer with alcohol consumption in postmenopausal women. Am J Epidemiol 1992; 136:1221-1231.
    151) Gengo FM, Gabos C, & Straley C: The pharmacodynamics of ethanol: Effects on performance and judgment. J Clin Pharmacol 1990; 30:748-754.
    152) Gershman H & Steeper J: Rate of clearance of ethanol from the blood of intoxicated patients in the emergency department. J Emerg Med 1991; 9:307-311.
    153) Gibson PJ, Cant AJ, & Mant TGK: Ethanol poisoning. Acta Pediatr Scand 1985; 74:977-978.
    154) Gill R, Hatchett SE, & Broster CG: The response of evidential breath alcohol testing instruments with subjects exposed to organic solvents and gases. 1. Toluene, 1,1,1-Trichloroethane and butane. Med Sci Law 1991b; 31:187-200.
    155) Gill R, Warner HE, & Broster CG: The response of evidential breath alcohol testing instruments with subjects exposed to organic solvents and gases. II. White spirit and nonane. Med Sci Law 1991a; 31:201-213.
    156) Gimenez ER, Vallejo NE, & Roy E: Percutaneous alcohol intoxication. Clin Toxicol 1968; 1:39-48.
    157) Goldfrank LR, Flomenbaum NE, & Lewin NA: Goldfrank's Toxicologic Emergencies, 6th ed, Appleton & Lange, Stamford, CT, 1998.
    158) Goldfrank LR, Flomenbaum NE, & Weisman RS: Vital signs and toxic syndromes, in: Goldfrank LR, Flomenbaum NE, Lewin NA et al (Eds): Goldfrank's Toxicologic Emergencies, 5th ed, Appleton & Lange, Norwalk, CT, 1994, pp 143-149.
    159) Gomez HR, Moore L, & Davis M: Elevation of breath ethanol measurements by metered dose inhalers (Abstract). Vet Human Toxicol 1992; 34:358.
    160) Gossel TA & Bricker JD: Principles of Clinical Toxicology, 3rd ed, Raven Press, New York, NY, 1994.
    161) Grant WM & Schuman JS: Toxicology of the Eye, 4th ed, Charles C Thomas, Springfield, IL, 1993.
    162) Greene T, Ernhart CB, & Ager J: Prenatal alcohol exposure and cognitive development in the preschool years. Neurotoxicol Teratol 1991; 13:57-68.
    163) Gregory M: Alcohol-induced hypoglycaemia presenting as drug intoxication. J Clin Forens Med 2003; 10:191-192.
    164) Grieve SJ & Littleton JM: Br J Parmacol 1978; 63:375-376.
    165) Gronbaek M & Sorensen TIA: Alcohol consumption and risk of coronary heart disease - studies suggest that wine has additional effect to that of ethanol. BMJ 1996; 313:365.
    166) Grossmann A, Astley SJ, & Liggitt HD: Immune function in offspring of nonhuman primates (macaca- nemestrina) exposed weekly to 1.8 g/kg ethanol during pregnancy - preliminary observations. Alcohol Clin Exp Res 1993; 17:822-827.
    167) Guardian Manufacturing Group: Guardian Gloves Test Results. Guardian Manufacturing Group. Willard, OH. 2001. Available from URL: http://www.guardian-mfg.com/guardianmfg.html. As accessed 12/11/2001.
    168) Gutierrez CA, Lambert C, & Harrah J: Moderate alcohol intoxication directly reduces peripheral oxygen delivery and utilization (abstracts). Acad Emerg Med 1999; 6:391-392.
    169) HSDB : Hazardous Substances Data Bank. National Library of Medicine. Bethesda, MD (Internet Version). Edition expires 10/31/2000; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    170) HSDB: Hazardous Substances Data Bank. National Library of Medicine. Bethesda, MD (Internet Version). Edition expires 2002; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    171) HSDB: Hazardous Substances Data Bank. National Library of Medicine. Bethesda, MD (Internet Version). Edition expires 2009; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    172) HSDB: Hazardous Substances Data Bank. National Library of Medicine. Bethesda, MD, USA (Internet Version). Edition expires 2002; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    173) Haddad LM, Shannon MW, & Winchester JF: Clinical Management of Poisoning and Drug Overdose, 3rd ed, WB Saunders Company, Philadelphia, PA, 1998.
    174) Hakim RB, Gray RH, & Zacur H: Alcohol and caffeine consumption and decreased fertility. Fertil Steril 1998; 70:632-637.
    175) Hammond KB, Rumack BH, & Rodgerson DO: Blood ethanol: a report of unusually high levels in a living patient. JAMA 1973; 226:63-64.
    176) Hannigan JH, Abel EL, & Kruger ML: Population characteristics of birthweight in an animal model of alcohol-related developmental effects. Neurotoxicol Teratol 1993; 15:97-105.
    177) Hanson JW: J Pediatr 1978; 92:457-460.
    178) Harbison RD: Hamilton & Hardy's Industrial Toxicology, 5th ed, Mosby-Year Book, Inc, St. Louis, MO, 1998a.
    179) Harbison RD: Hamilton & Hardy's Industrial Toxicology, 5th ed, Mosby-Year Books, St. Louis, MO, 1998.
    180) Hardell L, Bengtsson NO, & Jonsson U: Br J Cancer 1984; 50:389-397.
    181) Hartmann RJ: Proc West Pharmacol Soc 1984; 27:251-253.
    182) Hasumura Y, Trschke R, & Lieber CS: Increased carbon tetrachloride hepatotoxicity, and its mechanism, after chronic ethanol consumption. Gastroenterology 1974; 66:415-422.
    183) Hathaway GJ, Proctor NH, & Hughes JP: Chemical Hazards of the Workplace, 4th ed, Van Nostrand Reinhold Company, New York, NY, 1996.
    184) Hayes RB, Brown LM, & Schoenberg JB: Alcohol use and prostate cancer risk in US blacks and whites. Am J Epidemiol 1996; 143:692-697.
    185) Heatley MK & Crane J: The relationship between blood and urine alcohol concentration at autopsy. Med Sci Law 1989; 29:209-217.
    186) Hegenbarth MA & American Academy of Pediatrics Committee on Drugs: Preparing for pediatric emergencies: drugs to consider. Pediatrics 2008; 121(2):433-443.
    187) Hekmatpanah J, Haghighat N, & Adams CR: Alcohol consumption by nursing rats and its effect on the cerebellum of the offspring. Alcohol Alcohol 1994; 29:535-547.
    188) Heminki K & Vineis P: Teratogen Carcinogen Mutagen 1985; 5:251-318.
    189) Hendrikx JJ, Lagas JS, Daling R, et al: Severe lactic acidosis in a diabetic patient after ethanol abuse and floor cleaner intake. Basic Clin Pharmacol Toxicol 2014; 115(5):472-475.
    190) Henning RJ, Wilson LD, & Glauser JM: Cocaine plus ethanol is more cardiotoxic than cocaine or ethanol alone. Crit Care Med 1994; 22:1896-1906.
    191) Henretig F & Vuignier B: Mouthwash ingestions in young children (Abstract). Vet Human Toxicol 1989; 31:338.
    192) Hill RM, Hegemier S, & Tennyson LM: The fetal alcohol syndrome: a multihandicapped child. Neurotoxicol 1989; 10:585-596.
    193) Hills BW & Venable HL: Am J Ind Med 1982; 3:321-334.
    194) Hinds MW, Kolonel LN, & Lee J: Br J Cancer 1980; 41:929-940.
    195) Hoey L, Joslin S, & Vance-Bryan K: Letters to the Editor. Ann Pharmacother 1994; 28:972.
    196) Hoffman RS & Goldfrank LR: Ethanol-associated metabolic disorders. Emerg Med Clin North Am 1989; 7:943-961.
    197) Hornfeldt CS: A report of acute ethanol poisoning in a child: mouthwash versus cologne, perfume and after-shave. Clin Toxicol 1992; 30:115-121.
    198) Howard PH: Handbook of Environmental Fate and Exposure Data for Organic Chemicals, Volume III: Pesticides, Lewis Publishers, Chelsea, MI, 1991.
    199) Howard PH: Handbook of Environmental Fate and Exposure Data for Organic Chemicals. Volume II: Solvents, Lewis Publishers, Chelsea, MI, 1990.
    200) Howland MA: Ethanol, in: Goldfrank LR, Flomenbaum NE, Lewin NA et al (Eds): Goldfrank's Toxicologic Emergencies, 5th ed, Appleton & Lange, Norwalk, CT, 1994, pp 841-843.
    201) Hulten BA, Heath A, & Mellstrand T: Does alcohol adsorb to activated charcoal?. Human Toxicol 1985; 5:211-212.
    202) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: 1,3-Butadiene, Ethylene Oxide and Vinyl Halides (Vinyl Fluoride, Vinyl Chloride and Vinyl Bromide), 97, International Agency for Research on Cancer, Lyon, France, 2008.
    203) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol, 88, International Agency for Research on Cancer, Lyon, France, 2006.
    204) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Household Use of Solid Fuels and High-temperature Frying, 95, International Agency for Research on Cancer, Lyon, France, 2010a.
    205) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines, 89, International Agency for Research on Cancer, Lyon, France, 2007.
    206) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Non-heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures, 92, International Agency for Research on Cancer, Lyon, France, 2010.
    207) IARC: List of all agents, mixtures and exposures evaluated to date - IARC Monographs: Overall Evaluations of Carcinogenicity to Humans, Volumes 1-88, 1972-PRESENT. World Health Organization, International Agency for Research on Cancer. Lyon, FranceAvailable from URL: http://monographs.iarc.fr/monoeval/crthall.html. As accessed Oct 07, 2004.
    208) ICAO: Technical Instructions for the Safe Transport of Dangerous Goods by Air, 2003-2004. International Civil Aviation Organization, Montreal, Quebec, Canada, 2002.
    209) ILC Dover, Inc.: Ready 1 The Chemturion Limited Use Chemical Protective Suit, ILC Dover, Inc., Frederica, DE, 1998.
    210) ILO : Encyclopaedia of Occupational Health and Safety, 4th ed, Vols 1 - 4. (CD ROM Version). International Labour Organization. Geneva, Switzerland. 1998a.
    211) ILO : Encyclopedia of Occupational Health and Safety, 4th ed. Vol 1-4. (CD ROM Version). International Labour Organization. Geneva, Switzerland. 1998.
    212) ITI: Toxic and Hazardous Industrial Chemicals Safety Manual, The International Technical Information Institute, Tokyo, Japan, 1995.
    213) Ida Y, Tsujimaru S, & Nakamaura K: Effects of acute and repeated alcohol ingestion on hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal functioning in normal males. Drug Alcohol Depend 1992; 31:57-64.
    214) Ifudu O & Markel M: Rhabdomyolysis associated with pneumococcal pneumonia and sepsis in an abstinent alcohol abuser (Letter). State J Med 1992; 92:24-25.
    215) Ikonomidou C, Bittigau P, & Ishimaru MJ: Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 2000; 287:1056-1060.
    216) International Agency for Research on Cancer (IARC): IARC monographs on the evaluation of carcinogenic risks to humans: list of classifications, volumes 1-116. International Agency for Research on Cancer (IARC). Lyon, France. 2016. Available from URL: http://monographs.iarc.fr/ENG/Classification/latest_classif.php. As accessed 2016-08-24.
    217) International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. World Health Organization. Geneva, Switzerland. 2015. Available from URL: http://monographs.iarc.fr/ENG/Classification/. As accessed 2015-08-06.
    218) Jacobson JL, Jacobson SW, & Sokol RJ: Effects of alcohol use, smoking, and illicit drug use on fetal growth in black infants. J Pediatr 1994; 124:757-764.
    219) Jacobson SW, Jacobson JL, & Sokol RJ: Prenatal alcohol exposure and infant information processing ability. Child Development 1993; 64:1706-1721.
    220) Jarvenpaa T, Rinne JO, Koskenvuo M, et al: Binge drinking in midlife and dementia risk. Epidemiology 2005; 16(6):766-771.
    221) Jatlow P: Acute toxicology of ethanol ingestion. Role of the clinical laboratory. AJCP 1980; 74:721-724.
    222) Jeffreys DB, Flanagan RJ, & Volans GN: Reversal of ethanol-induced coma with naloxone. Lancet 1980; 1:308-309.
    223) Jenkins DW, Eckel RE, & Craig JW: Alcoholic ketoacidosis. JAMA 1971; 217:177-183.
    224) Jennison KM & Johnson KA: Drinking-induced blackouts among young adults: results from a national longitudinal study. Internat J Addict 1994; 29:23-51.
    225) Jerrells TR, Saad AJ, & Domiati-saad R: Effects of ethanol on parameters of cellular immunity and host defense mechanisms to infectious agents. Alcohol 1992; 9:459-463.
    226) Johnson HRM: At what blood levels does alcohol kill?. Med Sci Law 1985; 25:127-130.
    227) Johnson RA, Noll EC, & Rodney WM: Survival after a serum ethanol concentration of 1.5% (Letter). Lancet 1982; 2:1394.
    228) Johnstone RE & Reier CE: Acute respiratory effects of ethanol in man. Clin Pharmacol Ther 1973; 14:501-508.
    229) Jones AW: Low alcohol drinks and risk of high blood alcohol in children (letter). Clin Toxicol 1996; 34:349-350.
    230) Jones AW: Relationship between blood and breath alcohol concentration in a subject absorbing alcohol at the time of testing (Letter). J Anal Toxicol 1991; 15:44-45.
    231) Jones KL & Smith DW: Description of the fetal alcohol syndrome in early infancy. Lancet 1973; 2:999.
    232) Jung AL, Roan Y, & Temple AR: Neonatal death associated with acute transplacental ethanol intoxication. Am J Dis Child 1980; 134:419-420.
    233) Juntunen J: Alcoholism in occupational neurology: diagnostic difficulties with special reference to the neurological syndromes caused by exposure to organic solvents. Acta Neurol Scandinav 1982; 66:89-108.
    234) Kallas P & Sellers EM: Blood glucose in intoxicated chronic alcoholics. CMA J 1975; 112:590-592.
    235) Kanwar KC & Tikoo A: Hematological lesions in rat following heavy alcohol ingestion. J Environ Pathol Toxicol Oncol 1992; 11:241-245.
    236) Kanzaki T & Hori H: Late phase allergic reaction of the skin to ethyl alcohol. Contact Dermatitis 1991; 25:252-253.
    237) Kappler, Inc.: Suit Smart. Kappler, Inc.. Guntersville, AL. 2001. Available from URL: http://www.kappler.com/suitsmart/smartsuit2/na_english.asp?select=1. As accessed 7/10/2001.
    238) Kartsonis A, Reddy KR, & Schiff ER: Alcohol, acetaminophen, and hepatic necrosis (Letter). Ann Intern Med 1986; 105:138-139.
    239) Kartsonis A, Reddy KR, & Schiff ER: Alcohol, acetaminophen, and hepatic necrosis. Ann Int Med 1986a; 105:138-9.
    240) Kay HH, Grindle KM, & Magness RR: Ethanol exposure induces oxidative stress and impairs nitric oxide availability in the human placental villi: a possible mechanism of toxicity. Am J Obstet Gynecol 2000; 182:682-688.
    241) Keim ME, Bartfield JM, & Raccio-Robak N: Accuracy of an enzymatic assay device for serum ethanol measurement. Clin Toxicol 1999; 37:75-81.
    242) Keim ME, Bartfield JM, & Racciorobak N: Blood ethanol estimation - a comparison of three methods. Acad Emerg Med 1996; 3:85-87.
    243) Kimberly-Clark, Inc.: Chemical Test Results. Kimberly-Clark, Inc.. Atlanta, GA. 2002. Available from URL: http://www.kc-safety.com/tech_cres.html. As accessed 10/4/2002.
    244) Kon S & Ikeda M: Br J Cancer 1979; 40:449-455.
    245) Kotch LE, Chen SY, & Sulik KK: Ethanol-induced teratogenesis - free radical damage as a possible mechanism. Teratology 1995; 52:128-136.
    246) Koul PB, Sussmane JB, Cunil-De Sautu B, et al: Atrial fibrillation associated with alcohol ingestion in adolescence: holiday heart in pediatrics. Ped Emerg Care 2005; 21:38-39.
    247) Kouvaras G & Cokkinos D: Effects of alcohol on the heart: current views. Angiology 1986; 37:592-600.
    248) LaCrosse-Rainfair: Safety Products, LaCrosse-Rainfair, Racine, WI, 1997.
    249) Lam KC, Yu MC, & Leung JWC: Cancer Res 1982; 42:5246-5248.
    250) Langhan ML: Acute alcohol intoxication in adolescents: frequency of respiratory depression. J Emerg Med 2013; 44(6):1063-1069.
    251) Laposata EA, Scherrer DE, & Lange LG: Fatty acid ethyl esters in adipose tissue: a laboratory marker for alcohol-related death. Arch Pathol Lab Med 1989; 113:762-766.
    252) Larremore T: Alcohol-induced ketoacidosis and hypoglycemia. Topics Emerg Med 1984; 6:48-57.
    253) Larroque B, Kaminski M, & Dehaene P: Moderate prenatal alcohol exposure and psychomotor development at preschool age. Am J Public Health 1995; 85:1654-1661.
    254) Lee BH: Korean J Biochem 1977; 9:29-42.
    255) Leung AKC: Ethyl alcohol ingestion in children: a 15-year review. Clin Pediatr 1986; 25:617-619.
    256) Lewis RA: Lewis' Dictionary of Toxicology, Lewis Publishers, Boca Raton, FL, 1998.
    257) Lewis RJ: Hawley's Condensed Chemical Dictionaly, 13th ed, John Wiley & Sons, Inc, New York, NY, 1997a.
    258) Lewis RJ: Hawley's Condensed Chemical Dictionary, 13th ed, John Wiley & Sons, Inc, New York, NY, 1997.
    259) Lewis RJ: Sax's Dangerous Properties of Industrial Materials, 10th ed, Van Nostrand Reinhold Company, New York, NY, 2000.
    260) Lheureux P & Askenasi R: Efficacy of flumazenil in acute alcohol intoxication: double blind placebo-controlled evaluation. Human Exp Toxicol 1991; 10:235-239.
    261) Li J, Mills T, & Erato R: Intravenous saline has no effect on blood ethanol clearance. J Emerg Med 1999; 17:1-5.
    262) Lieber CS & DeCarli LM: Hepatotoxicity of ethanol. J Hepatol 1991; 12:394-401.
    263) Lien D & Mader TJ: Survival from profound alcohol-related lactic acidosis. J Emerg Med 1999; 17:841-846.
    264) Lignian H, Fontaine J, & Askenase R: Naloxone alcoholic intoxication. Ann Intern Med 1982; 97:255-256.
    265) Lin RC, Shahidi S, & Kelly TJ: Measurement of hemoglobin-acetaldehyde adduct in alcoholic patients. Alcohol Clin Exp Res 1993; 17:669-674.
    266) Lin YJ, Weidler DJ, & Garg DC: Effects of solid food on blood levels of alcohol in man. Res Commun Chem Pathol Pharmacol 1976; 13:713-722.
    267) Linneberg A, Petersen J, Gronbaek M, et al: Alcohol during pregnancy and atopic dermatitis in the offspring. Clin Exp Allergy 2004; 34:1678-1683.
    268) Little RE & Streissguth AP: CMA J 1981; 125:159-164.
    269) Little RE, Anderson KW, Ervin CH, et al: Maternal alcohol use during breast-feeding and infant mental and motor development at one year. N Engl J Med 1989; 321:425-430.
    270) Loddenkemper T & Goodkin HP: Treatment of Pediatric Status Epilepticus. Curr Treat Options Neurol 2011; Epub:Epub.
    271) Ludwig E & Hausen BM: Contact Dermatitis 1977; 3:240-244.
    272) Lynch J: J Occup Med 1979; 21:333-341.
    273) Lyon LJ & Antony J: Reversal of alcoholic coma by naloxone. Ann Intern Med 1982; 96:464-465.
    274) MAPA Professional: Chemical Resistance Guide. MAPA North America. Columbia, TN. 2003. Available from URL: http://www.mapaglove.com/pro/ChemicalSearch.asp. As accessed 4/21/2003.
    275) MAPA Professional: Chemical Resistance Guide. MAPA North America. Columbia, TN. 2004. Available from URL: http://www.mapaglove.com/ProductSearch.cfm?id=1. As accessed 6/10/2004.
    276) Macdonald RC & Kimmerer TW: Metabolism of transpired ethanol by eastern Cottonwood (Populus deltoides Bartr). Plant Physiol 1993; 102:173-179.
    277) Madlom MM: Alcohol consumption during pregnancy and infants' development (Letter). Br Med J 1991; 303-646.
    278) Manno EM: New management strategies in the treatment of status epilepticus. Mayo Clin Proc 2003; 78(4):508-518.
    279) Mar-Mac Manufacturing, Inc: Product Literature, Protective Apparel, Mar-Mac Manufacturing, Inc., McBee, SC, 1995.
    280) Mardel S, Phair I, & O'Dwyer F: Intravenous pyridoxine in acute ethanol intoxication. Human Exp Toxicol 1994; 13:321-323.
    281) Marigold Industrial: US Chemical Resistance Chart, on-line version. Marigold Industrial. Norcross, GA. 2003. Available from URL: www.marigoldindustrial.com/charts/uschart/uschart.html. As accessed 4/14/2003.
    282) Martin JB, Craig JW, & Eckel RE: Hypokalemic myopathy in chronic alcoholism. Hypokalemic myopathy in chronic alcoholism 1971; 21:1160-1168.
    283) Marway JS, Maheshwari HG, & Norman M: Tumor necrosis factor, interleukin-6 and growth hormone binding protein in acute and chronic experimental ethanol toxicity. Biochem Soc Trans 1994; 22:351S.
    284) Mattila MJ, Nvotto E, & Seppala T: Naloxone is not an effective antagonist of ethanol. Lancet 1981; 1:775-776.
    285) Mattson SN, Riley EP, & Gramling L: Heavy prenatal alcohol exposure with or without physical features of fetal alcohol syndrome leads to IQ deficits. J Pediatr 1997; 131:718-721.
    286) Mayo-Smith MF: Pharmacological management of alcohol withdrawal: a meta- analysis and evidence-based practice guideline. JAMA 1997; 278:144-151.
    287) McCowan C & Marik P: Refractory delirium tremens treated with propofol: a case series. Crit Care Med 2000; 28:1781-1784.
    288) McGinnity de Laveaga J & Caravati EM: Successful treatment of severe pediatric alcohol poisoning with hemodialysis: 2015 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT). Clin Toxicol 2015; 53(7):755-756.
    289) McGivern RF, Handa RJ, & Redei E: Decreased postnatal testosterone surge in male rats exposed to ethanol during the last week of gestation. Alcohol Clin Exp Res 1993; 17:1215-1222.
    290) Memphis Glove Company: Permeation Guide. Memphis Glove Company. Memphis, TN. 2001. Available from URL: http://www.memphisglove.com/permeation.html. As accessed 7/2/2001.
    291) Mennella JA & Beauchamp GK: The transfer of alcohol to human milk: effects on flavor and the infant's behavior. Obstet Gynecol Survey 1992; 47:166-168.
    292) Miller MW: Effect of pre- or postnatal exposure to ethanol on the total number of neurons in the principal sensory nucleus of the trigeminal nerve - cell proliferation and neuronal death. Alc Clin Exp Res 1995; 19:1359-1363.
    293) Minera G & Robinson E: Accidental acute alcohol intoxication in infants: review and case report. J Emerg Med 2014; 47(5):524-526.
    294) Minocha A, Herold DA, & Barth JT: Activated charcoal in oral ethanol absorption: lack of effect in humans. Clin Toxicol 1986; 24:225-234.
    295) Miwa K, Igawa A, & Miyagi Y: Importance of magnesium deficiency in alcohol-induced variant angina. Am J Cardiol 1994; 73:813-816.
    296) Moghadam BKH, Gier R, & Thurlow T: Extensive oral mucosal ulcerations caused by misuse of a commercial mouthwash. Cutis 1999; 64:131-134.
    297) Montgomery Safety Products: Montgomery Safety Products Chemical Resistant Glove Guide, Montgomery Safety Products, Canton, OH, 1995.
    298) Morse JMD & Thomas E: Hepatic toxicity from disinfectant abuse. JAMA 1984; 252:1904.
    299) Moss MH: Alcohol induced hypoglycemia and coma caused by alcohol sponging. Pediatrics 1970; 46:445-447.
    300) Mrvos R & Krenzelok EP: Pediatric Ingestions of Hand Sanitizers: Debunking the Myth. Pediatr Emerg Care 2009; 25(10):665-666.
    301) Myerson RM & Rubin W: Ethanol: mimicry, masquerade, and mayhem. Prim Care Rep 1992; 8:51-58.
    302) NFPA: Fire Protection Guide to Hazardous Materials, 12th ed, National Fire Protection Association, Quincy, MA, 2002a.
    303) NFPA: Fire Protection Guide to Hazardous Materials, 13th ed., National Fire Protection Association, Quincy, MA, 2002.
    304) NIOSH : Pocket Guide to Chemical Hazards. National Institute for Occupational Safety and Health. Cincinnati, OH (Internet Version). Edition expires 1998; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    305) NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 1, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2001.
    306) NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 2, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2002.
    307) NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 3, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2003.
    308) NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 4, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2004.
    309) Nakao S, Harada M, & Kondo K: Reversible bone marrow hypoplasia induced by alcohol. Am J Hematol 1991; 37:120-123.
    310) Naradzay J & Barish RA: Approach to ophthalmologic emergencies. Med Clin North Am 2006; 90(2):305-328.
    311) Nat-Wear: Protective Clothing, Hazards Chart. Nat-Wear. Miora, NY. 2001. Available from URL: http://www.natwear.com/hazchart1.htm. As accessed 7/12/2001.
    312) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2,3-Trimethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d68a&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    313) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2,4-Trimethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006m. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d68a&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    314) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2-Butylene Oxide (Proposed). United States Environmental Protection Agency. Washington, DC. 2008d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648083cdbb&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    315) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2-Dibromoethane (Proposed). United States Environmental Protection Agency. Washington, DC. 2007g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064802796db&disposition=attachment&contentType=pdf. As accessed 2010-08-18.
    316) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,3,5-Trimethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d68a&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    317) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 2-Ethylhexyl Chloroformate (Proposed). United States Environmental Protection Agency. Washington, DC. 2007b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648037904e&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    318) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Acrylonitrile (Proposed). United States Environmental Protection Agency. Washington, DC. 2007c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648028e6a3&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    319) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Adamsite (Proposed). United States Environmental Protection Agency. Washington, DC. 2007h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    320) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Agent BZ (3-quinuclidinyl benzilate) (Proposed). United States Environmental Protection Agency. Washington, DC. 2007f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803ad507&disposition=attachment&contentType=pdf. As accessed 2010-08-18.
    321) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Allyl Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2008. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648039d9ee&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    322) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Aluminum Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    323) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Arsenic Trioxide (Proposed). United States Environmental Protection Agency. Washington, DC. 2007m. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480220305&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    324) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Automotive Gasoline Unleaded (Proposed). United States Environmental Protection Agency. Washington, DC. 2009a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cc17&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    325) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Biphenyl (Proposed). United States Environmental Protection Agency. Washington, DC. 2005j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064801ea1b7&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    326) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Bis-Chloromethyl Ether (BCME) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006n. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648022db11&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    327) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Boron Tribromide (Proposed). United States Environmental Protection Agency. Washington, DC. 2008a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803ae1d3&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    328) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Bromine Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2007d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648039732a&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    329) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Bromoacetone (Proposed). United States Environmental Protection Agency. Washington, DC. 2008e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809187bf&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    330) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Calcium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    331) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Carbonyl Fluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2008b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803ae328&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    332) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Carbonyl Sulfide (Proposed). United States Environmental Protection Agency. Washington, DC. 2007e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648037ff26&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    333) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Chlorobenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2008c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803a52bb&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    334) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Cyanogen (Proposed). United States Environmental Protection Agency. Washington, DC. 2008f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809187fe&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    335) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Dimethyl Phosphite (Proposed). United States Environmental Protection Agency. Washington, DC. 2009. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cbf3&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    336) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Diphenylchloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    337) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethyl Isocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648091884e&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    338) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethyl Phosphorodichloridate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480920347&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    339) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2008g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809203e7&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    340) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethyldichloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    341) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Germane (Proposed). United States Environmental Protection Agency. Washington, DC. 2008j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963906&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    342) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Hexafluoropropylene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064801ea1f5&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    343) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ketene (Proposed). United States Environmental Protection Agency. Washington, DC. 2007. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ee7c&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    344) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Magnesium Aluminum Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    345) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Magnesium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    346) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Malathion (Proposed). United States Environmental Protection Agency. Washington, DC. 2009k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809639df&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    347) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Mercury Vapor (Proposed). United States Environmental Protection Agency. Washington, DC. 2009b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a8a087&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    348) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyl Isothiocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963a03&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    349) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyl Parathion (Proposed). United States Environmental Protection Agency. Washington, DC. 2008l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963a57&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    350) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyl tertiary-butyl ether (Proposed). United States Environmental Protection Agency. Washington, DC. 2007a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064802a4985&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    351) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methylchlorosilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2005. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5f4&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    352) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyldichloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    353) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyldichlorosilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2005a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c646&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    354) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Mustard (HN1 CAS Reg. No. 538-07-8) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6cb&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    355) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Mustard (HN2 CAS Reg. No. 51-75-2) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6cb&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    356) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Mustard (HN3 CAS Reg. No. 555-77-1) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6cb&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    357) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Tetroxide (Proposed). United States Environmental Protection Agency. Washington, DC. 2008n. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648091855b&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    358) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Trifluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2009l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963e0c&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    359) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Parathion (Proposed). United States Environmental Protection Agency. Washington, DC. 2008o. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963e32&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    360) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Perchloryl Fluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2009c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e268&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    361) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Perfluoroisobutylene (Proposed). United States Environmental Protection Agency. Washington, DC. 2009d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e26a&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    362) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phenyl Isocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008p. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096dd58&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    363) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phenyl Mercaptan (Proposed). United States Environmental Protection Agency. Washington, DC. 2006d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020cc0c&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    364) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phenyldichloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    365) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phorate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008q. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096dcc8&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    366) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phosgene (Draft-Revised). United States Environmental Protection Agency. Washington, DC. 2009e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a8a08a&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    367) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phosgene Oxime (Proposed). United States Environmental Protection Agency. Washington, DC. 2009f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e26d&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    368) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Potassium Cyanide (Proposed). United States Environmental Protection Agency. Washington, DC. 2009g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cbb9&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    369) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Potassium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    370) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Propargyl Alcohol (Proposed). United States Environmental Protection Agency. Washington, DC. 2006e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ec91&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    371) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Selenium Hexafluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2006f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ec55&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    372) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Silane (Proposed). United States Environmental Protection Agency. Washington, DC. 2006g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d523&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    373) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Sodium Cyanide (Proposed). United States Environmental Protection Agency. Washington, DC. 2009h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cbb9&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    374) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Sodium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    375) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Strontium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    376) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Sulfuryl Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2006h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ec7a&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    377) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tear Gas (Proposed). United States Environmental Protection Agency. Washington, DC. 2008s. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096e551&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    378) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tellurium Hexafluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2009i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e2a1&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    379) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tert-Octyl Mercaptan (Proposed). United States Environmental Protection Agency. Washington, DC. 2008r. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096e5c7&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    380) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tetramethoxysilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2006j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d632&disposition=attachment&contentType=pdf. As accessed 2010-08-17.
    381) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Trimethoxysilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2006i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d632&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    382) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Trimethyl Phosphite (Proposed). United States Environmental Protection Agency. Washington, DC. 2009j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7d608&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    383) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Trimethylacetyl Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2008t. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096e5cc&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    384) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Zinc Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    385) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for n-Butyl Isocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008m. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064808f9591&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    386) National Institute for Occupational Safety and Health: NIOSH Pocket Guide to Chemical Hazards, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Cincinnati, OH, 2007.
    387) National Research Council : Acute exposure guideline levels for selected airborne chemicals, 5, National Academies Press, Washington, DC, 2007.
    388) National Research Council: Acute exposure guideline levels for selected airborne chemicals, 6, National Academies Press, Washington, DC, 2008.
    389) National Research Council: Acute exposure guideline levels for selected airborne chemicals, 7, National Academies Press, Washington, DC, 2009.
    390) National Research Council: Acute exposure guideline levels for selected airborne chemicals, 8, National Academies Press, Washington, DC, 2010.
    391) Nava-Ocampo AA, Velazquez-Armenta Y, Brien JF, et al: Elimination kinetics of ethanol in pregnant women. Reproductive Toxicol 2004; 18:613-617.
    392) Neese Industries, Inc.: Fabric Properties Rating Chart. Neese Industries, Inc.. Gonzales, LA. 2003. Available from URL: http://www.neeseind.com/new/TechGroup.asp?Group=Fabric+Properties&Family=Technical. As accessed 4/15/2003.
    393) Nelson BK: Environ Health Perspect 1984; 57:255-259.
    394) Neuvonen PJ, Olkkola KT, & Alanen T: Effect of ethanol and pH on the adsorption of drugs to activated charcoal: studies in vitro and in man. Acta Pharmacol Toxicol 1984; 54(1):1-7.
    395) North: Chemical Resistance Comparison Chart - Protective Footwear . North Safety. Cranston, RI. 2002. Available from URL: http://www.linkpath.com/index2gisufrm.php?t=N-USA1. As accessed April 30, 2004.
    396) North: eZ Guide Interactive Software. North Safety. Cranston, RI. 2002a. Available from URL: http://www.northsafety.com/feature1.htm. As accessed 8/31/2002.
    397) OHM/TADS : Oil and Hazardous Materials/Technical Assistance Data System. US Environmental Protection Agency. Washington, DC (Internet Version). Edition expires 2002a; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    398) OHM/TADS : Oil and Hazardous Materials/Technical Assistance Data System. US Environmental Protection Agency. Washington, DC (Internet Version). Edition expires August/6/2002; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    399) Obe G: Prog Mutat Res 1981; 2:19-23.
    400) Oda H, Suzuki M, & Oniki T: Alcohol and coronary spasm. J Vasc Dis 1994; 45:187-197.
    401) Odeleye OE, Watson RR, & Eskelson CD: Enhancement of cocaine-induced hepatotoxicity by ethanol. Drug Alcohol Depend 1993; 31:253-263.
    402) Odesanmi WO: Observations on unusual cases of sudden unexpected death from acute ethanol poisoning. J Forens Sci Soc 1979; 19:131-133.
    403) Olkkola KT: Factors affecting the antidotal efficacy of oral activated charcoal, Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland, 1985.
    404) Olsen H & Morlan J: Ethanol-induced increase in drug acetylation in man and isolated rat liver cells. Br Med J 1978; 2:1260-1262.
    405) Olson KR: Comprehensive evaluation and treatment of poisoning and overdose, in: Olson KR (Ed): Poisoning & Drug Overdose, Appleton & Lange, Norwalk, CT, 1994a.
    406) Olson KR: Ethanol, in: Olson KR (Ed): Poisoning & Drug Overdose, Appleton & Lange, Norwalk, CT, 1994.
    407) Olyunin IV: Mater Obl Sezda Gig, Sanit Vrachei. Epidemiol, Mikrobiol Infek, 2nd 1970; 39-43.
    408) Ophaswongse S & Maibach HI: Alcohol dermatitis: allergic contact dermatitis and contact urticaria syndrome: a review. Contact Dermatitis 1994a; 30:1-6.
    409) Ophaswongse S & Maibach HI: Alcohol dermatitis: allergic contact dermatitis and contact urticaria syndrome: a review.. Contact Dermatitis 1994; 30:1-6.
    410) Osborn H: Ethanol, in: Goldfrank LR, Flomenbaum NE, Lewin NA et al (Eds): Goldfrank's Toxicologic Emergencies, 5th ed, Appleton & Lange, Norwalk, CT, 1994, pp 813-824.
    411) Oshima A, Tsukuma H, & Hiyama T: Internat J Cancer 1984; 34:775-779.
    412) Ouellette EM, Ouellette EM, & Rosett HL: Adverse effects on offspring of maternal alcohol abuse during pregnancy. New Engl J Med 1977; 297:528-530.
    413) Parker BM: The effects of ethyl alcohol on the heart. JAMA 1974; 228:741-742.
    414) Paula-Barbosa MM, Brandao F, & Madeira MD: Structural changes in the hippocampal formation after long-term alcohol consumption and withdrawal in the rat. Addiction 1993; 88:237-247.
    415) Pavienko SM & Guseva VA: Itogi Nauki Tech, Farmakol, Khimioter Sredstva, Toksikol, Probl Toksikol 1973; 5:110-119.
    416) Pearn JH: Med J Aust 1983; 2:16-20.
    417) Peate WF: Work-related eye injuries and illnesses. Am Fam Physician 2007; 75(7):1017-1022.
    418) Perr IM: Forens Sci 1986; 31:806-811.
    419) Pieninkeroinen IP, Telakivi TM, & Hillborn ME: Outcome in subjects with alcohol-provoked seizures. Alcohol Clin Exp Res 1992; 16:955-959.
    420) Pierog S, Chandavasu O, & Wexler I: Withdrawal symptoms in infants with the fetal alcohol syndrome. J Pediatr 1977; 90:630-633.
    421) Pittman JG & Decker JW: Acute and chronic myopathy associated with alcoholism. Neurology 1971; 21:293-296.
    422) Playtex: Fits Tough Jobs Like a Glove, Playtex, Westport, CT, 1995.
    423) Pohanish RP & Greene SA: Rapid Guide to Chemical Incompatibilities, Van Nostrand Reinhold Company, New York, NY, 1997.
    424) Poklis A & Pearson MS: An unusually high blood ethanol level in a living patient. Clin Toxicol 1977; 10:429-431.
    425) Pollack CV Jr, Jorden RC, & Carlton FB: Gastric emptying in the acutely inebriated patient. J Emerg Med 1992; 10:1-5.
    426) Polychronopoulou A, Tzonou A, & Hsieh CC: Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Internat J Cancer 1993; 55:402-407.
    427) Preedy VR, Siddiq T, & Why HJF: Ethanol toxicity and cardiac protein synthesis in vivo. Am Heart J 1994; 127:1432-1439.
    428) Product Information: ROMAZICON(R) IV injection, flumazenil IV injection. Roche Pharmaceuticals, Nutley, NJ, 2004.
    429) Product Information: diazepam IM, IV injection, diazepam IM, IV injection. Hospira, Inc (per Manufacturer), Lake Forest, IL, 2008.
    430) Product Information: lorazepam IM, IV injection, lorazepam IM, IV injection. Akorn, Inc, Lake Forest, IL, 2008.
    431) Przybilla B & Ring J: Anaphylaxis to ethanol and sensitization to acetic acid (Letter). Lancet 1983; 1:483.
    432) Purssell R, Pudek M, & Brubacher J: Derivation of a formula to calculate the contribution of ethanol to the osmolar gap (abstract). J Tox Clin Tox 1999; 37:655.
    433) Puschel K: Percutaneous alcohol intoxication. Eur J Pediatr 1981; 136:317-318.
    434) RTECS : Registry of Toxic Effects of Chemical Substances. National Institute for Occupational Safety and Health. Cincinnati, OH (Internet Version). Edition expires 2002; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    435) Radike MJ: Environ Health Perspect 1977; 21:153-155.
    436) Rae HG: Retrospective review of ethanol concentration measurements in patients with ethanol overdose treated with naloxone. Curr Ther Res 1986; 49:960-964.
    437) Ragan FA Jr, Samuela MS, & Hite SA: Ethanol ingestion in children. JAMA 1979; 242:2787-2788.
    438) Rall TW: Hypnotics and sedatives; ethanol, in: Gilman AG, Rall RW, Nies AS et al (Eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, Pergamon Press, New York, NY, 1990.
    439) Ramcharitar V, Levine BS, & Goldberger BA: Bupropion and alcohol fatal intoxication: case report. Forens Sci Internat 1992; 56:151-156.
    440) Randall CL, Anton RF, & Becker HC: Teratology 1991; 44:521-529.
    441) Rangno RE, Kreeft JH, & Sitar DS: Ethanol dose dependent elimination: Michaelis-Menten v classical kinetic analysis. Br J Clin Pharmacol 1981; 12:667-673.
    442) Rathlev NK, D'Onofrio G, & Fish SS: The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. Ann Emerg Med 1994; 23:513-518.
    443) Razani-Boroujerdi S, Savage SM, & Sopori ML: Alcohol-induced changes in the immune response: immunological effects of chronic ethanol intake are genetically regulated. Toxic Appl Pharm 1994; 127:37-43.
    444) Reed RJ, Grant I, & Rourke SB: Long-term abstinent alcoholics have normal memory. Alcohol Clin Exp Res 1982; 16:677-683.
    445) Reed RR, Michels JE, & Richardson WH: Two cases of intoxication in children after accidental ingestion of alcohol-based liquid hand sanitizer. Clin Toxicol (Phila) 2010; 48:654.
    446) Rees LH, Besser GM, & Jeffcoate WJ: Alcohol-induced pseudo-Cushing's syndrome. Lancet 1977; 1:726728.
    447) Ricci LR & Hoffman SA: Ethanol-induced hypoglycemic coma in a child. Ann Emerg Med 1982; 11:202-204.
    448) Richardson ED, Malloy PF, & Longabough R: Liver function tests and neuropsychologic impairment in substance abusers. Add Behav 1991; 16:51-55.
    449) Ridker PM, Gibson CM, & Lopez R: Atrial fibrillation induced by breath spray (Letter). N Engl J Med 1989; 320:124.
    450) Riihimaki V, Laine A, & SavolainenK: Acute solvent-ethanol interactions with special reference to xylene. Scand J Work Environ Health 1982; 8:77-79.
    451) Riihimaki V: in: A Aitio et al (Eds), Biological Monitoring and Surveillance of Workers Exposed to Chemicals, Hemisphere, Washington, DC, 1984, pp 231-245.
    452) River City: Protective Wear Product Literature, River City, Memphis, TN, 1995.
    453) Roberts HS, Self RJ, & Coxon M: An unusual complication of hand hygiene (letter). Anaesthesia 2005; 60:100-101.
    454) Rodenberg HD, Bennett JR, & Watson WA: Clinical utility of a saliva alcohol dipstick estimate of serum ethanol concentrations in the emergency department. DICP 1990; 24:358-361.
    455) Rosett HL: J Am Coll Ob Gyn 1983; 61:539-546.
    456) Rubin E, Gang H, & Misra PS: Inhibition of drug metabolism by acute ethanol intoxication: a hepatic microsomal mechanism. Am J Med 1970; 49:801-806.
    457) Ruck B , Calello DP , & Marcus S : Pediatric ingestions of hand sanitizers. Pediatr Emerg Care 2010; 26(9):688-689.
    458) S Budavari : The Merck Index, 12th ed on CD-ROM. Version 12:3a. Chapman & Hall/CRCnetBASE. Whitehouse Station, NJ. 2000a.
    459) Safety 4: North Safety Products: Chemical Protection Guide. North Safety. Cranston, RI. 2002. Available from URL: http://www.safety4.com/guide/set_guide.htm. As accessed 8/14/2002.
    460) Sanap M & Chapman MJ: Severe ethanol poisoning: a case report and brief review. Crit Care Resusc 2003; 5(2):106-108.
    461) Sandmann BJ & Widders IM: Liquid expressions: what they really mean. Am Pharm 1988; NS28:48.
    462) Santucci L: Alcohol Clin Exp Res 1983; 7:135-139.
    463) Scherger DL, Wruk KM, & Kulig KW: Ethyl alcohol (ethanol)-containing cologne, perfume, and after-shave ingestions in children. Am J Dis Child 1988; 142:630-632.
    464) Schmeltz I: J Anal Toxicol 1978; 2:265-268.
    465) Schneir AB & Clark RF: Death caused by ingestion of an ethanol-based hand sanitizer. J Emerg Med 2013; 45(3):358-360.
    466) Scott R, Besag FMC, & Neville BGR: Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomized trial. Lancet 1999; 353:623-626.
    467) Selbst SM, De Maio JG, & Boenning D: Mouthwash poisoning: report of a fatal case. Clin Pediatr 1985; 24:162-163.
    468) Servus: Norcross Safety Products, Servus Rubber, Servus, Rock Island, IL, 1995.
    469) Sheehy TW: Alcohol and the heart: how it helps, how it harms. Postgrad Med 1992; 91:271-277.
    470) Shim JS, Jung JT, & Sofer S: Oxidation of ethanol vapors in a spiral reactor. J Chem Technol Biotechnol 1995; 64:49-54.
    471) Shoemaker WJ: Neurobehav Toxicol Teratol 1981; 3:431-436.
    472) Shu XO, Ross JA, & Pendergrass TW: Parental alcohol consumption, cigarette smoking, and risk of infant leukemia - a Childrens Cancer Group study. J Nat Cancer Inst 1996; 88:24-31.
    473) Siddiq T, Patel VB, & Richardson PJ: Biochem Soc Trans 1994; 22:173S.
    474) Siddiq T, Salisbury JR, & Richardson PJ: Synthesis of ventricular mitochondrial proteins in vivo: effect of acute ethanol toxicity. Alcohol Clin Exp Res 1993; 17:894-899.
    475) Sidell FR & Pless JE: Ethyl alcohol: blood levels and performance decrements after oral administration to man. Psychopharmacol 1971; 19:246-261.
    476) Silber E, Reilly M, & Al-Moallem M: Brachial plexopathy related to alcohol intoxication. J Neurol Neurosurg Psychiat 1999; 67:411-412.
    477) Silverman BL: Perfumes possibly perilous to pediatric patients (Letter). Am J Dis Child 1990; 144:15.
    478) Singh M & Simsek H: Ethanol and the pancreas: current status.. Gastroenterology 1990; 98:1051-1062.
    479) Singh NP, Lai H, & Khan A: Ethanol-induced single-strand DNA breaks in rat brain cells. Mutat Res 1995; 345(3-4):191-196.
    480) Sittig M: Handbook of Toxic and Hazardous Chemical and Carcinogens, 3rd ed, Noyes Publications, Park Ridge, NJ, 1991a.
    481) Sittig M: Handbook of Toxic and Hazardous Chemicals and Carcinogens, 3rd ed, Noyes Publications, Park Ridge, NJ, 1991.
    482) Smith DM & Atkinson RM: Alcoholism and dementia. Int J Addict 1995; 30:1843-1869.
    483) Smith-Warner S, Spiegelman D, & Yaun SS: Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998; 279:535-540.
    484) Snyder R: Ethel Browning's Toxicity and Metabolism of Industrial Solvents: Alcohols and Esters, 2nd ed, 3, Elsevier Science Publishing Company Inc, New York, NY, 1992a.
    485) Snyder R: Ethel Browning's Toxicity and Metabolism of Industrial Solvents: Vol 3, Alcohols and Esters, 2nd ed, Elsevier Science Publishing Company, Inc, New York, NY, 1992.
    486) Sorensen SC & Mattisson KW: Naloxone as an antagonist in severe alcohol intoxication (Letter). Lancet 1978; 2:68-689.
    487) Soskolne CL: Am J Epidemiol 1984; 120:358-369.
    488) Sporer KA, Ernst AA, Conte R, et al: The incidence of ethanol-induced hypoglycemia. Am J Emerg Med 1992; 10:403-405.
    489) Sreenath TG, Gupta P, Sharma KK, et al: Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: A randomized controlled trial. Eur J Paediatr Neurol 2009; Epub:Epub.
    490) Stal P & Hultcrantz R: Iron increases ethanol toxicity in rat liver. J Hepatol 1993; 17:108-115.
    491) Standard Safety Equipment: Product Literature, Standard Safety Equipment, McHenry, IL, 1995.
    492) Starc R, Brucan A, & Bunc M: Acute myocardial infarction induced by alcohol ingestion in an asymptomatic individual. Europ J Emerg Med 1999; 6:403-406.
    493) Stenback F: Acta Pathol Microbiol Scand 1969; 77:325-326.
    494) Streissguth AP, Aase JM, & Clarren SK: Fetal alcohol syndrome in adolescents and adults. JAMA 1991; 265:1961-1967.
    495) Streissguth AP, Barr HM, & Sampson PD: Prenatal alcohol and offspring development: the first fourteen years. Drug Alcohol Depend 1994a; 36:89-99.
    496) Streissguth AP, Sampson PD, & Olson HC: Maternal drinking during pregnancy - attention and short-term memory in 14-year-old offspring - a longitudinal prospective study. Alcohol Clin Exp Res 1994; 18:202-218.
    497) Sulaiman ND, Florey CduV, & Taylor DG: Alcohol consumption in Dundee primigravidas and its effect on outcome of pregnancy. Br Med J 1988; 296:1500-1503.
    498) Szpak D, Groszek B, & Obara M: Thermoregulatory dysfunction secondary to acute ethanol poisoning. Przeglad Lekarski 1995; 52:281-283.
    499) Taberner PV: Pharmacokinetics of alcohol and the law. Trends Pharmacological Sci 1988; 9:47-48.
    500) Tanaka K, Hirohata T, & Takeshita S: Jap J Cancer Res 1987; 79:1075-1082.
    501) Taylor CL, Jones KL, & Jones MC: Incidence of renal anomalies in children prenatally exposed to ethanol. Pediatrics 1994; 94:209-212.
    502) Thomas AP, Rozanski DJ, & Renard DC: Effects of ethanol on the contractile function of the heart: a review. Alcohol Clin Exp Res 1994; 18:121-131.
    503) Thomas RG , Plumb J , & Dudley N : Coma after intentional ingestion of a hand sanitizer in a child. Clin Toxicol (Phila) 2010; 48(6):652-653.
    504) Thomson JS, Donald C, & Lewin K: Use of Flumazenil in benzodiazepine overdose. Emerg Med J 2006; 23(2):162-.
    505) Thorton JR: Atrial fibrillation in healthy non-alcoholic people after an alcoholic binge. Lancet 1984; 2:1013-1014.
    506) Tingley: Chemical Degradation for Footwear and Clothing. Tingley. South Plainfield, NJ. 2002. Available from URL: http://www.tingleyrubber.com/tingley/Guide_ChemDeg.pdf. As accessed 10/16/2002.
    507) Tominack RL & Spyker DA: Debunking alcohol breathalyzer myths: Denture adhesive and smokeless tobacco (Abstract). Vet Human Toxicol 1987; 29:490.
    508) Trelleborg-Viking, Inc.: Chemical and Biological Tests (database). Trelleborg-Viking, Inc.. Portsmouth, NH. 2002. Available from URL: http://www.trelleborg.com/protective/. As accessed 10/18/2002.
    509) Trelleborg-Viking, Inc.: Trellchem Chemical Protective Suits, Interactive manual & Chemical Database. Trelleborg-Viking, Inc.. Portsmouth, NH. 2001.
    510) Triantafillidis JK, Vekini J, & Nicolakis D: Ethanol-induced proctitis: another kind of chemical proctitis (Letter). Letters to the Editor 1994; 89:1270-1271.
    511) Trichopoulos D, Day NE, & Kaklamani E: Internat J Cancer 1987; 39:45-49.
    512) Tsuang JW, Irwin MR, & Smith TL: Characteristics of men with alcoholic hallucinosis. Addiction 1994; 89:73-78.
    513) Tuohimma P & Wichmann L: in: K Hemminki et al (Eds), Occupational Hazards and Reproduction, Hemisphere, Washington, DC, 1981, pp 73-79.
    514) Tuyns AT, Pequignot G, & Gignoux M: Internat J Cancer 1982; 30:9-11.
    515) U.S. Department of Energy, Office of Emergency Management: Protective Action Criteria (PAC) with AEGLs, ERPGs, & TEELs: Rev. 26 for chemicals of concern. U.S. Department of Energy, Office of Emergency Management. Washington, DC. 2010. Available from URL: http://www.hss.doe.gov/HealthSafety/WSHP/Chem_Safety/teel.html. As accessed 2011-06-27.
    516) U.S. Department of Health and Human Services, Public Health Service, National Toxicology Project : 11th Report on Carcinogens. U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. Washington, DC. 2005. Available from URL: http://ntp.niehs.nih.gov/INDEXA5E1.HTM?objectid=32BA9724-F1F6-975E-7FCE50709CB4C932. As accessed 2011-06-27.
    517) U.S. Environmental Protection Agency: Discarded commercial chemical products, off-specification species, container residues, and spill residues thereof. Environmental Protection Agency's (EPA) Resource Conservation and Recovery Act (RCRA); List of hazardous substances and reportable quantities 2010b; 40CFR(261.33, e-f):77-.
    518) U.S. Environmental Protection Agency: Integrated Risk Information System (IRIS). U.S. Environmental Protection Agency. Washington, DC. 2011. Available from URL: http://cfpub.epa.gov/ncea/iris/index.cfm?fuseaction=iris.showSubstanceList&list_type=date. As accessed 2011-06-21.
    519) U.S. Environmental Protection Agency: List of Radionuclides. U.S. Environmental Protection Agency. Washington, DC. 2010a. Available from URL: http://www.gpo.gov/fdsys/pkg/CFR-2010-title40-vol27/pdf/CFR-2010-title40-vol27-sec302-4.pdf. As accessed 2011-06-17.
    520) U.S. Environmental Protection Agency: List of hazardous substances and reportable quantities. U.S. Environmental Protection Agency. Washington, DC. 2010. Available from URL: http://www.gpo.gov/fdsys/pkg/CFR-2010-title40-vol27/pdf/CFR-2010-title40-vol27-sec302-4.pdf. As accessed 2011-06-17.
    521) U.S. Environmental Protection Agency: The list of extremely hazardous substances and their threshold planning quantities (CAS Number Order). U.S. Environmental Protection Agency. Washington, DC. 2010c. Available from URL: http://www.gpo.gov/fdsys/pkg/CFR-2010-title40-vol27/pdf/CFR-2010-title40-vol27-part355.pdf. As accessed 2011-06-17.
    522) U.S. Occupational Safety and Health Administration: Part 1910 - Occupational safety and health standards (continued) Occupational Safety, and Health Administration's (OSHA) list of highly hazardous chemicals, toxics and reactives. Subpart Z - toxic and hazardous substances. CFR 2010 2010; Vol6(SEC1910):7-.
    523) U.S. Occupational Safety, and Health Administration (OSHA): Process safety management of highly hazardous chemicals. 29 CFR 2010 2010; 29(1910.119):348-.
    524) US DHHS: Toxicological profile for carbon disulfide (update), Agency for Toxic Substances and Disease Registry, Atlanta, GA, 1992.
    525) US DHHS: Toxicological profile for carbon disulfide (update), Agency for Toxic Substances and Disease Registry, Atlanta, GA, 1993.
    526) Ukita K, Fukui Y, & Shiota K: Effects of prenatal alcohol exposure in mice - influence of an ADH inhibitor and a chronic inhalation study. Reprod Toxicol 1993; 7:273-281.
    527) Ungvary G: Prog Clin Biol Res 1985; 163b:295-300.
    528) United States Environmental Protection Agency Office of Pollution Prevention and Toxics: Acute Exposure Guideline Levels (AEGLs) for Vinyl Acetate (Proposed). United States Environmental Protection Agency. Washington, DC. 2006. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6af&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    529) Urben PG: Bretherick's Handbook of Reactive Chemical Hazards, & CD-ROM. Vol 1-2, 6th ed, Butterworth-Heinemann Ltd, Oxford, England, 1999.
    530) Urso T, Gavaler JS, & Van Thiel DH: Blood ethanol levels in sober alcohol users seen in an emergency room. Life Sci 1981; 28:1053-1056.
    531) Uszenski RT, Gillis RA, & Schaer GL: Additive myocardial depressant effects cocaine and ethanol. Am Heart J 1992; 124:1276-1283.
    532) VanDierendonk DR & Dire DJ: Baclofen and ethanol ingestion: a case report. J Emerg Med 1999; 17:989-993.
    533) Vasileva TF: Gig Truda Prof Zabol 1975; 6:48-49.
    534) Verschueren K: Handbook of Environmental Data on Organic Chemicals, 4th ed. (CD-ROM Version) , Wiley-Interscience, John Wiley & Sons, Inc, New York, NY, 2000.
    535) Virji SK: The relationship between alcohol consumption during pregnancy and infant birthweight. An epidemiologic study. Acta Obstet Gynecol Scand 1991; 70:303-308.
    536) Vogel C, Caraccio T, & Mefenson H: Alcohol intoxication in young children. Clin Toxicol 1995; 33:25-33.
    537) Wade T & Gammon A: Ingestion of mouthwash by children (letter). Br Med J 1999; 318:1078.
    538) Walsh FB: Clinical Neuro-Ophthalmology, Williams & Wilkins, Baltimore, MD, 1957.
    539) Watabe T & Endo A: Sexual orientation of male mouse offspring prenatally exposed to ethanol. Neurotoxicol Teratol 1994; 16:25-29.
    540) Watson WC, Sallam M, & Allan G: Acute upper gastrointestinal tract bleeding and recent alcohol ingestion. CMA J 1974; 110:529.
    541) Weiss M & Thurnheer U: Die osmotische lucke zur diagnose der alkoholintoxikation. Schweiz Med Wschr 1988; 118:845-848.
    542) Weller-Fahy ER, Berger LR, & Troutman WG: Mouthwash: a source of acute ethanol intoxication. Pediatrics 1980; 66:302-305.
    543) Wells Lamont Industrial: Chemical Resistant Glove Application Chart. Wells Lamont Industrial. Morton Grove, IL. 2002. Available from URL: http://www.wellslamontindustry.com. As accessed 10/31/2002.
    544) Werler MM, Lammer EJ, & Rosenberg L: Maternal alcohol use in relation to selected birth defects. Am J Epidemiol 1991; 134:691-698.
    545) Weyman AE, Greenbaum DM, & Grace WJ: Accidental hypothermia in an alcoholic population. Am J Med 1974; 56:13-21.
    546) Whitby KE, Collins TFX, & Welsh JJ: Developmental effects of combined exposure to ethanol and vitamin A. Food Chem Toxicol 1994; 32:305-320.
    547) Whitcomb DC & Block GD: Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272:1845-1850.
    548) Whorton MD: West J Med 1982; 137:521-524.
    549) Wilcosky TC & Tyroler HA: J Occup Med 1983; 25:879-885.
    550) Wilkinson IMS, Kime R, & Purnell M: Alcohol and human eye movement. Brain 1974; 97:785-792.
    551) Willoughby EW: Nystagmus and alcohol intoxication (Letter). N Z Med J 1987; 100:232.
    552) Wilson E & Waring WS: Severe hypotension and hypothermia caused by acute ethanol toxicity. Emerg Med J 2007; 24(2):e7-.
    553) Workrite: Chemical Splash Protection Garments, Technical Data and Application Guide, W.L. Gore Material Chemical Resistance Guide, Workrite, Oxnard, CA, 1997.
    554) Wu YL, Guo HR, & Lin HJ: Fatal alcohol immersion during the SARS epidemic in Taiwan. Forens Sci Intl 2005; 149:287.
    555) Yamauchi M, Kimura K, & Maezawa Y: Urinary level of l-fructose as a marker of alcoholic liver disease. Alcohol Clin Exp Res 1993; 17:268-271.
    556) Yamauchi M, Maezawa Y, & Toda G: Association of a restriction fragment length polymorphism in the alcohol dehydrogenase 2 gene with Japanese alcoholic liver cirrhosis. J Hepatol 1995; 23:519-523.
    557) Zaitsu M, Inada Y, Tashiro K, et al: Acute alcohol intoxication in a 15-day-old neonate. Pediatr Int 2013; 55(6):792-794.
    558) Zehtabchi S, Sinert R, Baron BJ, et al: Does ethanol explain the acidosis commonly seen in ethanol-intoxicated patients?. Clin Toxicol 2005; 43:161-166.
    559) Zellweger JP: Alcohol-induced asthma: not only in Asians (letter). J Allergy Clin Immunol 1997; 860.
    560) Zenz C: Occupational Medicine, 3rd ed, Mosby Year Book, Inc, St Louis, MO, 1994.
    561) Zubaran C, Fernandes JG, & Rodnight R: Wernicke-Korsakoff syndrome. Postgrad Med J 1997; 73:27-31.